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Abstract 
Prenatal exposure to maternal infection has been thought as a major risk factor 
for neurodevelopmental brain damage and thus contributes to the 
pathophysiology of neurodegenerative diseases including schizophrenia and 
autism. The mechanisms of aberrant neurodevelopmental processes on the 
offspring, in which primary cerebral insults occur during early brain 
development, are not fully understood. In the present investigation, maternal 
infection was modelled in timed-pregnant rats at embryonic day (E) 14, 16 and 
18 by administering intraperitoneal injections of polyriboinosinic-
polyribocytidilic acid,poly(I:C), a viral mimetic double stranded RNA complex 
which activates Toll-Like-Receptor-3 (TLR-3). The aim was to examine the 
impact of maternal inflammatory response on the regulation of expression of 
neurodevelopmental proteins that play important roles in many 
neurodevelopment aspects, including maintenance of synaptic plasticity, 
intracellular signalling and neurogenesis which may be relevant in cognitive and 
behavioural functions. An examination of embryo brains 5 h after maternal 
poly(I:C) showed significant differences in expression of the NMDA receptor NR2 
subunits. The expression of NR2A subunits was reduced, whereas infection 
induced during pregnancy enhanced NR2B subunit expression. Expression levels 
of both subunits at postnatal day 21 (P21) were not affected by prenatal 
poly(I:C) exposure. In utero viral challenge led to significant changes among 
neurogenesis factor only at P21. In the fetal brain, acute poly(I:C) exposure had 
no effect on the expression of SHH,  PCNA and also SOX2 proteins. However, 
when poly(I:C) was administered during mid and late gestation in the rodent 
model, long term effects of prenatal viral challenge on survival and maintenance 
of cell in the brain as indicated by the expression of SOX2 and SHH was clearly 
demonstrable. Expression of SOX2 level was increased,while SHH was 
significantly decreased, suggesting possible increase in the number of cells and 
changes in the rate of differentiation, respectively.  The results demonstrate 
that poly(I:C) challenge in pregnant dams results in selective molecular changes 
in the brain, with transient alteration in the levels of NMDA receptor subunit 
NR2A and NR2B in the foetal brain, and also affecting molecules associated with 
cell genesis processes at later stages of developmental age of offspring.  
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On the other hand, recent pharmacological interest in kynurenines with respect 
to CNS diseases has mainly focussed on two neuroactive molecules: quinolinic 
acid (QUIN) and kynurenic acid (KYNA). Manipulation of the kynurenine pathway 
and its neuroactive metabolites has been associated with N-methyl-D-aspartate 
(NMDA) receptor neurotoxicity and dysfunction which linked to the development 
of various neurological disorders. An early developmental event has been 
proposed to precipitate alterations in the NMDA receptor function. In this 
respect, early development during the gestational period of rats is most suitable 
for investigating the modulating effect of kynurenine pathway inhibition by 
compound Ro61-8048 (3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-
yl]benzenesulphomide) an inhibitor of kynurenine-3-monooxygenase (KMO) in 
shifting the balance towards the production of neuroprotective, kynurenic acid. 
Western blots were generated to indicate the expression of a range of proteins 
relevant to different aspects of CNS development including neuritogenesis, axon 
guidance, maintenance of synaptic plasticity, intracellular signalling and cell 
proliferation and migration. Within 5 h of Ro61-8048, there was a significant 
decrease in NR2A expression and increased NR2B in the embryo brains, with 
subsequent changes in SHH and NFB at 24 h post treatment. The litters were 
left undisturbed until weaning on P21 and other groups were allowed to develop 
to P60, at which time they euthanized and the brains removed for analysis. At 
P21, western blot analysis revealed significantly increased protein expression of 
the NR2A and NR2B subunits and postsynaptic density protein (PSD95). Among 
several neurodevelopmental proteins, the expression of NFB and proliferating 
cell nuclear antigen (PCNA) was increased, while reduced level of SHH was 
detected. We demonstrate here persisting changes in NR2A expression, with 
reduced level in the hippocampus while a raised level was noted in the cortex 
suggesting prenatal modulation of kynurenine pathway causes long lasting 
modifications of NMDA receptor composition and function. It is important to note 
that kynurenine pathway inhibition can generate a consistent set of long term 
changes in the SHH in which the levels of this protein remained repressed in 
some regional areas of the brain including hippocampus, cerebellum and cortex. 
We show that there are some common pathways that are affected by kynurenine 
pathway inhibition, and this early modulation tends to disrupt critical molecular 
processes that are known to be actively occurring at each specific 
developmental time. Overall, given these selective and differing developmental 
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profile, an early life modulation of the kynurenine pathway might be expected 
to cause a sufficient disturbance of biological processes that are actively 
occurring at the time of exposure and also able to leave a series of molecular 
changes that persist into adulthood. This disruption is likely to influence the 
resulting physiology of the adolescent and adult brain and subsequently can lead 
to impairments in social behaviour. It is hoped that this study provides a broad 
analysis of the long term molecular effects of developmental kynurenine 
metabolism, and that it allows for a viable opportunity of potential therapeutic 
targets for disease intervention.  
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1 Research background 
1.1 Maternal infection 
The recent widespread interest in the interaction of mind/body and diseases has 
undoubtedly stimulated the need to integrate research within this conceptual 
biological framework. There are many views on the aetiology of 
neurodevelopmental brain disorders, most notably autistic-spectrum disorder 
(ASD) and schizophrenia, which are highly heterogeneous with myriad causes. 
Several factors of infectious, neurological, metabolic, environmental and 
immunological origin have been thought to be involved in the disease 
development process of these neuropsychiatric disorders. Although the 
importance of genetic factors in this neuropsychiatric disease is strongly 
suggested by existing data, recent research in both animals and humans has 
discovered a number of gene-environment interactions where the exposure to 
pre- or post-natal environmental pathogens contributes to behavioural changes 
resembling essential symptoms of ASD or schizophrenia and produces lasting 
abnormalities in cognition and immune function including neuroinflammation in 
the offspring (Meyer et al., 2009, Patterson, 2009). 
Maternal infection is among the most studied and best-established nongenetic 
risk factor for schizophrenia. The connection between schizophrenia and 
maternal influenza infection was first indicated by the work of (Mednick et al., 
1988) which reported that the observed viral effect could be interpreted as 
being one of many potential perturbations of gestation. Studies examining the 
impact of influenza epidemics on schizophrenia found a higher incidence in 
offspring present in utero during these outbreaks compared with offspring in 
utero in a normal environment. One study featured a large pool of archived 
maternal serum samples collected in the 1960s that was linked to detailed 
medical records of both mothers and their children.  They found that in cases 
where they were able to confirm maternal influenza infection by assaying the 
serum, the offspring were 3–7 times more likely to develop schizophrenia than 
controls. Because of the high prevalence of influenza, they estimated that up to 
21% of all schizophrenia cases may be traced to maternal influenza infection 
(Brown et al., 2004). Similarly, epidemiological studies involving clinical 
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examination and serological testing have also reported a higher risk of 
schizophrenia and other psychosis-related disorders following prenatal exposure 
to rubella and Toxoplasma gondii (Brown et al., 2001, Brown et al., 2005). In 
addition, studies of other maternal infections demonstrated an association 
between periconceptional exposure to bacterial, genital and reproductive 
infections with the risk of schizophrenia spectrum disorders in adult offspring 
(Babulas et al., 2006, Sorensen et al., 2009). 
Epidemiological studies have demonstrated that infection-associated 
immunological events in the maternal host may be one of the key events leading 
to an enhanced risk for the offspring to develop severe neuropsychiatric 
disorders in later life. The precise mechanisms underlying the epidemiological 
link between maternal infection during pregnancy and increased risk for 
schizophrenia in the offspring remain largely unknown.  Considerable evidence 
has correlated the indirect effects via changes in maternal-foetal immunological 
parameters such as cytokines with the reported brain and behavioural 
dysfunctions emerging after prenatal exposure to infection. Elevation of  
cytokines in the maternal host and thereafter in the foetal environment has 
been seen as one of the key events responsible for the interaction between 
maternal infection during pregnancy, altered neuronal development and 
development of schizophrenia (Gilmore and Jarskog, 1997). It would now appear 
that many of the psychological changes associated with infections are directly 
caused by pro-inflammatory cytokines that are produced by infection or stress-
induced activation of immune cells. Just as neurotransmitters and hormones 
elicit their biological responses by activating specific receptors on cells or by 
combining with intracellular receptors, so the cytokines activate specific 
receptors on immune, endocrine or neural cells (Meyer et al., 2009, Smith et al., 
2010). Consequences of the infectious process during pregnancy are likely to 
affect foetal brain development. This effect is said to be mediated through pro-
inflammatory cytokines released by the maternal immune system which can 
cross the placenta and enter the foetal circulation (Gilmore and Jarskog, 1997). 
These molecules are critically important to the immune response, acting as the 
systemic mediators of the host response to infection. Cytokine elevations 
increase vulnerability to developmental brain damage and other reproductive 
outcomes (Damman and Leviton, 1997). Further studies have found links 
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between elevated levels of cord blood cytokines and development of 
schizophrenia, strengthening the association of influenza infection with 
schizophrenia risk (Brown, 2006). 
1.1.1 Infectious agents and models of maternal infection 
Animal studies are of great importance in the elucidation of the function of 
specific molecules and as models of disease. Several species are now widely used 
as systems for the functional analysis of molecules in vivo, which have led to a 
rapid development of the technology for processes such as gene mutation or 
gene expression. Other approaches allow the alteration of expression of a gene 
in particular windows of time and in a tissue-specific way. In addition, animal 
model studies indicate the plausibility of an infectious basis for a wide range of 
neuropsychiatric disorders and are increasingly available for testing potential 
risk factors. Using animal models to follow the effects of exposures to various 
exogenous factors may indicate an association between the time points during 
nervous system development at which they are introduced and the manifestation 
of the behavioural and neuropathological features (Boksa, 2010). This could be 
especially relevant for an animal model of schizophrenia, considering the late 
onset of the disease, and support the plausibility that early life infections can 
give rise to persistent effects on behaviour. Animal experimentation illuminates 
the behavioural consequences that discrete lesions and their interconnections 
can produce. This has been demonstrated in a rat model in which some striking 
behavioural abnormalities emerging during adolescence could be observed 
(Vicente and Kennedy, 1997). The pathophysiology for schizophrenia has been 
thought to result from neurodevelopmental processes that start long before the 
onset of clinical manifestations and are due to a combination of environmental 
and genetic factors. In addition, several adverse events like infection or harmful 
stressors during prenatal and postnatal periods have been associated with the 
development of schizophrenia (Rapoport et al., 2005).  
The most well appreciated cause of inflammation during pregnancy is due to 
infection by a pathogen. During inflammation there is an increase in the 
maternal circulation of inflammatory cytokines to which the foetus is then at 
risk of being exposed. Perturbations to the prenatal environment, in particular 
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maternal infection play a major role in the development of schizophrenia. Many 
studies have reported an association between influenza infection during 
pregnancy and an increased risk to schizophrenia in offspring. This association 
has also been shown in a variety of other maternal illnesses such as rubella and 
respiratory tract infections. Less is known about the possible relationship 
between early-life exposure to infectious agents other than viruses and the risk 
of schizophrenia. Although the environmental agents responsible for the initial 
neurodevelopmental insult in schizophrenia has not been discovered, prenatal or 
neonatal viral infections has received considerable attention based on 
epidemiological, immunological neuropathological studies. This have contributed 
to a link between viral infections and the etiopathogenesis of schizophrenia 
(Pearce, 2001).  
Several large epidemiological studies have shown that prenatal exposure to viral 
infection is among environmental factors that may detrimentally affect 
neurodevelopment and has been implicated in the risk of schizophrenia in 
adulthood (Adams et al., 1993, Torrey et al., 1988). However, the mechanisms 
that cause the late emergence of the central nervous system pathology during 
adulthood still remain unknown. A number of studies suggested that interference 
with normal development is caused particularly by the proinflammatory 
cytokines released by the maternal immune system in response to the infection. 
It is based from the finding that prenatal exposure to a variety of infections has 
been associated with an increased incidence of schizophrenia (Gilmore and 
Jarskog, 1997, Pearce, 2001). To study whether the consequences of prenatal 
infection are really due to the infection itself or to the maternal immune 
response following infection, a model of animal study on rodents that utilize 
systemic administration of the synthetic double-stranded RNA, 
polyriboinosinic:polyribocytidilic acid [poly(I:C)] has been developed. In this 
approach, pregnant dams were injected with poly(I:C) solution with set dosages 
to mimic viral exposure with the aim of inducing  a maternal immune response 
without exposure to a virus itself (Katafuchi et al., 2003, Kimura et al., 1994). 
Several experimental models of maternal infection challenge by agents such as 
the viral pathogen viral mimic polyriboinosinic-polyribocytidilic acid, [poly(I:C)], 
the bacterial endotoxin lipopolysaccharide (LPS) and the pro-inflammatory 
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cytokine interleukin (IL-6) have provided considerable support to the causal 
relationship between prenatal exposure to maternal infection and the disruption 
of neurodevelopment in the prenatal brain. This predisposes the offspring to 
long lasting pathological changes in the brain as well as profound disturbances in 
mental functions, emotions and behavioural changes in adolescence or early 
adulthood. A body of evidence from animal studies have indicated that prenatal 
immune activation causes a wide spectrum of structural and functional 
abnormalities implicated in schizophrenia and other psychosis-related disorders 
(Smith et al. 2007; Hao et al. 2010). However, little is known about the 
neurodevelopment mechanisms underlying this epidemiological link and 
empirical support to clarify whether immune dysfunction during early 
neurodevelopment leads directly to central nervous system abnormalities has yet 
to emerge. In addition, the finding of elevated antibody levels in maternal sera 
suggest that maternal infection with Toxoplasma gondii can be a potential risk 
for schizophrenia and schizophrenia spectrum disorder in the offspring. An 
association between the risk of psychosis in adulthood following such exposure, 
and elevated levels of the antibodies in the newborn blood is known to exist 
(Brown and Derkits, 2010). Taken together, these studies suggest that infectious 
agents may be involved in the risk of developing schizophrenia. 
1.1.2 Immune response to infection in the central nervous system 
The exact mechanisms that are associated with virus related prenatal 
neurodevelopmental damages are not thoroughly defined. Considering the 
multiplicity of viruses that are implicated in a multitude of neuropsychiatric 
conditions, common mediators of maternal immune responses are suspected. 
Studies have shown that infection to pregnant women has been implicated in the 
pathophysiology of schizophrenia and several viruses are thought to contribute 
to the mechanism of disease. This observation has led to propositions that these 
viruses may be acting through a common pathway, possibly involving increased 
levels of cytokines, which could impair several aspects of neurodevelopment. 
Support for this hypothesis include studies showing that cytokine levels are 
increased in pregnancies complicated by infection and altered level of several 
cytokines have been found in the neonates from infected mothers. Both protein 
and mRNA of IL-1β, IL-6, TNF-α and IL-10 are upregulated at various time points 
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ranging from 2 – 24 h post injection of either LPS or poly(I:C).Some of these 
responses seem to be dose-dependent, with more robust increases in fetal brain 
cytokines following higher doses of treatments. Furthermore, maternally 
produced cytokines (IL-6 and IL-2) can cross the placenta and enter the foetal 
circulation, and can also cross the blood brain barrier. It has been proposed that 
the alterations to foetal brain development caused by increased cytokine 
signalling likely contribute to the abnormal behaviour in the adult offspring 
(Urakubo et al., 2001, Gilmore and Jarskog, 1997, Ozawa et al., 2006, Meyer et 
al., 2006, Ashdown et al., 2006). One key mediator that plays a critical role in 
mediating the behavioural changes in the offspring is IL-6, and a single maternal 
injection of IL-6 was observed to cause deficits in prepulse inhibition and latent 
inhibition. Co-injection of an anti-IL-6 antibody prevented the behavioural 
deficits caused by poly(I:C). Moreover, blocking the effect of IL-6 also 
normalized maternal poly(I:C)-induced gene expression changes  in the adult 
offspring brain, as measured by RNA microarray. In the same study, Il-6 knockout 
mice did not show behavioural deficits after MIA (Smith et al., 2007). 
Cytokines are low molecular weight proteins that known to be produced during 
events associated with an increased risk to schizophrenia, like infection. 
Cytokines are able to modulate the systemic and central nervous system 
response to infection and inflammation, and it has been demonstrated that they 
also play important roles in the regulation of many neuronal functions such as 
neurotransmission, neuronal survival and synaptic plasticity (Rothwell and 
Hopkins, 1995). Studies have revealed abnormalities of cytokines in 
schizophrenic patients. It has been known that cytokines can modulate neuronal 
proliferation, survival, differentiation and function. Other CNS functions 
influenced by cytokines include regulation of cognition, social interaction and at 
a neurochemical level, modulation of corticosteroid secretion and turnover of 
monoamines.  Thus, cytokine production by the maternal immune system may be 
responsible for the interaction between maternal infection during pregnancy and 
altered neural development towards pathogenesis of neuropsychiatry diseases 
(Meyer et al., 2009, Watanabe et al., 2010). 
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1.1.3 Behavioral changes and neurochemical alterations 
The mechanisms by which MIA leads to behavioural changes are not fully 
understood. It is possible that MIA sets into motion an ongoing immune 
activation that include alteration in the level of proinflammatory cytokines in 
maternal and foetal compartments, which can potentially affect multiple 
aspects of neuronal development. This deregulation may be responsible for some 
of the behavioural abnormalities observed in the adult offspring. It is clear that 
MIA has the potential to cause ongoing inflammatory processes and alter the 
balance between pro and anti-inflammatory signalling. Chronic elevation of 
cytokines and associated cellular inflammation would have an adverse effect on 
behaviour (Ashdown et al., 2006, Urakubo et al., 2001). For instance, a report 
showed injection of certain cytokines  e.g. IL-6 triggers microglia activation in 
the brain, elevated IL-6 levels in the adult hippocampus, which indicate ongoing 
inflammation and increased glial fibriliary acidic protein (GFAP) and GABAA 
receptor levels that could all contribute to produce working memory deficit in 
the adult offspring (Nyffeler et al., 2006) 
Different experimental models provide support for persistent effects of viral 
infections during early life on host behaviour.  Experimental models of maternal 
infection have been used to model neurodevelopmental damage of relevance to 
neuropsychiatric disorders. Animal studies of rodents offspring prenatally 
exposed to influenza virus and viral mimic poly(I:C) display behavioural deficits. 
A range of behavioural methods has been used to examine various domains of 
schizophrenia-related behaviours in rodents such as sensorimotor gating, drug-
induced locomotion and learning and memory. Sensorimotor gating refers to the 
process by which a weak sensory stimulus inhibits a motor response elicited by a 
stronger sensory stimulus, and most commonly assessed by performance on 
prepulse inhibition (PPI) tasks. This task refers to an attenuation of the startle 
reflex when the startle eliciting stimulus (the pulse) is preceded by a weaker 
sensory stimulus (the prepulse). Individuals with schizophrenia display deficits in 
sensorimotor gating and a failure to attenuate the acoustic startle reflex on PPI 
tasks, which are the most commonly reported behavioural disturbances in 
rodents subjected to the MIA model. To this regard, reduced PPI has been 
observed in rat and mouse offspring born to dams prenatally exposed to LPS or 
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poly(I:C). Furthermore, the PPI deficits only occur after puberty, mimicking the 
adult onset of schizophrenia. The use of PPI as an operational measure of 
sensorimotor gating have made it possible to identify the underlying neuronal 
brain circuitries and may also be useful in understanding the biology of drug 
effects in the normal and abnormal human CNS (Borrell et al., 2002, Meyer et 
al., 2008b, Shi et al., 2003, Fortier et al., 2007). Although the focus of using the 
Morris water maze has been to investigate memory encoding and hippocampal 
activity, many have used this task in schizophrenia research and it is regarded as 
the standard procedure to evaluate the spatial learning and memory abilities of 
rodents. In addition, impairment in this ability has been noted following 
systemic maternal inflammation of LPS (Hao et al., 2010). Another commonly 
reported effect of MIA in offspring, specially related to schizophrenia is altered 
amphetamine (AMPH)-induced locomotion which is a behavioural measure of 
mesolimbic dopamine activity. Offspring born to immune-challenged dams 
display enhanced locomotor responses to a low dose of AMPH, suggesting that 
these offspring have enhanced susceptibility to dopaminergic stimulation and are 
highly relevant to the positive symptoms of schizophrenia.  MIA also affected the 
adult offspring‟s sensitivity to the locomotor-stimulating effects of systemic 
administration of non-competitive NMDAR antagonist, dizocilpine (MK-801). It 
has been shown that maternal poly(I:C) exposure enhanced the locomotor 
reaction to systemic MK-801 in the adult offspring. Many of these behavioural 
deficits respond to antipsychotic drugs (Meyer et al., 2008a, Meyer et al., 
2008b).  
In addition to behavioural abnormalities, MIA also potentially affects multiple 
aspects of neuronal development. Particularly relevant are the findings that 
suggests cytokines affect the development of hippocampal and cortical neurons 
including abnormal hippocampal structure and neuronal loss in mature periods of 
maternal immune activation models (Hao et al., 2010). Morphometric analysis 
showed a decreased hippocampal volume in offspring following prenatal viral 
infection which is consistent with the observed reductions of hippocampus in 
subjects with schizophrenia (Fatemi et al., 2009b). On the other hand, MIA also 
impairs synaptic function and synaptic protein expression. It has been 
demonstrated that the reduction of the presynaptic function-relevant molecule 
synaptophysin in the hippocampus is responsible for the synaptic dysfunction in 
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the offspring (Oh-Nishi et al., 2010). In addition to neuronal changes, there is 
also evidence for neuroanatomical changes in the central dopaminergic, 
GABAergic and glutamatergic systems following prenatal immune activation 
(Meyer et al., 2008a, Meyer et al., 2008c). Interactions between inflammatory 
cytokines and neurotrophins in the nervous system also have been studied 
following prenatal immune challenge in rodents. The levels of brain-derived 
neurotrophic factor (BDNF) and nerve growth factor (NGF) are differentially 
regulated by LPS or poly(I:C) depending on the severity and magnitude of the 
immune response within the maternal-fetal unit evoked following each agent. 
Taken together, alterations of these systematically generated neurotrophic 
factors after maternal infection may contribute to abnormal brain development 
and increase the risk of neurodevelopmental disorders (Gilmore et al., 2005b, 
Gilmore et al., 2003). In light of the neurodevelopmental hypothesis for 
schizophrenia, it is imperative to search for candidate genes related to 
pathogenetic processes that are induced by interaction of susceptibility genes 
and also environmental factors. There is now large body of evidence which 
demonstrates the altered expression of several genes that are involved in various 
neurodevelopmental aspects including neuronal proliferation and migration, 
neuronal polarization and axonal guidance, dendrite formation and myelination 
and synaptic plasticity (Fatemi et al., 2009b, Fatemi et al., 2008, Hayashi-
Takaga and Sawa, 2010, Liverman et al., 2006) 
Studies have widely demonstrated that MIA and related neuroinflammatory 
responses characterized by alterations to cytokine expression have detrimental 
effects on the behavioural and neurophysiological development of offspring, but 
the exact mechanisms by which maternally, placentally, and/or fetally-
generated cytokines ultimately disrupt brain and behavioral development remain 
unclear. Taken together, this evidence demonstrated that MIA not only alters 
both behaviour and immunological parameters in the adult offspring, but 
behaviour and immunological parameters are tightly regulated. It should be 
emphasized that a comprehensive approach to investigating the pathogenesis of 
neurodevelopmental disorders must consider the interaction of host and 
environmental factors in a broader context. Evidence is emerging from 
epidemiology and animal models suggesting that prenatal infection with a 
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variety of agents can trigger complex behavioural disorders by impacting the 
function of specific neural cells and circuits(Zuckerman and Weiner, 2005).  
1.2 The Kynurenine Pathway (KP)  
On the other hand, neurotoxicity associated with maternal-immune activation 
may be the result of a series of small perturbations in brain metabolism and this 
may include the involvement of kynurenine pathway enzymes and a series of 
metabolites produced along the pathway. It is known that the principal role of 
the essential amino acid tryptophan is to form a constituent of protein synthesis 
and serves as a precursor for serotonin. As animals cannot synthesize 
tryptophan, they are therefore dependent on ingestion of proteins containing 
tryptophan. Ingested tryptophan is primarily degraded in the liver through 
several metabolic steps known as the kynurenine pathway (KP). The specific 
reactions associated with each enzyme of the kynurenine pathway are shown in 
Figure 1-1. Under physiological conditions, the majority of tryptophan is 
metabolized in the liver by enzyme tryptophan 2,3-dioxygenase (TDO), which 
acts as the rate-limiting enzyme for tryptophan in the liver and is up-regulated 
by corticosteroid. Whereas indolamine 2,3-dioxygenase (IDO) is the first enzyme 
of the KP in extrahepatic tissues and this enzyme  is induced when tissues are 
invaded by viruses, bacteria or endotoxin. Oxidation of tryptophan, 
predominantly by the enzyme IDO can be found in numerous cells including 
macrophages, microglia, neurons and astrocytes. Generally, induction of this 
enzyme increases tryptophan metabolism leading to an increase in kynurenine 
and reductions in tryptophan concentrations. Kynurenine, a central compound of 
the pathway, can then be metabolized by several enzymes, namely kynurenine 
aminotransferases (KAT1, KAT2, KAT3), which generate kynurenic acid (KYNA), 
kynureninase which generates anthranilic acid (AA) and finally kynurenine 3-
monooxygenase (KMO) which is the enzyme responsible for the production of 3-
hydroxykynurenine (3-HK). The latter metabolite can be further metabolized 
into 3-hydroxyanthranilic acid (3-HAA) which subsequently is metabolized by 3-
hydroxyanthranilate 3,4-dioxygenase (HAAO) to 2-amino-3-carboxymuconic 
semialdehyde and is converted to either picolinic acid or quinolinic acid (QUIN). 
Finally, the end product nicotinamide adenosine dinucleotide (NAD) is produced 
via the action of the enzyme quinolinate phosphoribosyltransferase 
(QPRT)(Stone, 1993, Moroni, 1999). Recent studies on the biochemical and 
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molecular biological function of the kynurenine pathway have triggered renewed 
interest in the characteristics of individual kynurenine pathway enzymes.  
1.2.1 Neuroactive metabolites 
1.2.1.1 Quinolinic acid (QUIN) 
Interestingly, this pathway generates several immunomodulatory and 
neuroactive metabolites and can be induced by infections. It is up-regulated by 
inflammatory molecules such as lipopolysaccharide, amyloid peptide,human 
immunodeficiency virus proteins, and its potent stimulus, interferon- γ (IFN-γ), 
which is able to induce both the gene expression and enzymatic activity of IDO 
(Fujigaki et al., 2001; Takikawa, 2005). As tryptophan proceeds along the 
kynurenine pathway to achieve the final product  nicotinamide adenine 
dinucleotide (NAD), a number of neuroactive intermediates are subsequently 
generated, most importantly the free-radical generator  3-hydroxyanthranilic 
acid (3-HA), the excitotoxin and N-methyl-D-aspartate (NMDA) receptor agonist  
quinolinic acid (QUIN) and a broad spectrum excitatory amino acid receptor 
antagonist with a particularly high affinity for the glycine recognition site 
present on the NMDA receptor-ion channel complex kynurenic acid (KYNA) (Stone 
& Perkins 1981; Perkins & Stone 1982; Stone, 1993; Schwarcz et al., 1983). In 
contrast to KYNA, 3-hydroxykynurenine (3-HK) and quinolinic acid (QUIN) are 
synthesized from kynurenine en route to NAD+  by the enzyme kynurenine 3-
monooxygenase (KMO). This enzyme is increasingly viewed as a major 
gatekeeper of the kynurenine pathway. The ability to readily generate damage-
promoting free radicals and NMDA receptor activation accounts for QUIN‟s 
unique neurotoxicity and neurotoxic profile (Stone, 1993) .In experimental 
studies, high concentrations of KYNA are frequently employed to inhibit 
excitatory amino acid receptor function non-specifically and to protect against 
excitotoxic insults, whilst QUIN is primarily used as a tool to produce excitotoxic 
brain lesions (Schwarcz & Kohler 1983). Quinolinic acid is probably the most 
studied kynurenine metabolite because it may cause convulsions and 
excitotoxicity activity by interacting with glutamate receptors of the NMDA type 
(Stone and Perkins, 1981). The QUIN concentration is normally low within the 
brain tissue. However, during an immune response activation, the level of QUIN 
is highly elevated in the brain and exerts its excitatory effects at the NMDARs. In 
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this situation, the endogenous formation of kynurenine and its downstream 
metabolites are greatly enhanced due to the activation of IDO by interferon- 
(IFN-), cytokines, viral and bacterial insults. Infiltrating macrophages, microglia 
and dendritic cells have been shown as major sources of QUIN production under 
inflammatory conditions in the brain (Schrocksnadel et al., 2006, Chen and 
Guillemin, 2009). QUIN has been shown to induce neuronal and astrocytic 
apoptosis, and it has been thought that the over-activation of the NMDAR and 
subsequent Ca2+ influx into neurons activates the downstream enzyme  nitric 
oxide synthase (NOS) leading to the production of nitric oxide (NO) which 
promote free radical damage (Braidy et al., 2009, Stone and Perkins, 1981). In 
addition to NMDAR agonism, it also induces lipid peroxidation and generates free 
radicals which in part are responsible for the compound neurotoxic profiles 
(Forrest et al., 2002). In certain pathological conditions, in which microglia 
activation occurs, elevated QUIN levels were detected in the brain and the 
accumulation of this compound has been implicated in the etiology of a broad 
spectrum of neurological diseases, particularly those with inflammatory 
reactions. The most notable ones are AIDS-dementia, spinal trauma, epilepsy, 
Parkinson‟s disease, Huntington‟s disease and Alzheimer‟s disease (Schwarcz et 
al., 2012, Schwarcz and Pellicciari, 2002, Schwarcz, 2004, Schwarcz et al., 
2010).  
1.2.1.2 Kynurenic acid (KYNA) 
Importance is also attached to KYNA by the fact that this is one of the few 
known endogenous excitatory amino acid receptor blockers with a broad 
spectrum of antagonistic properties on the glycine modulatory site of the NMDA 
receptor at low concentrations. At high concentrations, antagonism at the 
glutamate site of the NMDA receptor and also on the α-amino3-hydroxy-5-
methyl-4-isoxazolepropionate (AMPA) receptors, suggesting its physiological 
function in glutamatergic neurotransmission (Perkins and Stone, 1982). In 
addition, it also non-competitively antagonizes α 7-nicotinic acetylcholine 
receptors (αNCRs). KYNA is present in the mammalian brain at low 
concentrations (nanomolar) and has been described as an inhibitory component 
exerting anticonvulsant and anti-excitotoxic actions (Foster et al., 1984).  As 
shown in Figure 1-1, KYNA is generated directly from L-Kynurenine by KAT 
enzymes. Two distinct enzymes have been described in rat and human brains, 
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KAT I and KAT II, which have shown immunoreactivity in astrocytes and also 
seems to be present in a small percentage of neurons. In most brain regions and 
lesioned brain tissue, KYNA results primarily from KAT II activity and newly 
synthesized KYNA is rapidly released into the extracellular space (Amori et al., 
2009, Alkondon et al., 2011). The levels of extracellular KYNA increase linearly 
with kynurenine availability, as astrocytes generally lack KMO and therefore 
favour KYNA synthesis, whereas microglia cells contain only a little enzyme KAT 
and preferentially produce intermediates of the QUIN branch of the pathway 
(Schwarcz and Pellicciari, 2002).  
Investigation of the KYNA arm of the pathway has provided an insight into their 
effects, that elevated level of this metabolite may cause cognitive impairment 
by virtue of its ability to antagonize the α-7 nicotinic acetylcholine presynaptic 
receptor (α7NCR) and the glycine site of the NMDA receptor. These are both  
critically involved in physiological processes underlying learning, memory and 
other manifestations of synaptic plasticity (Schwarcz et al., 2012).  It has been 
proposed that by shifting the kynurenine metabolism toward KYNA formation, it 
may be possible to reduce glutamate receptor activation and excitotoxic 
neuronal damage.  High concentrations of KYNA are anticonvulsant and 
neuroprotective, its glutamate antagonist activity is probably responsible for its 
ability to prevent brain damage following various pathological settings. It was 
found to be protective against brain NMDA neurotoxicity of ischemia and 
demonstrated the ability to block QUIN-induced excitation of CNS neurons, thus 
supporting the role of KYNA as an endogenous modulator of neurodegenerative 
and seizure phenomena(Foster et al., 1984). It has been shown that a reduction 
of KYNA level enhances the vulnerability to excitotoxic insults and the ability to 
decrease inflammatory molecules such as tumour necrosis factor-α (TNFα) and 
nitric oxide which is likely to be involved in LPS-mediated toxicity (Chen and 
Guillemin, 2009, Moroni, 1999, Stone, 2001, Vamos et al., 2009).  
On the other hand, up regulation of KYNA branch of the pathway has been 
theoretically thought to mediate the negative effects of kynurenine pathway up 
regulation on mental status. It has also been demonstrated that a minor 
elevation of KYNA causes a decrease in the extracellular levels of 
neurotransmitters associated with cognitive function, i.e. glutamate, 
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acetylcholine and dopamine. The reduced level of glutamate in cerebrospinal 
fluid of individuals with schizophrenia was consistent with hypoglutamatergic 
function (Linderholm et al., 2010). Evidence has also supported the observation 
that altering the concentration of KYNA during critical times of brain 
development can affect behaviour later in life. It should also be noted that 
chemical manipulation by injection of kynurenine induced alterations in working 
memory function in adulthood, therefore establishing a notion that altered 
concentration of KYNA is capable of influencing cognitive function that depends 
on intact NMDAR transmission (Akagbosu et al., 2010, Chess et al., 2007). With 
regard to schizophrenia risk, exposure to a number of infectious agents during 
early life or childhood has previously been associated to the later development 
of symptoms related to schizophrenia. Experimental studies have shown that 
exposure to various insults during early life can induce long term effects on gene 
expression in the brain as well as behaviour (Shi et al., 2003, Fatemi et al., 
2009a). However, the impact of CNS infections on the KP during early life in the 
brain is not fully described. Infection of neurotrophic influenza A virus during 
early postnatal period (P3) in mice triggered an altered expression of several 
genes in the KP whilst increased levels of IDO and KMO have been observed on P7 
of virus-infected brain accompanied with transient increase of KYNA 
concentration. The increased levels of KYNA appear to be caused by activation 
of tryptophan degradation in the brain and the inhibition of  NMDA receptors by 
KYNA would be one of the potential consequences which may functionally link 
infections with distorted  glutamatergic signalling in the developing brain 
(Holtze et al., 2008). Therefore, the elevation of KYNA as observed in 
schizophrenic patients provided a new insight into the possible effect of KYNA on 
the glutamatergic and dopaminergic systems and its potential role in the 
pathogenesis of schizophrenia (Erhardt et al., 2007, Barry et al., 2009). Novel 
treatment of the disease could rationally be directed towards brain KYNA 
formation. Thus, blockade of kynurenine aminotransferase (KAT II which 
catalyzes the conversion of kynurenine to KYNA) causes a decrease in brain KYNA 
and may have cognition enhancing effects in the treatment of schizophrenia 
(Wonodi and Schwarcz, 2010, Erhardt et al., 2009).  
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Figure 1-1 Reaction sequence in the kynurenine pathway for tryptophan degradation 
Figure adapted from (Stone, 1993) 
1.2.2 Modulation of kynurenine pathway metabolism 
By combining evidence of QUIN and KYNA action, excitoxicity and CNS 
inflammatory related disorders have been related to excessive stimulation of 
NMDAR by QUIN, while the other metabolite, KYNA affords protection against it. 
In line with this notion, a substantial body of research have indicated that 
changes in the endogenous levels of each of KP metabolites have been 
implicated in the pathophysiology of several brain disorders including 
Huntington‟s disease, Alzheimer‟s disease, affective disorders such as 
schizophrenia and depression and also been correlated with Autistic-spectrum 
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disorder (ASD). The presence of neuroactive kynurenines in the mammalian brain 
has led to the notion that it may be possible to affect synaptic transmission of 
excitatatory amino acid receptors by modulating kynurenine pathway 
metabolism in the brain. Some studies have found that pharmacological 
manipulations favouring KYNA in the brain extracellular space by intracerebral 
administration of exogenous KYNA protected against excitotoxins which may be 
beneficial in attenuating excessive NMDA receptor function and provide effective 
neuroprotection after an acute excitotoxic insult (Obrenovitch and Urenjak, 
2000).  
The pharmacological manipulation of the kynurenine pathway is still in its 
developmental stage and the pathway has been manipulated in several ways 
with the aim of developing therapies for the treatment of neurodegenerative 
diseases. The fact that NMDA receptor function is paramount to early brain 
development and since over activation of this receptor in the brain has been 
postulated as a cytotoxic mechanism involved in neurodegenerative process, 
many researchers have been prompted to look into the kynurenine pathway for a 
potential therapeutic approach. In this aspect, pharmacological challenges 
directed to enhance the endogenous formation of KYNA in brain tissue are 
considered as a successful strategy to counteract toxic events. Several ways of 
increasing the brain levels of endogenous KYNA have been discovered. One 
example is administration of a combination of kynurenine and probenecid, an 
organic acid transport blocker. The immediate precursor to KYNA, kynurenine 
has been shown to cross the brain barrier (BBB) effectively from the periphery 
and increased KYNA concentration while probenecid inhibits the efflux of KYNA 
from the brain via a probenecid-sensitive carrier. This association appears to be 
able to increase the brain extracellular concentration of KYNA and attenuate 
QUIN neurotoxicity (Santamaria et al., 1994, Santamaria et al., 1996). 
Neuroprotection of this combination has also been observed in animal models of 
Parkinson‟disease where systemic administration of kynurenine and probenecid 
attenuates the dopaminergic damage induced by 6-hydroxydopamine, suggesting 
that the combined treatment constitutes a pharmacological strategy of 
considerable therapeutic value to mitigate excitotoxic events (Silva-Adaya et 
al., 2011). Another approach involved the use of synthetic analogues of 
kynurenic acid or kynurenine that can easily penetrate the blood brain barrier 
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(in contrast with KYNA) as antagonists at glutamatergic NMDA receptors (Stone 
and Addae, 2002, Stone, 2001). A series of kynurenine analogues that have KMO 
and kynureninase inhibiting properties have also been tested. This includes 
nicotinylalanine (NAL) and meta-nitrobenzoylalanine (mNBA) which change the 
balance of the tryptophan metabolites towards the formation of KYNA (Moroni et 
al., 1991, Russi et al., 1992). The latter has been described as having more 
potent competitive and selective inhibitory activity than previous compounds in 
inhibiting KMO and caused an increase in the brain concentration of KYNA, an 
effect which is associated with sedative and anticonvulsant actions (Carpenedo 
et al., 1994).  Another possible method to decrease the effects of KP 
disturbances is by using enzyme inhibitors. It appears that in some pathological 
states, changes in the two KP metabolites are modest and could be balanced by 
elevating the level of the antiexcitotoxic metabolite, KYNA or blocking the 
formation of QUIN. Development of pharmacological agents designed to augment 
or attenuate the effects of specific kynurenine metabolites, such as QUIN and 
KYNA is underway and several prototype inhibitors of most kynurenine enzymes 
are now available. Several of these compounds have been used for proof-of-
concept in experimental animals (Nemeth et al., 2007, Moroni, 1999).  
It has been shown that inhibition of kynurenine 3-monooxygenase (KMO), an 
enzyme that is responsible for synthesizing quinolinic acid, will shift kynurenine 
pathway from the production of excitotoxin quinolinic acid towards the 
production of neuroprotective kynurenic acid.  Neuroprotection provided by the 
chemical inhibition of KMO has been shown in Huntington‟s disease model flies, 
in which decreases in 3-HK relative to KYNA is thought to confer neuroprotection 
by antagonizing NMDAR and decreasing glutamate-dependent excitoxcity as well 
as by scavenging free radicals (Campesan et al., 2011, Stone, 2000). Reductions 
in spontaneous locomotor activity and increases to the threshold level of 
electroshock-induced seizure are the effects produced by systemic 
administration of KMO inhibitors. In comparison, neuroprotective effects of KMO 
inhibitors in models of brain ischemia are primarily related to their ability to 
increase KYNA concentration in the brain and consequently antagonise the 
activation of NMDAR. Thus, it is reasonable to assume that by inhibiting KMO it is 
possible to reduce NMDAR function thus affording neuroprotection (Chiarugi et 
al., 1995, Moroni, 1999). However, it should be noted that the neuroprotective 
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properties of KMO inhibitors by increasing the KYNA concentration are observed 
under pathological settings such as in immune-stimulated conditions. 
Administration of inhibitors of KMO under basal conditions, however do not 
affect the levels of either blood or brain content of QUIN (Chiarugi and Moroni, 
1999). Therefore, it is important to further evaluate the physiological and 
pharmacological implications of increasing KYNA concentrations in the brain.  
A range of studies has been conducted to study the inhibition of KMO as a 
strategy for inducing a more favourable ratio of KYNA to QUIN in vivo. Among 
related molecules from a series of N-(4-phenylthiazol-2-yl)benzenesulfonamides,  
one member known as Ro61-8048 with the molecular structure as 3,4-dimethoxy-
N[4-(3-nitrophenylthiazol-2-yl]benzenesulfonamide has been characterized  as a 
highly effective inhibitor, and has been successfully used as a selective agent to 
probe the physiological and pathological roles of KP metabolites experimentally 
(Rover et al., 1997). Previous studies have shown that systemic administration of 
this compound caused a robust decrease in glutamate levels in selected regions 
of the brain and this intervention is useful as a pathological increase in 
glutamate neurotransmission is considered detrimental in various neurological 
and psychiatric disorders (Meldrum and Garthwaite, 1990, Moroni et al., 2005). 
Ro61-8048 is a competitive inhibitor of cerebral KMO and caused an increase in 
brain KYNA concentrations. It has been shown that a build up of this antagonistic 
intermediate could inhibit activation of brain NMDARs and decrease convulsion in 
hyperbaric oxygen (HBO)-induced seizure activity (Dale et al., 2000). Subsequent 
studies that provides both behavioural and biochemical evidence in support of 
the pharmacological interventions of KMO inhibition showed that Ro61-8048 was 
neuroprotective in rodent models of ischemia and sleeping sickness, and in 
model of levodopa-induced dyskinesias (movement disorders) in parkisonian 
monkeys. Mechanisms other than direct NMDA receptor blockade such as KYNA-
induced αNCR-mediated presynaptic inhibition of glutamate release may 
therefore have contributed to the therapeutic benefits of the compound 
(Gregoire et al., 2008, Cozzi et al., 1999, Rodgers et al., 2009). 
In this study, we evaluated the effects of KMO inhibition by a novel compound 
Ro61-8048, administered during the late gestation period of a rat model and 
later examine whether pharmacologically induced prenatal increases in brain 
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KYNA levels might interfere with developmentally essential neurological and 
glutamatergic functions. 
1.3 Neurodevelopmental Markers 
1.3.1 NMDA receptor subunit NR2A and NR2B 
In the vertebrate CNS the predominant mode of excitatory transmission is 
mediated by the neurotransmitter glutamate and the ionotropic glutamate 
receptors, which include N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors. The NMDA 
receptor plays critical roles in excitatory synaptic transmission, plasticity and 
excitotoxicity in the CNS and several researchers have indicated that activity-
dependent changes in excitatory synaptic function such as long term 
potentiation (LTP) and long term depression (LTD) are likely cellular correlates 
to learning and memory (Bliss and Collingridge, 1993). Research has shown that 
glutamate induced excitotoxic injury or overstimulation of the NMDA receptors  
may disturb normal glutamate neurotransmission in a variety of neurological 
disorders including Alzheimer‟s disease, ischemia, epileptic disorders and 
Huntington‟s disease (Bi and Sze, 2002, Engelhardt et al., 2007, Gascon et al., 
2008). On the other hand, NMDA receptor hypofunction is also implicated in 
other pathologies such as schizophrenia (Schmitt et al., 2007). Its involvement in 
diverse processes during CNS development and implication in various psychiatric 
disorders has made research enthralling around its function to govern synaptic 
trafficking and stabilization, and is crucial for our understanding of the various 
processes carried out by NMDA receptors (Bard and Groc, 2011). NMDA receptors 
are heteromeric ligand-gated ion channels assembled from two families of 
subunits, NR1 and one or more of the four closely related NR2 subunits. The 
mandatory NR1 subunit is encoded by a single gene that can generate eight 
splicing variant isoform and can be found ubiquitously throughout the brain. The 
NR2 subunit family is composed of NR2A, NR2B, NR2C and NR2D, which are 
encoded by four distinct genes and shows both regional and developmental 
variations in animals, with NR2B and NR2D subunits predominating in the 
neonatal brain, but over the course of development these are replaced by NR2A 
and in some regions NR2C as well as a mixture of NR2A and NR2B subunits. 
  41 
 
Another NMDA receptor subunit that has been characterized is known as NR3 and 
comprises two subtypes (A and B). Some studies showed variations in the NR2A 
and NR2B ratio which increases with age and this suggested that the composition 
of NMDA receptor complexes is dependent on the availability of the subunits (Al-
Hallaq et al., 2007). The functional and pharmacological properties of the 
receptors are determined by subunit composition, post-translational 
modification and its cellular localization in the CNS (Monyer et al., 1992, Monyer 
et al., 1994, Cull-Candy et al., 2001, Furukawa et al., 2005). Under normal 
circumstances, NMDA receptor activation occurs upon the binding of glutamate 
and glycine (co-agonist) to the NR2 and NR1 subunits, respectively (Figure 1). 
The channel is permeable to calcium ions and blocked by magnesium ions at 
resting potentials, which requires postsynaptic depolarization to release the 
magnesium block and to permit activation of NMDA receptor. Thus, the NMDA 
receptor is unique in that it requires membrane depolarization to remove the 
Mg2+ and also simultaneous co-activation by two ligands, glutamate/aspartate 
and glycine/D-serine, to be activated. In addition, the function of the receptor 
can also be modified through the use of extracellular Zn2+ and polyamines. The 
activated NMDA receptor is permeable to both K+ and Na+, but has particularly 
high permeability for Ca2+, which acts as a second messenger in the cell. The 
increased Ca2+, due to high glutamatergic activity, results in a permanent 
increase in synaptic efficacy. This process is known as long term potentiation 
(LTP) and is of critical importance for learning and memory. LTP is a form of 
synaptic plasticity and typically consists of a prolonged increase in synaptic 
transmission strength requiring NMDA receptor activation. The concept of NR2 
subunit-specific signals is also an ongoing area of interest within the synaptic 
plasticity field. It has been proposed that NR2A-containing NMDA receptors are 
preferentially involved in potentiation of synapses, while NR2B-containing NMDA 
receptors play a role principally in depression (Bartlett et al., 2007). However, 
there are contradicting findings that claimed a different point, in which NR2B-
containing NMDA receptors can mediate synaptic potentiation as well. Both 
excitoxicity and pro-survival effects of synaptic signalling can be mediated solely 
by NR2B-containing NMDA receptors (Martel et al., 2009). Growing evidence that 
indicates development in elucidating the molecular mechanisms underlying 
activation of NMDARs, driven by the availability of high resolution X-ray 
structures for the ligand binding domains, is likely to revitalize the search for 
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more effective and subtype-specific NMDA receptor  drugs (Cull-Candy et al. 
2001;Hunt and Castillo 0 AD;Hunt and Castillo 2012). 
Inappropriate activation of the receptor has been implicated in the pathogenesis 
of several disease states; in particular it has been related to the excessive 
calcium influx through the channel that can cause excitotoxicity. Thus, blockade 
of the NMDA receptors is considered neuroprotective. A number of 
pharmacological agents have been shown to distinguish the function of the 
various NMDA receptor subunits. Among competitive antagonists that exhibit 
moderate selectivity for certain subunit combinations are channel blockers such 
as MK-801(dizocipline), ketamine, phencyclidine and amantadine. Dopaminergic 
hyperactivity and behavioural characteristics of schizophrenia has been observed 
following treatment with non-competitive antagonists such as ketamine or 
phenylcyclidine. In electrophysiological experiments, administration of this 
NMDA receptor antagonists PCP, ketamine or MK-801 is associated with an 
increase in the firing rate and burst firing activity of ventral tegmental area 
(VTA) dopamine neurons (French et al., 1993). However, findings showed that 
chronic administration of PCP resulting in a reduced dopamine release in the 
prefrontal cortex and increased dopamine release in nucleus accumbens, which 
are conceivably related to negative symptoms and cognitive deficits consistently 
seen in schizophrenia. Administration of PCP also disrupted the prepulse 
inhibition, a behavioural model reflecting sensory gating deficits in 
schizophrenia (Jentsch and Roth, 1999).  Ifenprodil and haloperidol are non-
competitive antagonists that are effective at suppressing the activation of NMDA 
receptor. The usefulness of these drugs are however limited to their actions on 
normal synaptic transmission and sometimes accompanied by additional side 
effects. In addition, physiological metabolite in the brain known as kynurenic 
acid also serves as a broad antagonist at ionotropic glutamate receptors 
particularly those of NMDA type. In addition to its inhibition of AMPA and kainate 
receptor, it acts on the glycine recognition binding site of the NMDA receptor 
within low micromolar concentration and shared common characteristics with 
PCP and ketamine in which it could induce psychomimetic actions in human 
(Erhardt et al., 2007). 
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The mechanism linking NMDA receptor hypofunction and psychosis remains to be 
established. In view of the potential importance of the NMDA receptor in neural 
development, identifying the temporal regulation and spatial distribution of the 
various receptor subunits during development is really important in 
understanding the molecular mechanisms that modulate NMDA receptor 
signalling. Based on the receptor‟s unique properties, it is not surprising that 
NMDA receptor hypofunction or overstimulation can result in many cognitive 
defects and brain dysfunction, making these receptors prime therapeutic targets 
 
 
  
Figure 1-2 Schematic diagram of NMDA receptor with its binding sites 
Structure of NMDA receptor is tetraheteromeric combinations of NR1, NR2 and NR3 
subunits (diagram only for illustrative purposes). The NR1 subunit binds glycine and NR2 
subunits bind glutamate. The receptor is permeable to Na
+
, Ca
2+ 
and K
+
 and the pore 
channel is blocked by Mg
2+
 ions in a voltage-dependent manner. 
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1.3.2 Post synaptic density 95 (PSD95) 
Subunit composition determines multiple NMDA receptor function, including 
regulation of posttranslational modification, channel kinetics and downstream 
signalling involving intracellular protein association (Lin et al., 2004b). In this 
regards, the postsynaptic density-95 (PSD95), a scaffolding molecule abundantly 
enriched at glutamatergic synapses, is found to have important functions for the 
modulation of NMDA trafficking and stabilization on the cell surface. It belongs 
to the membrane-associated guanylate kinase (MAGUK) family which contains 
three PDZ(PSD-95/Dlg/ZO-1) domains, a SH3( Src Homology 3) domain and a 
carboxy terminal guanylate kinase domain (Kim and Sheng, 2004). Receptor 
subunit composition especially those of NMDA are dynamically remodelled during 
development and in response to neuronal activity and sensory experience.  Less 
is known about the remodelling process of the NMDA receptors, their scaffold 
and signalling proteins. Several studies have shown that this reorganization 
occurs by subunit insertion into the synaptic membrane or mobility between the 
synaptic and extrasynaptic membrane. Scaffolding molecules situated at synapse 
facilitate clustering of receptors by engaging in several potential interactions, 
thus changes to the content or organization of scaffold modules at the synapse 
could alter synaptic transmission by changing either receptor number or 
distribution. It has been shown that the induction of depression or potentiation 
is associated with scaffold modifications. Both AMPA and NMDA receptors 
mediate the postsynaptic effects of glutamate at central synapses and PSD95 
could regulate synaptic transmission and synaptic plasticity by selectively 
altering the ratio of synaptic responses mediated by both receptors (MacGillavry 
et al., 2011). Overexpression of PSD95 in the postnatal cultured brain slices has 
been found to change synaptic properties by increasing AMPA receptor-mediated 
synaptic transmission and favoured the emergence of LTD (Beique and Andrade, 
2003).  In addition, there is debatable evidence to show the cooperative role of 
protein-protein association between NR2 subunit domains and PSD95 (Delint-
ramirez et al., 2010). Alteration in the relationship between NMDA receptor 
subunit expression and PSD95 might be related to several neurodegenerative 
diseases. As PSD95 plays a fundamental role in the trafficking, membrane 
targeting and internalization of NMDA receptor complexes, changes to this 
molecule have been reported in many cases including depression, bipolar 
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disorder and schizophrenia (Kristiansen and Meador-Woodruff, 2005, Toro and 
Deakin, 2005). In a clinical sample of schizophrenic patients, alterations in the 
expression of PSD95 protein and mRNA  has been found in the brain, suggesting 
that glutamate dysfunction may involve changes in intracellular molecules 
critical for glutamate receptor-associated signal transduction (Clinton et al., 
2003, Clinton et al., 2006). Evidence also indicates that the amount of anchoring 
protein PSD95 in post-mortem brain of depressed subjects are elevated and 
highly correlated with an increase in NR2A subunit reactivity (Karolewicz et al., 
2009).  Many of these diseases may initially involve dysregulation of synaptic 
transmission resulting from defects in synaptic organization. 
1.3.3 Eprin type-A receptor 4 (EphA4) 
A signalling process that involves some form of cel-cell communication controls 
arrangement of cells in the correct locations and establishment of the correct 
pattern of neural connections. Several families of membrane-bound cell surface 
proteins have been implicated in the control of cell movement, which is crucial 
for tissue organization during development. These proteins include ligand-
receptor systems such as the Eph receptor tyrosine kinases. The Eph receptors 
represent the largest family of receptor protein tyrosine kinases and interact 
with their ligands, ephrins. The Eph receptors and ephrins are divided into two 
subclasses, A and B, based on their homologies, structures, and binding 
affinities. In general, EphA receptors (EphA1-EphA8) bind ephrin-A molecules 
(ephrinA1-ephrinA5) whereas the EphB receptors (EphB1-EphB6) bind ephrin-B 
molecules (ephrinB1-ephrinB3). However, one member of each class, 
namelyEphA4 and EphB2, can be activated by both types of ephrins. Most of the 
members of this family are predominantly expressed in the nervous system 
during development (Gale et al., 1996, Flanagan and Vanderhaegen, 1998). 
 
 Ephs and their cell surface-associated ephrin ligands are important regulators of 
central nervous system (CNS) development. They are involved in the guidance of 
axonal growth and establishment of neural connectivity (O'Leary and Wilkinson, 
1999). Several Eph receptors and ephrins are also widely expressed in the adult 
CNS, where they appear to regulate synaptic function and plasticity (Yamaguchi 
and Pasquele, 2004). Many of the Eph receptors may have overlapping functions 
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with each other. Protein expression pattern by in situ hybridization and 
immunohistochemistry have indicated the expression pattern and distribution of 
Eph proteins during development.  Eph receptors and ephrins are involved not 
only in early developmental processes, but also in the function of the adult 
organism. In the mature brain, Ephs regulate neuron–glia communication and 
play a role in synaptic plasticity. Among the subtypes, EphA4 shows widespread 
expression throughout the CNS starting from early development and persisting in 
the mature brain (Egea and Klein, 2007, Greferath et al., 2002, Pasquele, 2008).  
The genes for Eph receptors and ephrins have been recognized to be 
differentially expressed in various brain regions including the hippocampus. 
EphA4 is highly expressed in the hippocampus and is involved in hippocampal 
synaptic plasticity such as long-term potentiation, and therefore EphA4 may 
assume a role in hippocampus-dependent behaviour. EphA4 is expressed on 
dendritic spines of pyramidal neurons and axon terminals where it interacts with 
ephrin-A3 to shape dendritic spine morphology and inﬂuence synaptic plasticity.  
Eph dysfunction might be relevant to neuropsychiatric and neurodegenerative 
diseases characterized by abnormal dendritic spines in the hippocampus and 
cortex (Carmona et al., 2009, Glantz and Lewis, 2000, Yamaguchi and Pasquele, 
2004). Increasing evidence also implicates Eph family proteins in cancer in which 
interaction between Eph-ephrin regulate critical steps of tumour growth and 
metastasis. This signalling mainly affects the cell shape and also influences cell 
proliferation and cell fate determination, therefore it is speculated that Eph 
signalling could play some role in tumourigenesis as one of their possible 
consequences (Kaenal et al., 2012). 
1.3.4 Sonic hedgehog (SHH) 
Initially discovered in Drosophilia, sonic hedgehog (SHH) is a member of the 
hedgehog family of secreted signalling molecules, which is one of the key 
organizers of tissue patterning that undergo several post-translational 
modifications to gain full activity. SHH signalling plays a role in many 
developmental processes in different tissue types. SHH acts as a morphogen and 
induces distinct transcriptional programs on certain target cells depending on its 
concentration. In addition, this molecule also plays a central role in regulating 
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cell proliferation, differentiation and morphological patterning during 
embryogenesis. During development, interaction of various cell types is 
supported by many molecular events and inductive signals, secreted from within 
the CNS to ensure proper coordination and functional neuronal development 
(Marti and Bovolenta, 2002, Traiffort et al., 2010). The activation of SHH 
signalling is initiated by the binding of the SHH ligand to the membrane receptor 
Patched (Ptc), which relieves the Ptc-mediated inhibition of the transmembrane 
protein Smoothened (Smo). Activated Smo initiates an intracellular 
response/signalling cascade that ultimately drive the activation and nuclear 
translocation of the Gli transcription factor family member resulting in 
upregulation of hedgehog target genes including Gli and Ptc which respectively 
trigger the positive and negative feedback loops following pathway activation. 
This signalling cascade play fundamental roles during development and aberrant 
SHH signals underlie many disease conditions (Mullor et al., 2002, Ruiz i Altaba 
et al., 2002).  
Given the pathway‟s significant role in tissue patterning and cell number 
maintenance, events causing misregulation of the pathway are associated with 
certain cancers. Evidence that show the contribution of SHH signalling to 
tumourigenesis is emerging particularly in a model using in vitro approaches 
(Wicking et al., 1999). Inappropriate SHH signalling has been related to tumour 
initiation and maintenance, for instance in basal cell carcinoma (BCC) and 
medulloblastoma. The development of tumours such as those two above is 
through activation f the pathway by misregulation or mutation at the level of its 
receptor Ptc or Smo (Taipale and Beachy, 2001, Stecca and Ruiz i Altaba, 2005). 
These components are involved in the multi-molecular network which allows 
transduction of the SHH signal which drives proliferation and differentiation 
through the activation of specific downstream effectors of the pathway. 
Misregulation or mutations in the various elements of the SHH signalling pathway 
can lead to different phenotypes and also diseases associated with growth 
deregulation. As the pathway is involved in many developmental events, it will 
also be associated with human syndromes, defects and malformations (Mullor et 
al., 2002, Ming et al., 1998). 
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In addition to functioning in the embryo, SHH signalling components are 
expressed in postnatal and adult tissues, suggesting that they function in the 
mature organism. This molecule has been studied mainly in the context of 
development, however increasing evidence emerges to suggest the mitogenic 
properties of SHH are retained in the adulthood and promotes oncogenesis or 
tissue repair in different organs.  Regenerative roles of SHH in cell proliferation 
might be useful in a clinical setting, for instance in inflammation-induced events 
and mechanical brain injury.  Activation of the SHH pathway has been shown in 
response to hypoxia, in which protein levels of SHH and it transcription factor 
Gli1 were upregulated in the region of hippocampus after ischemic brain injury 
(Sims et al., 2009). 
1.3.5 Proliferating cell nuclear antigen (PCNA) 
The cell cycle is a complex and tightly regulated process by which cells duplicate 
their contents and divide into daughter cells. Among several cell cycle 
regulators, the most widely employed endogenous proliferation marker is 
Proliferating Cell Nuclear Antigen (PCNA). PCNA is a 36 kDa protein known as the 
cofactor of DNA polymerase delta and it is involved in cellular DNA replication 
and repair. Cell cycle analysis has shown that PCNA concentration increases 
rapidly in the mid-G1 phase of the cell cycle, immediately preceding the onset 
of DNA synthesis and remains elevated throughout the S phase, then rapidly 
decreases from the G2/M phase to G1 (Kurki et al., 1986). Because of its close 
relation to the cell cycle, PCNA is used as a physiological or pathological marker 
protein of proliferating cells (Valero et al., 2005, Valero et al., 2011). Due to the 
fact that PCNA is involved in DNA replication, it also has been used as a 
proliferation marker for adult hippocampal neurogenesis where 
immunoreactivity staining was detected in progenitor cells in the subgranular 
zone (SGZ) and also subventricular zone (SVZ) (Ino and Chiba, 2000). As DNA 
replication is a critical event in the cell; errors can be made and importantly 
unrepaired DNA damage upon DNA replication may give rise to mutations. Thus, 
many DNA repair proteins interact with the replication machinery in order to 
ensure efficient and reliable DNA duplication. Numerous studies have 
demonstrated correlations between dysregulation of the cell cycle machinery 
and neuronal death. Upregulation of cell cycle proteins occurs after various 
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injuries such as trauma and stroke and in neurodegenerative disease such as 
Alzheimer‟s disease. Failure of cell cycle regulation might be a common pathway 
of several neurodegenerative disorders and this implies that cell cycle regulation 
might be one of the promising therapeutic intervention in these disorders (Wang 
et al., 2009). 
1.3.6 Sex determining region of Y-chromosome related-HMG box 
2 (SOX2) 
The Sex determining region of Y-chromosome (SRY) was the first SOX gene 
identified in mammals where it was responsible for determination of the male 
sex. The transcription factor SOX2 is a member of the SOX gene family related to 
the SRY with the possession of a high-mobility group (HMG) DNA binding domain, 
thus the acronym SOX stands for  „SRY-related HMG box‟. Through protein 
sequence comparison analysis, 20 SOX genes have been identified and 
categorized into eight groups, A-H with two B subgroups, B1 and B2 (SOX14 and 
SOX21). The SOX-B group underwent further expansion into a B1 subgroup 
consists of three transcriptional activators SOX1, SOX2, SOX3 and a B2 subgroup 
of two transcriptional repressors SOX14 and SOX21. The SOX B group is of 
particular interest in that the five proteins are highly related and have 
overlapping expressions patterns (Lefebvre et al., 2007, Lovell-Badge, 2010, 
Wegner, 1999).  
Generally, SOX proteins have been characterized as important transcriptional 
regulators of many developmental processes during early embryogenesis and are 
essential for the maintenance of a stem/progenitor cell pool. SOX-B genes in 
particular perform a wide range of functions by a complex interplay with 
specific partner factors to regulate gene expression (Kamachi et al., 2000). They 
are best known for their role in pluripotency and self-renewal, but also have 
been implicated in specification, maturation and terminal differentiation events. 
The vertebrate group B genes, SOX1, SOX2 and SOX3, have similar effects and 
are expressed in progenitor cells from the early stages of CNS development. 
Reduction in the expression of one of these genes usually does not result in a 
significant loss of function, indicating possible compensation of function and 
functional redundancy appears to be confined to subgroup members. SOX2 is 
  50 
 
probably one of the best characterized SOX proteins and have a dynamic pattern 
of expression throughout embryogenesis and in a variety of adult tissue types. 
Expression of SOX2 is generally localized to proliferating and undifferentiated 
precursors whereby expression is downregulated with differentiation (Pevny and 
Placzek, 2005, Guth and Wegner, 2008). This is in line with evidence that 
constitutive expression of SOX2 inhibits neuronal differentiation resulting in the 
maintenance of progenitor characteristics (Graham et al., 2003). Thus, neural 
stem cells (NSC) at specific locations and developmental stages are especially 
vulnerable to SOX2 deficiency. It also should be noted that complex interactions 
of SOX2 with other regulatory factors explain its specificity of action and 
variably affect the outcome of SOX2 ablation or mutation (Pevny and Nicolis, 
2010). It has been shown that SOX2 and other regulatory transcriptional factors 
like Oct4 and Nanog collaborate to maintain pluripotency and self-renewal in 
human embryonic stem cell. Close interaction between this three factors was 
maintained in the undifferentiated state of the cells (Fong et al., 2008). In view 
of this, the use of mutant allelic series to decrease/abolish SOX2 function have 
shown that neural stem cells from SOX2 knockdown mice were unable to 
differentiate into mature neurons and undergo apoptosis, whereas homozygous 
SOX2 mutant embryos do not develop. Mutations of SOX2 in humans result in a 
complex syndrome anophthalmia, defective hippocampal development and 
cognitive defects and epilepsy, while mouse models reproduced a broad 
spectrum of severity mirroring those seen in human patients (Fantes et al., 
2003, Favaro et al., 2009, Sisodiya et al., 2006, Avilion et al., 2003).  
SOX2 represents a well known marker for NSC and progenitor cells in both 
embryonic and adult brains, the distribution of SOX2 expression in the adult 
brain can be found in areas where neurogenesis persists, the subventricular zone 
(SVZ) in the forebrain and in the subgranular zone (SGZ) of the hippocampal 
dentate gyrus (Komitova and Eriksson, 2004). Apart from their distribution in all 
stem/progenitor populations throughout CNS, SOX2 also can be found in other 
non-neural populations such as the stomach, lung, hair follicles and the tongue 
(Ishii et al., 1998, Okubo et al., 2006, Driskell et al., 2009). Functional 
redundancy roles within SOX-B1 factors in maintaining broad developmental 
processes and identity of NSC could be seen during neurogenesis stages. Their 
inhibition in the embryo results in premature differentiation of neural precursors 
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while mutation of SOX2 in the adult lead to a reduction in the proliferation of 
neural precursors suggesting a role for SOX2 in neural stem cell maintenance or 
proliferation in adult brains (Episkopou, 2005). Loss of its function induces cell 
cycle exit and advances neuronal differentiation. In a way, overexpression of 
SOX2 would inhibit neurogenesis while failing to reach a certain threshold of 
SOX2 expression by neural progenitors, render neurons unable to properly 
differentiate (Bylund et al., 2003, Avilion et al., 2003). In this regard, estimation 
of both precursors and early/immature neurons at an early differentiation stage 
could provide a basis indication of neurogenesis efficiency and support the 
notion that these regulatory proteins have important roles in several distinct 
cellular differentiation events (Suh et al., 2007). Recent evidence using 
immunoflourescence labelling revealed that SOX2 and nestin/vimentin are 
abundant in the primitive neuroepithelial tissue of immature teratomas of CNS 
which is indicative of  aggressive cellular populations (Phi et al., 2007). Higher 
levels of co-expression between SOX2 and nestin (with its expression indicative 
of pluripotency and regenerative potential) have also been noted in cultured 
melanoma cells. Nestin expression is enriched in metastatic tumors and support 
its role in cancer progression and over expression of both markers are 
anticipated, considering that the tumour-initiating cell is probably a cell of an 
immature nature in which SOX2 is reported to be expressed (Laga et al., 2011). 
In this regard, roles and involvement of SOX2 and other SOX family members in 
tumorigenesis need to be verified, as there are differences between cancerous 
stem-like cells and normal neural stem cells. To some extent, this marker has 
been shown to be involved in the regulation of cancer stem-like cells and the 
presence of this protein along with other regulatory factors seems to important 
for the self renewal capacity and the cell proliferation of cancer stem-like cells 
(Phi et al., 2008). 
1.3.7 Doublecortin (DCX) 
Normal brain development involves generation of new neurons throughout life 
and this process is known as neurogenesis, which is tightly regulated in the 
specialized areas of the mammalian brain. It is a continuous physiological 
process that occurs in the subventricular zone (SVZ) of the lateral ventricle and 
subgranular zone (SGZ) of the hippocampus dentate gyrus. These brain regions 
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contain a pool of neural progenitor cells (NPC) which are capable of producing 
new neurons (Eriksson et al., 1998, Rao et al., 2006). Normally in the adult, 
neurogenesis in these regions occurs at a low level; however, increased cell 
proliferation and the presence of newly generated neurons have been observed 
in various experimental setting including environmental enrichment, physical 
activity, learning and physiological stimulation (Valero et al., 2011). Increased 
neurogenesis may occur in response to neurodegenerative disease processes in 
the adult brain. In regards to this, an increased number of DCX positive cells 
have been observed following kainic acid-induced seizures in mice and in 
epileptic and Hungtington‟s patients, suggestive of a contribution for newborn 
neurons in the disease process (Liu et al., 2008, Jessberger et al., 2005).  
Conversely, formation of new neurons is decreased by age, stress and chronic 
exposure to adrenal steroids. This combined evidence suggest that the adult 
brain can respond to activity-induced stimulation and that differential effects in 
neurogenesis were likely as part of compensatory mechanisms or an attempt by 
the injured brain to replace lost cells.   
As part of detection techniques in neurogenesis, doublecortin (DCX) expression 
can be used as a candidate marker for adult neurogenesis.  DCX is a microtubule-
associated protein and its expression corresponds to the early stages of 
neurogenesis. The role of DCX in neuronal development has been associated with 
microtubule stabilization, nuclear translocation during neuronal migration and 
also axonal and dendritic maturation (Francis et al., 1999, Gleeson et al., 1999). 
In the adult brain, prominent DCX expression continues to persist within the two 
areas of continuous neurogenesis. The expression of DCX is observed in cell 
division as demonstrated by co-labeling with the cell cycle marker (Ki67) and 
downregulated once the cells became older and began expressing markers for 
mature neurons, thus reflecting a function for DCX in cell division apart from 
migration. Therefore it has been extensively incorporated as a specific marker of 
newly born or immature neurons in the adult and also to study the relation 
between neurogenesis, neurological and neurodegenerative disease processes in 
the search for putative therapeutic strategies (Brown et al., 2003, Verwer et al., 
2007). 
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1.3.8 Neuronal nuclear antigen (NeuN) 
It is known that adult neurogenesis consists of tightly regulated steps that 
include proliferation, cell cycle exit, differentiation and functional maturity. 
This process that takes place in the SGZ of the hippocampus and the SVZ of the 
lateral ventricles involves the development of late born neurons from early 
neural progenitors, committed neuronal precursors, immature migrating neurons 
to mature neurons. At various stages of this process, different specific molecules 
are expressed by the newly formed cells that can serve as a guide to monitor the 
different stages of neurogenesis (Halbach, 2007, Kempermann et al., 2004). The 
stability of new neurons might seem to be an important prerequisite for 
function, in which establishment of their synaptic contacts for signalling is 
functionally integrated. Neuronal nuclear antigen or NeuN is a neuron-specific 
nuclear protein that is identified by immunoreactivity with a monoclonal 
antibody, anti-NeuN. Because of its high specificity for most types of neuronal 
cells, and its cross reactivity with multiple species, anti-NeuN has gained 
widespread acceptance as a reliable tool to detect most postmitotic neuronal 
cell types in various research fields, notably neuroscience, developmental 
biology, stem cell research as well as diagnostic histopathology. Data from 
immunohistochemical analyses in embryonic and adult murine tissues have 
demonstrated the expression of NeuN throughout the nervous system, 
exclusively in postmitotic and differentiating neurons, and in association with 
terminal neuronal differentiation indicating permanent exit from the mitotic 
cycle. The staining using the antibody was primarily localized to nuclei, thus the 
name „Neuronal nuclei‟ and also in the neuronal cytoplasm of postmitotic 
neurons. Although most neuronal cell types express the antigen, there are some 
major cell types that do not, including cerebellar Purkinje cells, photoreceptor 
and mitral cells which are all devoid of staining (Mullen et al., 1992).  
NeuN has been used as a marker of postmitotic cells and labels both normal 
postmitotic neurons and newly generated postmitotic neurons in the 
hippocampus. Double labelling with other markers of neurogenesis such as 
doublecortin can help to distinguish between stages of this process and enable 
the monitoring the time course and fate of the newly generated cells in detail. 
Since the availability of markers to identify distinct stages of neurogenesis is 
diverse, a combination of different markers should allow for elucidation of the 
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roles and functions of adult neurogenesis under a variety of conditions, 
particularly in the context of neurological disorders (Halbach, 2011). The high 
specificity for neurons and the dense labeling of even small interneurons renders 
NeuN preparations suitable for semiautomated evaluation of neuronal densities 
by computer-assisted image analysis. In experimental animals, NeuN staining 
may be helpful for semiquantitative evaluation of neuronal cell loss in ischemic 
damage, epilepsy and neurodegenerative diseases. It has been proposed that a 
failure of adult hippocampal neurogenesis might partially underlie the 
pathogenesis of these conditions (Hartiga et al., 2009). 
1.3.9 Nuclear factor kappa-light-chain enhancer of activated B 
cells (NFB) 
The NFB proteins are a family of inducible transcription factors that activate a 
variety of cellular genes involved in control of the inflammatory response and in 
regulating cellular growth and survival.  The NFB signaling pathway is also 
implicated in control of neuronal death and survival (Kaltschmidt et al., 2005). 
The DNA binding, nuclear form of NFB is composed of one 50 kDa (p50) and one 
65 kDa (p65) subunit, which independently bind to DNA and potentially activate 
transcription. An inhibitory subunit called IB protein is required for the 
inducible activation of NFB. In complex with IB, NFB is present in the 
cytoplasm of non-stimulated cells. Extracellular stimulation causes 
phosphorylation of IB and allows translocation of NFB to the nucleus which 
then generally leads to an increase in the expression of target genes (Baeuerle 
and Henkel, 1994, O'Neill and Kaltschmidt, 1997). In most cell types, NFB 
mediates an early pathogenic response by coordinating the initiation of 
transcription of numerous genes encoding cytokines, chemokines and cell 
adhesion molecules. Stimuli that activate the preexisting factor mostly represent 
pathogenic conditions, such as viruses, bacteria and the inflammatory cytokines 
interleukin-1 (IL-1) and tumor necrosis factor. Upon stimulation, 
posttranslational activation of the TF directs its participation in nuclear signaling 
and activates multiple target genes which almost entirely encode proteins 
relevant for pathogen defense (Baeuerle and Henkel, 1994).  
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Immunocytochemical studies in cryosection from normal mouse tissue showed a 
wide distribution of NFB subunits in neurons and glial cells in the CNS, which 
are predominantly enriched in the nuclei of most cells. In accordance with 
ubiquitous distribution either detected as an inducible form(residing in the 
cytoplasm and associated with IB) or constitutive forms at low amounts (found 
in the nucleus free of IB and capable of binding DNA), suggesting NFB 
participation during synaptic transmission (Kaltschmidt et al., 1993). 
Immunostaining evidence indicates the presence of NFB in synaptosomes of the 
cerebral cortex and striatum. Besides, the distribution of NFB in the brain has 
also been noted  in the cytoplasm, which suggest that the factor may also be 
activated in response to postsynaptic stimulation, and has therefore the 
potential to participate in fundamental brain processes (Kaltschmidt et al., 
1993). While NFB is widely expressed in most cell types, in the nervous system 
the constitutively activated NFB (nuclear) was restricted to a subset of neurons 
in the cortex and hippocampus, suggesting that in neurons a physiological, 
endogenous stimulus was controlling the activity of the transcription factor 
(O'Neill and Kaltschmidt, 1997, Kaltschmidt et al., 2005).  
NFB is also expressed in the cerebellum, mainly concentrated in the cytoplasm 
areas that may represent postsynaptic regions. On this basis, the effect of 
neurotransmitters such as glutamate and NMDA has been tested in vitro on the 
immunoreactivity of NFB distribution. The data indicated that activation of 
NFB binding activity coincided with nuclear localization following glutamate 
and NMDA treatment in granular neurons, suggesting the involvement of NMDAR 
activation. Stimulation of glutamate receptors and elevation of intracellular 
calcium levels, indicative of membrane depolarization, lead to activation of 
NFB in hippocampal pyramidal neurons and cerebellar granule neurons 
(Guerrini et al., 1995). In addition, a robust increase in NFB p65 mRNA was 
observed after long term potentiation in vivo, which then leads to increased DNA 
binding activity. This activation may contribute to alterations in target gene 
expression that accompany activity-dependent synaptic plasticity (Meberg et al., 
1996). NFB activation in the hippocampus following passive avoidance learning 
tasks have also been observed which suggest roles for this TF in directing the 
synaptic reorganization which is required for long term memory formation. As an 
abundant TF in the brain, inappropriate activation can cause the expression of 
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genes whose products interfere with normal brain function or cause the immune 
system to target brain cells. Overall, alongside its well-known roles in immune 
and inflammatory responses, NFB family members also occupy an important 
role in neuronal processes including the regulation of the efficacy of synaptic 
transmission in the CNS. Further characterization of signaling mechanisms for 
this TF could shed light on physiological and pathological consequences. In 
addition it also provides more conclusive information about the relationship of 
these signaling processes in the CNS (O'Sullivan et al., 2010). 
1.3.10 Cyclooxygenase 2 (COX2) 
The discovery of isoforms of cyclooxygenase (COX) enzyme with distinct 
distribution and regulation has created new interest in the function of COX 
isoforms in the CNS as well as in other areas. The COX enzymes catalyze the 
conversion of arachidonic acid to prostaglandins (PGs) and other lipid mediators. 
COX exists in two related isoforms: COX1 and COX2. COX1 is constitutively 
expressed in most tissues where it catalyzes PG synthesis and its role is to 
support physiologic functions and maintaining homeostasis.  In contrast, the 
inducible form COX2 is tightly regulated and is predominantly induced by 
endotoxins, cytokines and growth factors. In addition to proinflammatory 
cytokines, oxidative stress and lipid peroxidation have also been reported to be 
inducers of COX2 gene expression (O'Banion, 1999). Remarkably, COX2 is 
continuously expressed within a distinct population of neurons in the brain, 
mainly in hippocampal and cortical glutamatergic neurons where it has a pivotal 
role in synaptic activity and long term synaptic plasticity. The pattern of COX2 
immunostaining in brains of normal rats shows that under physiological 
conditions, COX2 is expressed in a discrete subset of neurons. Intensity of COX2 
staining within a population of neurons represents induction of COX2 expression 
in response to natural excitatory synaptic activity (Breder et al., 1995, Yamagata 
et al., 1993).  In general agreement with an earlier study, localization of COX2 
in the adult rat brain was consistently found in neuronal dendrites and spines of 
excitatory pyramidal neurons in the cerebral cortex and granule cells neurons in 
the dentate gyrus, CA3 and hilus of the hippocampus. Because of higher levels of 
COX2 expression in hippocampal and cortical neurons involved in cognitive 
function, this has led to speculation regarding the involvement of COX2 in neural 
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plasticity (Yang and Chen, 2008).  In view of an active role for dendritic spines in 
shaping neuronal activity and synaptic signalling, this characteristic localization 
indicate a role for COX2 in cellular signalling of specific populations of excitatory 
neurons (Kaufmann et al., 1996). Due to this isoform being induced in response 
to inflammatory stimuli, COX2 has been linked to anti-inflammatory effects and 
non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to 
demonstrate a neuroprotective effect at least in part by an inhibition of the 
inflammatory reactions including increased COX2 expression. Thus, this makes 
the COX2 isoform an appropriate pharmacological target for anti-inflammatory 
therapy (Kaufmann et al., 1997). 
One of the most intensely studied aspects of COX2 is its role in inflammation and 
secondary brain injury. The inflammatory reaction in the brain associated with 
most acute or chronic neurodegenerative diseases is often termed 
neuroinflammation, which is characterized by a glial response prior to significant 
losses of neurons.  Neuroinflammation consists mainly of an innate immune 
response involving activation of glial cells and central production of cytokines, 
chemokines, prostaglandins (PGs), complement cascade proteins and reactive 
oxygen species in response to a central or peripheral immune challenge. COX2 is 
potentially one of the proteins that participate in the progression of many 
neurodegenerative diseases, possibly by propagation of inflammatory response 
elements and oxidative stress (Choi and Bosetti, 2009). In an acute phase 
response murine model, robust expression of mRNA was induced  in perivascular 
cells throughout the brain after systemic administration of bacterial LPS (Breder 
and Saper, 1996). Previous reports have demonstrated that expression of COX 
enzymes in a subset of neurons as evidenced by mRNA levels and immnostaining 
profiles has been associated with glutamatergic neurotransmission. In this 
regard, COX2 expression in kainate models of status epilepticus has been used as 
marker for glutamatergic activation in the epileptic brain. COX2 was profoundly 
induced by seizures and changes in expression within selected brain regions have 
been reported (Joseph et al., 2006).   
Compelling evidence supports the claim that inflammatory mechanisms are likely 
to contribute to some neurodegenerative conditions, such as in Parkinson‟s 
disease (PD), amyotrophic lateral sclerosis (ALS) and Alzheimer‟s disease (AD). In 
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keeping with this suggestion, inflammatory processes associated with increased 
expression of the enzyme COX2 and elevated levels of prostaglandin E2 (PGE2) 
have been implicated in the cascade of deleterious events leading to 
neurodegeneration in various pathological settings. Upregulation of COX enzymes 
may influence cellular integrity by contributing to toxicity, degenerative 
processes and cell death culminating in excitotoxic damage (Almer et al., 2001, 
Teisman et al., 2003, Nogawa et al., 2003, Ho et al., 1999). Several lines of 
research have noted an inflammatory response in the brain of schizophrenic 
patients in response to injuries. Neuronal damage and the inflammation 
response described in schizophrenia have been considered as a consequence 
from the production of molecules that exclusively mediate immune function 
(Yokota et al., 2004). In schizophrenia, COX2 inhibition showed beneficial 
effects mostly in the early stages of the disease. As COX2 is expressed in regions 
critically involved in cognitive function and memory, an effect on cognition 
could also have been expected from the animal data of COX2 inhibitors in which 
COX2 inhibition directly attenuates inflammation-induced inhibition of long-term 
potentiation (LTP), an animal model of cognition. Animals with genetic over-
expression of COX2 showed more prominent deficits in cognition, which were 
attenuated by a selective COX2 inhibitor (Muller et al., 2005). 
  
1.4  Research aims 
Since many infections during pregnancy in humans are caused by viruses, 
poly(I:C) has been administered during the late phases of gestation to simulate 
maternal immune activation response in the rat model. In the present study, we 
first set out to address this issue and undertook western blot analysis of virally 
exposed brains to gain insight into regulation of several molecules that play key 
roles in various neurodevelopmental process including neurogenesis, axonal 
guidance, synapse formation amongst many others. In another set of 
experiments, we employed a known KMO inhibitor (novel compound Ro61-8048) 
as a modulator of kynurenine metabolism during gestation to address the 
question of whether the physiological activity of the kynurenine pathway would 
have an impact in the developing brain. The general goal of the research project 
was to evaluate the involvement of the kynurenine pathway during brain 
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development. To this end, we provoked a selective increase of KYNA content in 
the brain to better understand its possible role in the modulation of NMDAR 
mediated signalling and transmission. We compared protein expression in brains 
from rat pups treated with Ro61-8048 in utero to those from saline-treated 
controls. Cellular localization and composition (using immunocytochemistry) of 
several neurogenesis markers in the hippocampus of mature offspring was also 
included. In addition, to examine changes in neuronal morphology on selected 
populations of cells in the hippocampus, dendritic architecture and the 
complexity of granule cells were examined using Golgi-Cox impregnation study.
 
 
2 Research materials & methodology 
2.1 Prenatal animal models set up 
All procedures on animal work was performed in accordance with the guidance 
established by the Animal (Scientific Procedure) Act 1986 and has been approved 
by the University of Glasgow Scientific Ethics Committee. Wistar rats were 
mated at about an age of 3 months and the first day after the occurrence of 
vaginal plug (an indication of copulation) was defined as day one of pregnancy. 
The pregnant dams were housed alone under pathogen-free environmental 
conditions at a constant temperature with food and water ad libitum.  
2.1.1 Prenatal immune challenge 
In the rat model prenatal poly(I:C) model (Figure 2-1), pregnant dams were 
exposed to the immunological manipulation at a specific gestational stage and 
the brain and neurochemical analyses of the prenatal immunological 
manipulation were then compared in the resulting offspring relative to offspring 
born to vehicle-treated  control mothers. Commercially available potassium salt 
poly(I:C) (P0913: Sigma (Poole, UK)) was dissolved in sterile isotonic 0.9% w/v 
NaCl solution and then heated up to 50oC to allow for complete solubility. The 
mixture was allowed to cool to room temperature to allow re-annealing of the 
double-stranded RNA. Solution of the drug for the treatment was sterilised and 
aliquoted in small sterilised tube and kept in -20oC until further use.  The 
desired dosage for the injection was 10mg/kg and it has been established in 
previous experiments in the lab that the dose could be given to pregnant dams 
during the last seven days of gestation with no signs of stress, behavioural 
changes or abnormal behaviour towards the neonatal pups after birth.  
2.1.1.1 Experiment 1: Acute study on embryonic day 18 (E18) 
For the acute study, gestational day 18 timed-pregnant rats were injected i.p. 
with 10mg/kg of poly(I:C) and saline (0.9% NaCl). This experiment was set up for 
the purpose of assessing the acute effects of maternal poly(I:C) administration 
on the cytokine and certain chemokine levels in maternal blood. After the 
  61 
 
injections the animals were left undisturbed for 5 hours and then anesthetized 
with an overdose of sodium pentobarbital and decapitated after blood was 
obtained by cardiac puncture. The blood was collected in heparinised vacutainer 
tube and kept in ice cold. The animals were dissected and the uterine horn 
containing embryonic day 18 pups were surgically removed. Placenta, fetal‟s 
whole brain and body were dissected and immediately frozen on dry ice. The 
collected whole brains were used in the western blot analysis. Maternal liver, 
thymus and brain were also dissected for further analysis i.e. HPLC analysis.  
2.1.1.2 Experiment 2: Postnatal day 21 (P21) 
For gestational poly(I:C) administration and vehicle treatment, groups of 
pregnant dams were  administered intraperitoneally (i.p.) at the dose indicated 
on days E14, E16 and E18 in order to extend the temporal impact of maternal 
immune activation on the embryos, with no apparent ill effects on the dam or 
her behaviour towards her litter after birth. The selected gestational window in 
this study corresponds roughly to the middle second to early third trimester of 
human pregnancy, with respect to developmental biology and comparable 
percentage of gestation in humans (Clancy et al., 2001). The selection of the 
time window was based on the intention to widen the time window over which 
potential interference with brain development could occur, because 
examination of the brains would not occur until at least the time of weaning at 
postnatal day 21 (P21). The long term effects of prenatal poly(I:C) exposure 
would be captured at around this postnatal age because it has been reported 
that the full spectrum of prenatal poly(I:C)-induced behavioral, cognitive and 
pharmacological abnormalities emerges only after the postpubertal stage of 
development (Zuckerman et al., 2003, Zuckerman and Weiner, 2005). Group of 
pregnant dams were injected on E14, 16 and 18 between 9am and 11am to 
minimise variation in responses. Our preliminary works showed that the selected 
dosage at 10mg/kg could be used repeatedly without producing signs of sickness 
behaviour in the pregnant dam. Control females were injected with the same 
volume of 0.9% NaCl. Gestation was allowed to proceed normally and the 
offspring were undisturbed until weaning on P21 when they were taken from the 
home cage for euthanasia followed by removal of the brain.  Each brain was 
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divided into the two cerebral hemispheres and frozen immediately on dry ice 
before being transferred to storage at -80ºC until required for analysis.  
Group of pregnant rats
P0 P21
E21E0
E14 E16 E18 Group of 
litters
saline  or poly(I:C) (10mg/kg)
5 hour post-injectionE0 E18
saline or poly(I:C) (10mg/kg)
 
Figure 2-1 Schematic diagram of experimental set up for prenatal immune challenge 
 
2.1.2 Prenatal modulation of kynurenine pathway 
Compound 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulphonamide 
(Ro61-8048) (Rover et al., 1997) was prepared at the dose of 100mg/kg by 
solubilising in a small volume of 60mM NaOH-NaCl and adjusted to pH 7.5 by 
adding 1M NaOH or 1M HCl.  Mixture was vortexed and checked for pH every 
time small volumes of 1M NaOH or 1M HCl were added. After the required pH has 
been reached, the volume of 1M NaOH or 1M HCl was calculated and 60mM 
NaOH-NaCl was added to make up the total volume. Solution of the drug for the 
treatment was sterilised and aliquoted in small sterilised tube and kept in -20oC 
until further use (Figure 2-2). 
2.1.2.1 Experiment 1: Acute study on embryonic day 18 (E18) 
This experiment was set up for the purpose of assessing the immediate effects of 
gestational modulation of kynurenine pathway on the levels of protein 
expression in the embryo brains measured 5 h and 24 h post administration. In 
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addition, the objective was to demonstrate the effect of the selected dosage in 
producing changes in the levels of several metabolites of kynurenine pathway.  
For this purpose, gestational day 18 timed-pregnant rats were assigned to 
receive i.p. injections of the following treatment regimens: (1) 5 h group: saline 
(0.9% NaCl) and (2) 5 h group: 100mg/kg Ro61-8048. After the injections the 
animals were left undisturbed for 5 hours and then anesthetized with an 
overdose of sodium pentobarbital and decapitated after blood was obtained by 
cardiac puncture. The blood was collected in heparinised vacutainer tube and 
kept in ice cold. The animals were dissected and the uterine horn containing 
embryonic day 18 pups were surgically removed. Placenta, foetal‟s whole brain 
and body were dissected and immediately frozen on dry ice.  In another set of 
experiment, two groups of pregnant rats were injected at gestational day 18 
with single injection of vehicle solution and compound Ro61-8048 (100mg/kg), 
respectively. Twenty four hours later, the animals were then sacrificed and 
dissected to obtain foetal whole brain and body, placenta along with mother‟s 
liver, brain and thymus. The levels of kynurenine and kynurenic acid from were 
measured by high performance liquid chromatography (HPLC) with 
electrochemical detection. HPLC analysis was solely performed by Dr Forrest 
(Forrest et al., 2013a).  
2.1.2.2 Experiment 2: Postnatal day 21 (P21) 
For gestational treatment, groups of pregnant dams were  administered 
intraperitoneally (i.p.) with compound Ro61-8048 (100mg/kg) at the dose 
indicated on days E14, E16 and E18 in order to extend the temporal impact of 
kynurenine pathway modulation on the embryos, with no apparent ill effects on 
the dam or her behaviour towards her litter after birth. Group of pregnant dams 
were injected on E14, 16 and 18 between 9am and 11am to minimise variation in 
responses. Control females were injected with the same volume of 0.9% NaCl. 
Gestation was allowed to proceed normally and the offspring were undisturbed 
until weaning on P21 when they were taken from the home cage for euthanasia 
followed by removal of the brain. The long term effects of pharmacological 
manipulation of kynurenine pathway during gestation would be studied at 
juvenile age as to capture any maturational delay onset of the pharmacological 
abnormalities. Each brain was divided into the two cerebral hemispheres and 
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frozen immediately on dry ice before being transferred to storage at -80ºC until 
required for analysis.  
2.1.2.3 Experiment 3: Postnatal day 60 (P60) 
In a separate experiment to evaluate the extended effect of prenatal exposure 
of compound Ro61-8048 in more mature animal, the neonates were being 
allowed to survive until around 60 days of age (young adult) at which time all 
litters were euthanized and their brains were removed. It is around this time of 
age that many studies have shown behavioral changes resulting from prenatal 
infection of mimetic agents. This study intended to explore the long term 
functional consequences on pharmacological activities of the brain.The brain 
was then sectioned into four main regions i.e hippocampus, cerebellum, cortex 
and midbrain and preserved for further western blot (WB) analysis. Hippocampus 
slices were prepared and examined for baseline excitability and other 
electrophysiological analysis including excitatory synaptic potentials. 
Electrophysiological analysis was exclusively performed by Prof Stone. Slices 
were then kept frozen for examination of the selected panel of neurochemical 
markers in order to detect differences in the CA1 region correlating with the 
electrophysiological responses. 
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Group of pregnant rats
5 hour post-injectionE0
E18
24 hour post-
injection
E0 E18
P0
E0
E14 E16 E18
E21 Group of litters
P21 P60
Saline or RO61-8048 (100mg/kg)
Saline or RO61-8048 (100mg/kg)
Saline or RO61-8048 (100mg/kg)
 
 
Figure 2-2 Schematic diagram of prenatal modulation of kynurenine pathway 
 
 
Each member of a litter from all set of experiments was treated identically, with 
whole litters being taken at the same time so that no animal would experience 
the possible trauma of losing littermates while themselves surviving to a later 
date. This protocol also ensured that changes of maternal behavior caused by 
the removal of some pups could not affect the development of survivors. Two 
pups from three separate litters (n=6) were used for each treatment and control 
group; there were at least 3 samples per treatment and control groups to 
minimize any litter effects. For postnatal day 21 experiment and acute study, 
three male and three female pups from three separate litters were used for the 
treatment and control groups. Postnatal age of 21 day in developmental rodent 
model was chosen as to represent pre-pubertal (adolescence) stages of 
development whereas postnatal day 60 is typically regarded as the post-pubertal 
(adulthood) life span. 
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2.2 General materials 
2.2.1 Solutions and reagents 
Solutions used in the main experiments including protein assay, gel 
electrophoresis and immunocytochemistry are shown in Table 2-1, Table 2-2 and 
Table 2-3, respectively. All chemicals listed in this section were supplied from 
BDH Laboratories, Fischer Scientific or Sigma-Aldrich unless otherwise stated. 
Solutions Chemical compositions 
RIPA buffer 
50mMTris, 150mM NaCl, 0.1% SDS, 0.5% Triton X-100, 
1% IGEPAL  
BSA standard  20mg/100ml in dH2O (Albumin Bovine A2153) 
50% BIORAD reagent 
5ml BIORAD Protein Assay (final volume 10ml of 
dH2O) 
Table 2-1 Protein assay solutions and reagents 
 
 
 
 
Solutions Chemical compositions 
Mix running buffer 
50ml NuPAGE MOPS/MEPS Running Buffer (Life 
Technologies,UK), 950ml dH2O, 0.5 ml antioxidant 
Transfer buffer 
50ml 20X NuPAGE Transfer Buffer (Life Technologies, 
UK), 1ml antioxidant, 100ml Methanol (Fischer 
Scientific), 850ml dH2O 
10x stock Tris-buffered 
saline (TBS) 
200mM Tris, 1.36M NaCl in 2000ml dH2O 
Tris-buffered saline (TBS) 
20mM Tris, 136mM NaCl, 0.05% Tween-20 (adjusted 
to pH 7.6 with 50% HCl) 
5% Milk-TBST 5g skimmed milk (Marvel) in 100ml TBST ph 7.6 
Table 2-2 General solutions used for gel electrophoresis and western blotting 
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Solutions Chemical compositions 
0.2M phosphate buffer 
(PB) 
Solution A: 37.44g of NaH2PO4 (2H2O) in 1200ml 
dH2O.Solution B: 84.90g of Na2HPO4 in 3000ml dH2O. 
Mix thoroughly 1120ml solution A with 2880ml 
solution B and adjust pH to 7.4  
0.3M NaCl buffered 
saline (PBS) 
100ml 0.2M PB, 1900ml dH2O, 36g NaCl 
Mammalian Ringer 
solution 
45g NaCl, 2g KCl, 1.25g CaCl, 0.025g MgCl, 2.5g 
NaHCO3, 0.25g NaH2PO4, 5 g glucose in 5000ml dH2O 
4% Paraformaldehyde 
40g paraformaldehyde (6005, SIGMA), 400ml dH2O 
(preheat to 68oC),500ml 0.2M PB and  a few drop of 
NaOH 
Table 2-3 General solutions used for immunocytochemistry 
 
 
2.2.2 Drugs  
The drugs used in experiments are listed in Table 2-4. 
Final 
concentration 
drugs 
Quantity Supplier 
0.9 % Saline 0.9g NaCl dissolved in dH2O BDH Laboratories 
10mg/kg poly(I:C) 10mg dissolved in 1ml of sterile 0.9% 
saline and heated to 50oC 
P0913, Sigma-
Aldrich  
60mM NaOH-NaCl 240mg NaOH dissolved in 100ml of 
sterile 0.9% NaCl 
BDH Laboratories 
100mg/kg  
Ro61-8048 
300mg dissolved in 3ml of 60mM NaOH-
NaCl, adjusted to pH 7.5 using HCl, 
sterilised and aliquoted 
Synthesized by F. 
Hoffmann-La 
Roche Ltd. 
Table 2-4 Drugs solutions 
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2.3 Western blot (WB) analysis 
The western blot (WB) or also known as immunoblot is a semi-quantitative 
method to detect a specific protein in biological samples, for example tissue 
homogenate or extract. Generally, it involves multistep processes in which 
samples are first separated by LDS-PAGE (lithium dodecyl sulphate- 
polyacrylamide gel electrophoresis) and then the separated protein are 
transferred to a membrane where they are incubated with an antibody specific 
which binds to the protein band immobilized on the membrane (target protein). 
The antibody is then visualized with a detection system that is usually based on 
a secondary protein binding which is linked to a colour-yielding reaction.  
2.3.1 Sample preparation 
The preparation of the sample for protein analysis is the first step in the 
complete workflow of WB. The main principle is to ensure that the sample is in 
the best possible environment for analysis.  Following prenatal administration of 
compound, the offspring for each treatment group were killed by overdose 
sodium pentobarbital (Euthatal) followed by decapitation. The brains were then 
quickly removed and separated into two hemispheres. Each hemisphere from the 
same animal was wrapped in a foil and marked before being stored at -80oC for 
later use (for experiment 2). For experiment 3 of postnatal day 60, the brain was 
removed rapidly from the skull and rinsed with cold artificial cerebro-spinal fluid 
(ACSF) solution. The brain area under study was then separated into four main 
region of interest which constitute of cerebellum, cortex, midbrain and 
hippocampus.  Fresh dissection of brain tissue has the advantage that particular 
brain regions can easily be dissected based on visual information, such as 
differences in colour of adjacent tissue and on the natural anatomical 
boundaries of certain regions present in the brain. Examples of these are the 
cerebellum that can be easily taken off from the medulla and pons and are 
distinct in colour, and the hippocampus that differs from the occipital cortex by 
colour and loosely connected to the thalamus by the fornix. For embryonic brain 
dissection, the impregnated rats (E18) from respective treatment groups were 
killed with overdose injection of Euthatal and a small incision was made over the 
belly before a string of embryos were pulled out and transferred to a petri dish 
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on ice filled with ice-cold PBS. The embryos were dissected out of the uterus 
wall and removed all the membranes including visceral yolk sac. The head was 
separated from the rest of the body before being wrapped and kept frozen at -
80oC. Important consideration for successful sample preparation for the 
subsequent assay analysis includes maintaining the sample at low temperature 
throughout the processes and minimizing elapsed time in between procedure 
(time from sacrificing an animal to homogenization of the sample) in which all 
procedure steps were kept constant and as short as possible. 
Careful control of presence of the target protein in the starting material and its 
preparation and storage under non-degrading conditions is essential in preserving 
the epitope abundance for antibody recognition. Standard and validated method 
for the extraction purpose has been employed to provide good yields and 
consistent results. For this purpose, brain tissues were lysed/homogenized using 
a mechanical homogenizer in RIPA buffer containing 60mg TRIS, 87.6mg NaCl, 
10mg SDS, 50μl TRITON X-100, 100 μl IGEPAL, 9850 μl distilled water to 
encourage lysis of tissues and cells and to solublize proteins.The process of 
proteolysis and denaturation of protein in the lysate were slowed down by 
adding one tablet of protease inhibitor (Protease Inhibitor Cocktail tablets- 
CompleteTM , Boehringer Mannheim GmBH, Mannheim, Germany).Protease 
inhibitors are often added to prevent the digestion of the sample by its own 
enzyme. Then, the whole lysate was centrifuged at 13 000 rpm for 5 minutes at 
4oC and finally the supernatant was aspirated and aliquots kept at -80 oC prior to 
use. 
2.3.2 Protein concentration 
Prior to western blot analysis, determination of protein concentration in each 
sample was performed using the BIORAD protein assay system. Protein 
concentration in the brain homogenates (half brain or regional area of the brain) 
for western blot analysis was normalised against a standard curve of a known 
protein content, Bovine Serum Albumin (BSA; Sigma-Aldrich) dissolved in an 
appropriate volume of dH2O to give a concentration range of 0,0.25,0.50,1.0,1.5 
and 2.0 (mg/ml). Then, brain samples dilution was prepared by diluting it twice 
with dH2O at the ration of 1:10 and 1:100 (only hippocampal lysate was straight 
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diluted into 1:100). Bio-Rad protein reagent (Bio-Rad laboratories, UK) was 
diluted 1:1 ratio before mixed thoroughly with each BSA standard reagents and 
brain samples. Subsequently, each BSA standard and samples was pipetted in 
duplicate into 96-well plate. An automated plate reader Opsys MR (Dynex 
Technologies) was used to measure optical density at 595nm using the 
BIORAD.assay program in Revelation Quicklink software (Dynex Technologies, 
version 4.25). A linear curve fit was plotted using the reading from the BSA 
standard concentration and was used to quantify the protein content of unknown 
brain lysates. A calibration curve was established each time a protein assay was 
performed with freshly prepared BSA standard dilutions. Using the standard 
curve, the concentration of each sample was determined according to its 
absorbance by interpolation.   The measurements for each brain lysate from the 
program were then multiplied by 10 (hippocampal lysates were multiplied by 
100) to compensate for the dilution factor applied during the sample 
preparation. Protein concentrations were then normalised to load 20-30 μg of 
protein onto the gels.  
2.3.3 Protein separation 
To characterize immunodetection of the antibody (refer Table 2-5), western 
blotting was carried out following procedures already established in the lab. 
Prior to the electrophoresis process, proteins from the lysate of brain samples 
(65% protein sample, 25% LDS sample buffer and 10% reducing agent) was 
denatured by centrifugation and heating at 2000rpm for 2 minutes at 4oC and for 
10 minutes at 70oC, respectively. Equal amount of proteins from each sample 
(20-30 μg) was loaded into wells in the NuPAGE 4-12% (1.0mm) Bis-Tris  
polyacrylamide gel 15 lanes (Invitrogen: Life Technologies, Paisley, UK). The 
first lane on each gel usually reserved for a molecular weight marker: a mixture 
of proteins with defined molecular weight (SeeBlue pre-stained standard (Life 
Technologies, Paisley, UK). When voltage is applied along the gel, proteins 
migrate at different speed and separate into bands based upon size and charge 
(electrophoretic mobilities), characteristically smaller proteins migrate through 
the gel faster than larger proteins. Proteins in the sample travel only in the 
dimension along the gel for most blots. The separation of the protein which 
employs polyacrylamide gels and buffers loaded with lithium dodecyl sulphate 
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(LDS) and treated with 10% reducing agents to sufficient final concentration was 
electrophoresed through 4-12% Bis-Tris NuPAGE gel in 20X NuPAGE  MOPS/MEPS 
running buffer (Life Technologies,UK) at 150V for 100 minutes. 
2.3.4 Protein transfer and blocking 
The separated protein then electrophoretically transferred onto a hydrophobic 
Invitrolon poly(vinylidene difluoride) (PVDF) membranes (Invitrogen: Life 
Technologies, Paisley, UK). For this procedure, the stacking gel removed from 
the separating gel and the back of the gel was placed on a wet filter paper 
which had been soaked with transfer buffer. Thereafter the PVDF membrane was 
applied on top of the gel (the membrane was activated by dipping into 
methanol). Each layer was gently pressed using a small roller before the next 
was applied to remove any air bubbles. The sandwich of membrane PVDF, gel, 
filter papers and appropriate number of fiber pads were then stacked to gel 
holder cassette and put in the Novex tank cell. Finally, the cell was filled up 
with transfer buffer and an electric current at 220mAmp, 30 volts for 80 minutes 
was applied to the gel so that the proteins transfer through the gel and onto the 
membrane in the same pattern as they separated on the gel. To check the 
uniformity and transfer efficiency of the transfer, membranes were rinsed in 
dH2O and stained with Ponceau red dye (Sigma-Aldrich). Following transfer, 
membranes were placed in blocking solution containing 5% (w/v) dried skimmed 
milk powder (Marvel) diluted in Tris-buffered saline containing 0.05% Tween-20 
(TBST) for at least one hour. The step was included to minimize background 
staining due to non-specific binding of the antibody by saturating the proteins 
which are not reacting with the antibody. The accessibility of a target protein 
for primary antibody  is achieved by washing the blocked membranes with TBST 
for 3 times 15 minutes each, before incubation with primary antibody. 
2.3.5 Western blotting: antibodies incubation 
Evaluation of effect of maternal infection induced by poly(I:C) and also systemic 
administration of kynurenine 3-monooxygenase inhibitor, Ro61-8048 were 
studied on selected panel of neurodevelopmental markers that are involved in 
many aspect of central nervous system (CNS) development. These target markers 
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are known to participate in various roles spanning from neural development, 
neurite outgrowth, neurogenesis, synaptogenesis, neurotransmission and 
intracellular signalling, among many others.  
The primary antibody is the major determinant of the specificity of the target 
recognition (Table 2-5). Trial set up of membrane with range of dilutions was 
initiated to check reactivity and also specificity of the selected antibodies. The 
optimal dilution of the primary antibody has to be determined experimentally 
for the detection system used as different batch or source of the antibody may 
even result in different recognition pattern when applied to the same sample 
(commonly used dilution is between 1:500 – 1:10,000). The incubation with 
primary antibody in blocking solution (5% milk-TBST) occurred at 4oC under 
continuous shaking condition. Post incubation: the membrane was washed three 
times with TBST solution for 15 minutes at room temperature (RT) to remove 
unbound primary antibody. In order to detect the antibody which have bound, 
the membrane was exposed to a secondary antibody reactive against the 
respective primary antibody used (for instance: anti-rabbit to detect primary 
antibody raised in a rabbit) (Table 2-6). This secondary antibody is known as 
horse-radish peroxidise (HRP) conjugated antibody dissolved in blocking solution 
and applied to the membrane and incubated for 1 hour at RT. All antibodies used 
in this study were commercially available and have been used previously in 
numerous regions of the human or rat brain as well as in vitro studies. Western 
blot analysis was carried out using the following primary antibodies raised 
against target proteins as listed in Table 2-5. 
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Primary 
antibody 
Isotype Dilution Source 
NR2A Rabbit polyclonal 
1:1000, 
1:5000 
PPS012, R&D Systems, 
Abingdon, UK 
NR2B Rabbit polyclonal 
1:1000, 
1:5000 
PPS012, R&D Systems, 
Abingdon, UK 
PSD95 Rabbit monoclonal  1:10000 
3450, Cell Signalling, New 
England Biolabs, Hitchin, UK) 
EphA4 Rabbit polyclonal 1:5000 
sc-921, Santa Cruz, Insight 
Biotechnologies, Wembley, UK 
NFB Rabbit polyclonal 
1:1000, 
1:5000 
sc-372, Santa Cruz, Insight 
Biotechnologies, Wembley, UK 
COX2 Goat polyclonal 1:1000 
sc-1745, Santa Cruz, Insight 
Biotechnologies, Wembley, UK 
PCNA Mouse monoclonal  1:1000 
sc-56, Santa Cruz, Insight 
Biotechnologies, Wembley, UK 
SHH Goat polyclonal  1:1000 
sc-1194, Santa Cruz, Insight 
Biotechnologies, Wembley, UK 
SOX2 Goat polyclonal 1:500 
sc-17320, Santa Cruz, Insight 
Biotechnologies, Wembley, UK 
Table 2-5 Primary antibodies used for western blotting 
 
 
 Secondary antibody Dilution Source 
Goat anti-rabbit HRP 1:5000 12-348, Millipore, Watford, UK 
Donkey anti-goat HRP 1:5000 sc-2020, Santa Cruz, Insight 
Biotechnologies, Wembley, UK 
Goat anti-mouse HRP 1:5000 sc-20050, Santa Cruz, Insight 
Biotechnologies, Wembley, UK 
Table 2-6 Secondary antibodies used for western blotting 
 
2.3.6 Detection method: Chemiluminescence 
Subsequently excess of secondary antibody was washed free of the blot by 
applying three times washes with TBST for 15 minutes each. For reproducibility 
purposes, volumes and times are constantly kept during the whole washing 
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procedure. The immunoblots were exposed to a substrate which will precipitate 
upon reaction with the secondary, resulting in a visible band where the primary 
antibody bound to the protein. For this step, enhanced chemiluminescence 
solution from Thermo Scientific (Pierce® ECL2 Western Blotting Substrate) was 
added onto the membrane and incubated for 5 minutes. Finally membranes were 
placed into a cassette and developed using x-ray films (Kodak, UK) on a Kodak X-
OMAT 2000 processor with the exposure time varied depending on the antibody 
used. In each case the aim was to achieve an optimal balance between signal-
background ratios. 
2.3.7 Image analysis and membrane quantification 
Protein intensity in each membrane developed on an X-ray film was quantified 
by measuring their relative optical density (OD) using the analysis of gels options 
in Image J software (http://rsbweb.nih.gov/ij/). First, the X-ray films developed 
from  chemiluminescence were scanned onto a  computer in full colour using HP 
Scanjet 4400cc Scanner and saved as Jpeg file. On Image J software, the 
selected image was transformed into 8 bit image. The relative OD measurements 
for control and treated samples run on the same gel were normalised to relative 
OD of the β-actin signal within each lane, because treatment with either 
poly(I:C) or Ro61-8048 at the desired dosage did not affect β-actin content in 
the brain (data not shown). 
2.3.8 Data analysis 
The immunoreactive bands were detected using chemiluminescence and 
quantification involved densitometry measurements where comparisons were 
made statistically between groups of pups born to mothers treated (either with 
poly(I:C) or compound Ro61-8048) and groups of pups born to mothers injected 
with saline vehicle. Statistical analysis was performed using unpaired t tests to 
examine differences between the two groups. The level for a statistical 
difference in the data was set at P<0.05. Unless otherwise noted, statistical 
difference is cited in the text when the data for the respective treatment group 
were different from the data from control group. We have determined earlier 
that there was no effect of gender on the treatment of Ro61-8048 at P21, the 
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data of the male and female offspring in each treatment group were combined 
for the purpose of statistical analysis.  
2.4 Immunocytohemistry (ICC) procedures 
Immunocytochemistry is a technique that uses antibodies which target antigenic 
receptors on the cell membranes. The reaction site can be identified in the 
specimen and associated with specimen structure by attaching a microscopically 
probe to the antigen-antibody complex. Thus, microscopical analysis by this 
technique can therefore be used to obtain a unique view of macromolecular 
changes within individual cells. ICC is widespread in use for light and electron 
mircroscope studies in almost every area of biological research from routine 
diagnostic work through to more complex research projects. The feasibility of 
the technique in living specimens, making it possible to study dynamic 
processes, such as gene expression, molecular binding interactions and as part to 
understand the distribution and localization of specific molecular markers in 
different parts of a tissue (Beesley, 1993). 
2.4.1 Animals and operative procedures 
Groups of litter from saline and Ro61-8048-treated animals (n=7-9/group) were 
killed at postnatal day 60s after gestational treatment at E14, 16 and 18. Both 
control and Ro61-8048-treated animals were deeply anesthesized using Euthatal 
(sodium pentobarbiturate) before transcardially perfused via the left ventricle. 
In general, conventional tissue fixation protocols for microscopy analysis involve 
the use of fixative solution, which should allow excellent morphological 
preservation. The fixation procedure needs to be a compromise between good 
morphological preservation and the conservation of antigenicity; ideally the 
composition of the fixative should ensure both. Furthermore, an ideal fixative 
should stabilize and protect tissues and cells from the damaging effects 
associated with subsequent treatment.  There are a number of ﬁxation 
procedures used, which are based on various ﬁxatives such glutaraldehyde, 
formaldehyde and also ethanol, methanol, acetone and formalin. In this respect, 
the best concentration of fixative we used in all animal study for ICC procedure 
is 4% parformaldehyde (PFA), which is less damaging to many antigens and give a 
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good compromise between retention of morphology and antigenicity.  After the 
animal has been anesthesized, mammalian Ringer solution was flushed through 
each animal to dilate blood vessels and prevent clotting and fixation of the 
tissues was followed by perfusion with approximately (850ml to 1000ml) of 
freshly made, warm 4% paraformaldehyde (PFA) (Sigma-Aldrich 16005) in 0.2M 
phosphate buffer (PB), pH 7.2. Right after perfusion, the brains were removed 
from the skull and postfixed the same fixative solution for another 4 hour at 4oC. 
After thorough rinsing in 0.1M phosphate buffer, the brains were protected in a 
30% sucrose solution where they remained until equilibrium. In our laboratory, 
samples were fixed, stored in phosphate buffer for up to one month and 
subsequently processed  and successfully immunolabelled. It should be noted 
that prompt fixation after perfusion is essential to achieve consistent results. 
Prolonged fixation for the tissue samples were also avoided as many antigens 
show a progressive reduction in immunoreactivity with increasing fixation times 
by producing cross-linking with protein that could diminish the epitopes for the 
applied antibodies. Therefore, 4 hour post fixation with PFA for adult brain 
tissue is thought to be optimal that can give adequate untrastructural 
preservation.  
2.4.2 Tissue processing  
Vibratome is an excellent basic vibratory tissue sectioning system. It cuts fresh 
or fixed, animal or plant tissue without freezing or embedding. Brain samples 
were divided into two hemispheres and cut to an appropriate size, embed in 5% 
agar and cooled for a few minutes before mounted on the vibratome base plate 
with the aid of super glue to stabilize the specimen. All the parameters were set 
accordingly; section thickness, speed and angle of the sectioning blade. Initial 
sectioning was performed one or two times to obtain a flat specimen surface. As 
section quality is influenced by several factors, the setting parameters of the 
vibratome (Leica 1000) were appropriately checked when performing sectioning. 
In relation to brain tissue, setting parameters of: low bath temperature (a 
physiological compatible buffer: 0.1M PB), slow sectioning speed (setting 1-2), 
section thickness (60 µm) and low steep blade angle were adopted. After initial 
sectioning, sixty-micrometer thick free floating sections were then cut coronally 
through the entire hippocampus and collected serially in a series of tubs filled 
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with 0.1M PB. The sections were incubated with 50% ethanol for 30 minutes to 
permeabilize and improving the penetration of the antibody, before 3 times 
washed with 0.3M PB and stored at -20oC in glycerol.  
2.4.3 Antibody incubation and staining procedure 
For analyses of hippocampal  neurogenesis, serial free-floating sections were 
first washed in 0.3M phosphate buffer saline (PBS) before incubated with 
optimally diluted primary antibodies in 0.1% Triton in PBS (PBST; pH 7.4) for 72 h 
at 4oC under continuous shaking condition. The major consideration when 
choosing the antibodies for multiple immunolabelling is the the possibility of 
cross reactions between reagents. In this study we adopted simultaneous 
multiple immunolabelling using antibodies raised in different species. 
Immunolabelling was performed by incubating the specimen with mixtures of 
chosen antibodies followed by mixtures of appropriate secondary probes. The 
optimal concentration of each antibody used in this study was optimized 
individually to obtain maximal contrast between specific signal and background 
staining. The mixture of primary and secondary antibodies were diluted in tris-
buffered saline (TBS) containing gentle detergent (Tween 20) with the purpose 
to help keeping the tissues/cells permeabilized. Primary antibodies used in our 
study were monoclonal mouse anti-NeuN (1:500; MAB377 Millipore, Temecula 
CA92590), polyclonal goat anti-Doublecortin (DCX, 1:250; sc-8066 Santa Cruz 
Biotechnology, Santa Cruz, CA) and polyclonal rabbit anti-SHH (1:100; sc-9024 
Santa Cruz Biotechnology, Santa Cruz, CA). Rinses were performed between all 
steps using 0.3M PBS before or after the primary and secondary antibody 
incubation.  
Following primary antibody treatment, sections subsequently incubated 
overnight at 4oC in species specific Alexa Flour-tagged secondary antibodies: 
Alexa 488 (1:500), Alexa 647 (1:500) (Molecular Probes) and Rhodamine-
conjugated secondary antibody (1:100) (Jackson Immunoresearch Laboratories 
Europe Ltd.).  The uses of conjugated antibody flourochromes have been 
successfully used for multiple immunostaining. The fluorescent probes are 
particularly useful since each probe can be visualized separately without 
hindrance from the other by use of different wavelengths of light for excitation 
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and detection. Sections were mounted and coverslipped with an aqueous 
mounting medium for flouresence H-1000: Vectashield (Vector Laboratories Inc. 
Burlingame, CA 94010). Covering the sections with a glass coverslip preserves 
and protects the section and improves optics. Special mountant containing 
fluorescent anti-fades was used to protect against photobleaching effect. 
Another aspect when choosing mounting medium is to match its refractive index 
with objective immersion medium, it is to avoid incorrect depth discrimination 
and spherical aberration which could lead to loss of light at the detector (Smith, 
2008) In all experiments designed to compare the immunolabelling in saline-
control and Ro61-8048 animals, sections from the two groups of animals were 
processed identically and in parallel for each step of the immunocytochemical 
procedures. Considering that there was a possible high risk of cross 
contamination in all multiple immunolabelling schedules, even if totally 
different species were used, a control specimen from each animal with omission 
of primary antibodies is included and tested in parallel with the samples. The 
specimens can be kept at 4oC if the material is going to be processed within 1-2 
weeks as fluorescence may last up to 2-3 weeks, long term storage should 
preferentially be at -20oC in a covered boxes. However for best results the 
specimen should be viewed as soon as possible using confocal microscopy.  
2.4.4 Confocal microscopy and image processing  
Over the years, confocal microscopy has developed to form as essential research 
tool for assessing immunocytochemical preparations. The most common 
application of confocal microscopy is to compare the distributions or behavioural 
characteristic of multiple probes in the same tissue samples and also reveal the 
three dimensional structure of the specimen reconstructed from a series of 
optical sections at different depths (Smith, 2008).  Flourescent signals from each 
section were examined and photographed using an inverted confocal laser 
scanning microscope (Nikon Eclipse TE300) equipped with RADIANCE2100 BIORAD 
and Lasersharp 2000 software. In principal, laser scanning microscope captures 
images by scanning the specimen with a focussed beam of light from a laser and 
collecting the emitted fluorescent signals with a photodetector. This is made 
possible by the development of the system that are capable of efficiently 
detects multiple flourophores either simultaneously or sequentially by its laser 
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optics with a wide range of wavelengths from ultraviolet through the infrared. 
The system employs a pair of pinhole apertures to limit the specimen focal plane 
by blocking the light from out of focus areas thus determines the exact emitted 
fluorescence of the focal spot in the specimen (Smith, 2008). Relatively thick 
specimens can be imaged in successive volumes by acquiring a series of sections 
along the optical (z) axis of the microscope. Moreover, the use of oil-immersion 
objective that have similar refractive index with mounting medium for 
specimens would ensure better image quality. 
In this experimental set up, stacks of 20 images were taken through the z-axis 
using a 40X oil objective and 10X magnification and a frame box of 289µm (x) X 
289µm (y) X 20µm (z) (1024x1024 pixels).Setting parameters that needs to be 
controlled and standardized throughout the scanning include photomultiplier 
gain for the channels, scan line speed, brightness and pinhole aperture size. By 
properly adjusting the pinhole size, separation of the background out of focus 
signal can be achieved thus improves image quality. Whereas the scan speeds 
slider is adjusted to achieve the maximum scan rate with a minimum amount of 
signal noise. As the scan speed is increased, a corresponding increase in the 
amount of background noise is also captured by the photomultipliers (detector).  
By using 20x magnification the regional areas (CA1, CA3 and dentate gyrus) were 
delimited by morphological criteria and under 40x magnification objective the 
dimensions of the area in the specimen were scanned. Within this dimension 
only immunopositive cells showing a stained unit area sufficient to ensure that 
the majority of their volume was contained within the selected area were scored 
for counting purposes. At least 3 coronal sections per animal were 
immunolabelled and in every section, two to four images were taken followed by 
image processing to optimally visualize the staining area. Immunopositive cells 
from the pyramidal layer of CA1 and CA3 as well as granule cell layer of the 
hippocampus were quantified using a number of gridded counting frames that 
were within the specific subregions of the hippocampus and cerebellum with 
each individual counting frame measured 50 x 50 µm. The counting of the DCX, 
SHH  and NeuN positive cells was conducted in a total of 15 grids of area for 
dentate gyrus and CA1 regions, 25 grids for CA3 region and grid sizes of  4 x 4 for 
cerebellum. For all the selected subregions, we calculated the number of 
immunopositive cells that were inside the counting frames for each section and 
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the total number of immunopositive cells across all counting frames was 
averaged to give one mean value per animal per subregions. Cell quantification 
was performed with adherence to several characteristics which includes (i) the 
presence of nucleus, (ii) immunopostive cells were of homogenously shape and 
(iii) labelling intensities of immunopositive cells were distinguishable from 
background staining.  
2.4.5 Data analysis 
All cell counts were performed blindly with respect to treatment, using 
immunolabeled sections reacted with selected antibodies. The data set obtained 
by capturing a series of optical sections through the specimen was used to 
compute views of the specimen from different viewing angles. Each subregion of 
the hippocampus (CA1, CA3 and DG) and cerebellum was analysed using Nikon 
Eclipse TE300 microscope. For counting purpose, a two-dimensional display of 
both z-series projection and xy projection formed by merging multiple image 
planes were conducted. The most common type of projection is a maximum 
projection in which each pixel represents the intensity of the brightest pixel in 
the z-axis. The cell number analysis was done on a total of 3 sections per animal 
with at least 2-3 observations per section using ImageJ software (Version 1.43M; 
National Institute of Health). Immunopositive cells count of 3 sections was 
averaged to obtain a single value for the number of positive- stained cells per 
animal. A mean ± standard error (SE) was calculated from the date in each group 
(n= 7-9 animals).We chose to use mean cell counts as representative of 
immunopositive labelling as this protocol would permit valid comparisons among 
treatment groups. Sections from animals with faint immunolabelling for 
respective antibody were excluded from statistical analyses, producing some 
variability in sample sizes across groups.  
2.5 Golgi staining 
2.5.1 Animals and operative procedures 
Pregnant rats were injected with compound Ro61-8048 (100mg/kg) on embryonic 
days 14, 16 and 18, and gestation was allowed to proceed normally. Both male 
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and female pups were included in this study and they remained with their 
mothers until weaning at postnatal day 21 (P21) and were assessed at postnatal 
day 60 for the post-pubertal or adult group. Control animals were born from 
saline-treated mothers and were evaluated at the same age. At postnatal day 
60, the pups from respective group of litters (4 pups per litter) were deeply 
anesthetized with sodium pentobarbital before cervical dislocation.  
2.5.2 Tissue processing and staining procedure 
The brains were then rapidly removed, rinsed briefly in dH2O and straight away 
immersed in impregnation solution at room temperature for 2 weeks in the dark. 
Golgi-Cox staining was performed using the FD rapid GolgiStain kit (FD 
NeuroTechnologies) as per the manufacturer‟s instructions. The impregnation 
solution was made by mixing equal volumes of solutions A and B at least 24 hours 
prior to use and left unstirred at room temperature. The impregnation solution 
was refreshed after initial 24 hour of immersion. The tissue is then transferred 
into solution C and stored at 4oC for at least 48 hour in the dark. The solution 
was replaced after the first 24 hour of immersion.  
Coronal sections of 200m thickness were obtained using a vibratome (VT1000s, 
Leica). Each section was then mounted on gelatin-coated microscope slides      
(3 sections/slide). A tiny drop of solution C was placed onto the mounted tissue 
before being dried naturally in the dark at room temperature. For the final 
development process, slides were arranged in a slide rack and washed twice in 
dH2O for 2 minutes each. Then the slide rack was placed in a mixture consisting 
of one part solution D, one part solution E and two parts dH2O for 10 minutes 
with gentle agitation every 2 minutes. The sections were rinsed two times with 
dH2O, four minutes each and followed with dehydration process with graded 
concentration of ethanol in successive baths of 70% (4 minutes), 90% (4 minutes) 
and 100% (3 x 4 minutes). Subsequently, the sections were dipped in Histoclear 
solution (2 x 4 minutes) before cover slipped with histological mounting medium 
(Histomount, ThermoFisher Scientific). 
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2.5.3 Morphological and data analysis 
The ability to obtain good images of neuronal processes allowed us to use this 
technique for morphological and quantitative studies using appropriate image 
analysis software. From each group, three litters with four pups in each litter 
were used for dendritic morphology study in the hippocampus. Brain region 
identification was aided by a standard atlas of the rat brain. Golgi-stained 
principal cells in the dentate gyrus, the granule cells were then visualized by 
light microscopy (Nikon Eclipse E400, Nikon Instruments, Inc., NY, USA). Under a 
40x objective lens, Golgi-impregnated dentate granule neurons were identified 
by their location within granule cell layers and by the shape of their soma and 
dendritic arbor.   Dendrites were visualized under a 40x objective blindly to the 
pretreatment group for manual tracing and dentate granule cells quantification.  
A minimum of one neuron in each hippocampus section were drawn individually. 
Based on those criterion mentioned above, as a whole for each group of 
treatments, a total of 68 neurons from control and 69 neurons from Ro61-8048-
treated animals were traced in their entirety. Fully stained cells within the 
panel were first visualized under minimal magnification (4 x objectives). Thus, 
each examined granule cell body was carefully viewed at various magnifications 
(4x, 20x and 40x) to determine the continuity of processes in its vicinity. By 
carefully adjusting the fine focus, it was possible to determine whether basal 
dendrite was present and to distinguish a passing dendrite from one that was 
attached to the examined cell body. To ensure consistency of sampling the 
following criteria were applied: (1) granule cells exhibited vertically orientated 
dendrites that extended into the dentate molecular layer; (2) granule cells did 
not have cut off dendrites in close proximity to the cell body and (3) dendrites 
had negligible overlap with the dendrites of neighbouring cells so that all 
dendritic branches could be traced explicitly. In addition to those parameters, 
we also generally observe other morphological criteria prior to the selection of 
the neurons such as integrity of the selected neuron, homogenous impregnation 
(dark and consistent impregnation seen throughout the extent of the dendrites) 
and relative isolation from the blood vessels and deposits of other impregnated 
cells located nearby (Zhao et al., 2006). Morphometric parameters included 
were the total number of branches and total dendrite length and used to assess 
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the overall magnitude of morphological change following prenatal modulation of 
kynurenine pathway. The number of dendritic branches was calculated manually 
from the camera drawings. The dendritic branches originating directly from cell 
bodies were designated as first order or primary segments and until they 
branched off into second order segments (secondary).To measure the extent of 
dendritic growth away from the soma and the branching of dendrites at different 
distances from the soma, the concentric circle analysis of was performed (Sholl, 
1953, Gibb and Kolb, 1998). A transparent grid with equidistant 20m was 
centred over the cell soma and the number of ring intersections was used to 
estimate the total dendritic length and dendritic arborisation. The branching 
complexity of dendritic trees was evaluated by applying the method of 
concentric rings. Rings were calculated at 20µm intervals (0-20, 20-40, 40-60, 
60-80, 80-100, 100-120, 120-140). Sholl analyses were conducted on the mean 
values per animal for the above morphometric parameters. In Sholl analysis, the 
number of concentric ring intersections was used as an estimate of total 
dendritic length. While dendritic branching was also measured by counting the 
total number of dendritic branches at each order away from the cell body. 
Graphically, this generates a profile which can be statistically compared with 
other profiles from other groups. Morphological data were analysed using an 
unpaired t-test to assess differences in the number of dendritic branches and 
their length between control and Ro61-8048 treated groups of animals. The 
analysis of dendritic complexity (Sholl, 1953) was subjected to a two-way 
analysis of variance (ANOVA) followed by Tukey‟s post hoc analysis to examine 
the contributions of drug treatment, sample number and distance from the cell 
soma. A probability value of 0.05 was taken as the criterion for significance. 
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3 Effect of maternal immune activation on 
neurodevelopmental markers expression in 
foetal and postnatal day 21 (P21) brain 
3.1 Introduction 
A body of evidence has indicated that prenatal immune activation causes a wide 
spectrum of structural and functional abnormalities implicated in a diverse 
range of disease process including AIDS-dementia complex, schizophrenia, 
autistic spectrum disorder, among many others. However the neurodevelopment 
mechanisms and biochemical changes underlying these abnormalities are not 
definitively established. The most widely debated possibility is that a maternal 
antiviral antibody in some genetically predisposed mothers may cause an 
immunological reaction that is harmful to the foetal brain (Gilmore and Jarskog, 
1997). Maternal inflammation that caused a disruption to the maternal 
environment has been linked to the above disease states in adult life. Several 
reports showed that activation of the immune system and increased levels of 
cytokines during gestation affects the development of brain areas involved in 
social interaction and memory which later results in a schizophrenia-like 
phenotype (Ashdown et al., 2006, Hsiao and Patterson, 2012). This finding is also 
supported by epidemiological studies that demonstrate an association between 
maternal infection and the development of schizophrenia (Brown et al., 2004).  
The use of animal models to model maternal immune activation has provided 
insights into the host‟s response to an immunological stimulus, as well as the 
acute and lasting effects of immune activation on offspring development. 
Precise manipulation of a number of variables of interest, such as the immune 
stimulus, route of administration, dosage and timing of exposure, allows for the 
testing of various hypotheses regarding the mechanisms of action on the 
developing foetal brain. The most well known cause of inflammation during 
pregnancy is due to infection by a pathogen. As previously discussed in the 
introduction, the two major maternal immune activation models use either LPS 
or poly(I:C) administered to pregnant dams, although there are a number of 
other additional models which have used the human influenza virus and 
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individual cytokines such as TNF-α or IL-6 (Boksa and Luheshi, 2003, Boksa, 
2010).  
Despite the large number of studies describing abnormalities in rodent brains 
following exposure to prenatal immune stimulus, the precise molecular 
mechanisms by which infection during gestation and the effect of maternal 
immune response on the developing central nervous system remain unclear. The 
fact that a wide variety of pathogens are able to increase schizophrenia risk in 
the offspring suggests that these pathogens alter foetal development by one or 
more common mechanisms. A major causal link underpinning this relationship is 
thought to be the cytokines released following a maternal immune response to 
infection (Ashdown et al., 2006, Brown, 2006). Maternal immune activation is 
thought as a plausible mechanism due to all of the implicated pathogens 
triggering a maternal immune response, which will alter the biochemical 
environment of the foetus in a way that increases the risk for 
neurodevelopmental disorders. Despite the postnatal onset of clinical symptoms, 
evidence suggests that schizophrenia have their origins in early brain 
development. In line with the neurodevelopmental hypothesis of schizophrenia, 
which postulates that neuronal development is affected by events that modify 
physiological course of maturation in neuronal system. Therefore, maternal 
immune activated rodent models have been particularly helpful for examining in 
vivo effects of the maternal immune system on the developing foetal and 
postnatal brain (Patterson, 2009). These models predominantly involve 
administration of either bacterial lipopolysaccahride (LPS) or double-stranded 
viral RNA (polyI:C) to pregnant rats or mice. This induces an immune response, 
which increases circulating levels of cytokines without the confounding effects 
of the pathogen itself. The offspring of mothers with infections display diverse 
neuropathology, depending in part on the nature and timing of the infection. 
Offspring of these immune activated have been reported to show a 
„schizophrenia like‟ phenotype including deficits in prepulse inhibition (PPI), 
latent inhibition (LI), anxiety, locomotion and social interaction (Meyer et al., 
2008c, Meyer et al., 2008a, Ito et al., 2010, Shi et al., 2003). 
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3.2 Research aims 
Based on the in vitro evidence of pro-inflammatory cytokine action in the brain, 
it is hypothesized that the presence of cytokines in the foetal brain as a result of 
maternal infection could result in altered brain neurochemical development. 
The main aim was to investigate if exposure to viral mimetic poly(I:C) during 
early life can affect the neurochemical balance of a selected panel of 
neurodevelopmental markers in the young offspring that could undermine 
normal brain development and predispose the offspring to developing psychiatric 
illness. 
3.3 Experimental approaches 
Exposure to a wide range of viruses pre-or perinatally has been implicated in the 
pathogenesis of neuropsychiatric disorders.  To this aim, a synthetic analog of 
double stranded RNA (polyriboinosinic-polyribocytidilic acid, [poly(I:C)] was 
administered intraperitoneally in mouse dams on embryonic days (E) 14, 16 and 
18 in order to extend the temporal impact of maternal immune activation with 
no apparent ill effects on the dam or her behaviour towards her litter after 
birth. Administration of this agent to rat dams at three different time points 
during pregnancy (E14, E16 and E18) correspond roughly to the later periods 
during the second trimester of human pregnancy. In another set of experiments, 
poly(I:C) was administered to pregnant dams on embryonic day 18 (E18) as to 
demonstrate the effect of the immune activation in terms of changes in the 
levels of cytokine in the maternal plasma as well as protein expression in the 
embryo. Poly(I:C) is used experimentally to model viral infections because it 
stimulates the antiviral activities of the innate immune system including 
cytokine production, without the  confounding effects of viral infection. We 
have decided to focus on poly(I:C) as we find it as a more reliable and consistent 
activator of the immune system and also because viral rather than bacterial 
infections predominate in human pregnancy. Injection at a dose of 10mg/kg of 
poly(I:C) is the highest dose which can be given to a pregnant mouse with no 
signs of acute stress, behavioural changes or abnormal behaviour towards the 
neonatal pups. Preliminary work on the neurochemical analyses showed little 
changes in the selected molecular markers at postnatal day 2 (P2) with a 
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significant increase of EphA4 at P7 and a reduction of both EphA4 and VAMP-1 
expression at P21. In this study, we therefore concentrated on the molecular 
analyses of brain samples collected from E18 and P21. These two developmental 
time-points were aimed at capturing early and later/persisted changes in protein 
expression levels. It is therefore of considerable interest to evaluate biological 
markers that are involved in the early development of the brain. The goal of the 
study is to assess differences in the expression profiles of selected 
neurochemical markers after poly(I:C) induced-maternal immune activation and 
from unchallenged normal mice by analyzing the activated expression signalling 
pathways following infection.  
3.3.1 Animals and drug preparation 
All procedures on animal work was performed in accordance with the guidance 
established by the Animal (Scientific Procedure) Act 1986 and has been approved 
by the University of Glasgow Scientific Ethics Committee. Wistar rats were 
mated at an age of around 3 months and the first day after the occurrence of 
vaginal plug (an indication of copulation) was defined as day 1 of pregnancy. The 
pregnant dams were housed alone under pathogen-free environmental conditions 
at a constant temperature with food and water ad libitum. Potassium salt 
poly(I:C) (P0913: Sigma (Poole, UK)) was dissolved in sterile isotonic 0.9% w/v 
NaCl solution and then heated to 50oC to allow for complete solubility. The 
mixture was allowed to cool to room temperature to allow re-annealing of the 
double-stranded RNA. The desired dosage for the injection was 10mg/kg and it 
has been established in previous experiments in the lab that the dose could be 
given to pregnant dams during the last seven days of gestation with no signs of 
stress, behavioural changes or abnormal behaviour towards the neonatal pups 
after birth (Forrest et al. 2012). The solution for the drug treatments was 
sterilised and aliquoted in small sterilised tube and kept in -20oC until further 
use. 
3.3.1.1 Experiment 1: Acute study on embryo  
For the acute study, gestational day 18 timed-pregnant rats were injected i.p. 
with 10mg/kg of poly(I:C). Age-matched pregnant rats were injected with the 
same volume of saline (0.9% NaCl). This experiment was set up for the purpose 
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of assessing the acute effects of maternal poly(I:C) administration on several 
cytokine and chemokine levels in maternal blood. After the injections the 
animals were left undisturbed for 5 hours and then anesthetized with an 
overdose of sodium pentobarbital and decapitated after blood was obtained by 
cardiac puncture. The blood was collected in a heparinised vacutainer tube and 
kept ice cold. The animals were dissected and the uterine horn containing 
embryonic day 18 pups were surgically removed. The placenta, foetal whole 
brains and bodies were dissected and immediately frozen on dry ice. The 
collected whole brains were used in the western blot analysis. Maternal liver, 
thymus and brain were also dissected for further analysis for example HPLC 
analysis. ELISAs for detecting cytokines and HPLC analysis was performed by 
respected colleague Dr Forrest and some findings are mentioned in the text.  
3.3.1.2 Experiment 2: Postnatal day 21(P21) 
For gestational poly(I:C) administration and vehicle treatment, groups of 
pregnant dams were  administered intraperitoneally (i.p.) at the dose 10 mg/kg 
on days E14, E16 and E18 in order to extend the temporal impact of maternal 
immune activation on the embryos, with no apparent ill effects on the dam or 
her behaviour towards her litter after birth. Repeated systemic challenges 
during this time point was meant to examine the effect or repeated viral 
stimulation on the progression of neurological changes at postnatal day 21 since 
this represents pre-pubertal stage of development. Group of pregnant dams 
were injected on E14, 16 and 18 between 9am and 11am to minimise variation in 
responses. We have shown that treatment of pregnant dams with poly(I:C) at the 
dose indicated did not affect litter size and pup body weight and could be given 
during the last seven days of gestation with no sign of stress, behavioural 
changes of abnormal behaviour towards the neonatal pups after birth. The 
dosage regime at 10mg/kg was well tolerated in our experimental approach and 
could provide the maximum advantage for observing any changes in the 
offspring. In the control group, pregnant dams were injected with the same 
volume of 0.9% NaCl. Gestation was allowed to proceed normally and the 
offspring were undisturbed until weaning on P21 when they were taken from the 
home cage for euthanasia followed by removal of the brain. Each brain was 
  89 
 
divided into the two cerebral hemispheres and frozen immediately on dry ice 
before being transferred to storage at -80ºC until required for analysis. 
Each member of a litter from all set of experiments was treated identically; with 
whole litters being taken at the same time so that no animal would experience 
the possible trauma of losing littermates while themselves surviving to a later 
date. This protocol also ensured that changes of maternal behavior caused by 
the removal of some pups could not affect the development of survivors. To 
avoid possible litter-specific effects, groups of at least three independent litters 
were used in which two pups from three separate litters (n=6) were used for 
each treatment and control group; there were at least 3 samples per treatment 
and control group. For postnatal day 21 experiments and acute studies, three 
male and three female pups from three separate litters were used for the 
treatment and control groups.  
Group of pregnant rats
P0 P21
E21E0
E14 E16 E18 Group of 
litters
saline  or poly(I:C) (10mg/kg)
5 hour post-injectionE0 E18
saline or poly(I:C) (10mg/kg)
 
Figure 3-1 Summary of diagrammatic representative of the experimental approach 
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3.3.2 Western blot analysis 
The preparation of the sample is the first step in the complete protocol for 
western blotting. The main principle is to ensure that the sample is in the best 
possible environment for analysis. For this purpose, brain tissues were 
lysed/homogenized in RIPA buffer containing 60mg TRIS, 87.6mg NaCl, 10mg 
SDS, 50μl TRITON X-100, 100 μl IGEPAL, 9850 μl distilled water, with the process 
of proteolysis and denaturation of protein in the lysate slowed down by adding 
one tablet of protease inhibitor (Protease Inhibitor Cocktail tablets- CompleteTM 
, Boehringer Mannheim GmBH, Mannheim, Germany). The whole lysate was then 
centrifuged at 13 000 rpm for 5 minutes at 4oC and finally the supernatant was 
aspirated and aliquots kept at -80 oC prior to use. Total protein concentrations 
for all samples were determined using the BIORAD protein assay system. This 
was achieved by comparing each brain lysate against a standard curve of known 
protein content – Bovine Serum Albumin (BSA: Sigma-Aldrich) dissolved in dH2O 
to obtain a concentration range 0, 0.25, 0.5, 0.5, 1.0, 1.5 and 2.0 (in mg/ml). 
The brain lysate (diluted 1/10) and BSA standard was mixed with diluted BIO-
RAD protein assay dye reagent (1:1 in dH2O) (BIO-RAD Laboratories, UK). 
Subsequently each standard and brain lysate was pipetted twice into a 96-well 
plate and the absorbance measured with an Opyss MR plate reader (Dynex 
Technologies,UK) using  the BIORAD.assay program  of Revelation Quicklink 
software (Dynex Technologies, version 4.25) at a wavelength of 595nm. Protein 
concentrations were then normalised to load 20-30 μg of protein onto the gels.  
To characterize immunodetection of the antibody for the selected markers 
mentioned above, western blotting was carried out following procedures already 
established in the lab. Prior to the electrophoresis process, proteins from the 
lysate of brain samples (65% protein sample, 25% sample buffer and 10% reducing 
agent) was denatured by centrifugation at 2000rpm for 2 minutes at 4oC and 
heated for 10 minutes at 70oC. Equal amount of proteins from each sample (20-
30μg) was separated according to molecular weight on NuPAGE 4-12% (1.0mm) 
Bis-Tris polyacrylamide gels 15 lane gels (Invitrogen: Life Technologies, Paisley, 
UK) for 80 min at 150 volts. SeeBlue pre-stained standard (Life Technologies, 
Paisley, UK) was included on each gel as a molecular weight marker. The 
separated proteins were then electrophoretically transferred onto hydrophobic 
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Invitrolon poly(vinylidene difluoride) (PVDF) membranes (Invitrogen: Life 
Technologies, Paisley, UK) for 60 min at 30 volts. The membranes were 
incubated for 1 hour at room temperature with 5% non-fat dried milk in Tris-
buffered saline (TBS: 20mM Tris Base and 0.14M NaCl, pH 7.6) containing 0.05% 
Tween-20 to block nonspecific binding sites and then incubated with the 
selected panel of primary antibody (see Antibodies section below) overnight on a 
shaker at 4 oC. After washing 3 times for 15 minutes each with TBS containing 
0.05% Tween 20 (TBST), membranes were incubated for 1 hour at room 
temperature on a shaker with the appropriate horseradish peroxidase (HRP) 
conjugated secondary antibody prepared in 5% milk-TBST. Following secondary 
antibody incubation, blots were rinsed with distilled water followed by 3 times 
wash with TBST (15 minutes each). Protein bands were developed using 
Enhanced Chemiluminescence Plus western blotting detection reagents (GE 
Healthcare, Chalfont St Giles, UK) and immediately exposed to film (KODAK 
Medical X-ray) and visualized using XOMAT. 
For ELISA analysis, this procedure was performed by Dr Forrest as part of the aim 
to evaluate the maternal immune response following poly(I:C) administration 
during pregnancy. For these experiments, maternal plasma was obtained after 
centrifuging heparin-treated blood samples for 15 min at 2000 rpm. Specific rat 
inflammation profiling strips (SIGNOSIS, EA-1201) which simultaneously detects 4 
inflammatory cytokines was used i.e. macrophage inflammatory protein-1α (MIP-
1α), monocyte chemotactic protein-1 (MCP-1), interleukin-1β (IL-1β) and tumour 
necrosis factor- α (TNF- α). The assay was performed in 96 well plates according 
to the manufacturer‟s instruction. Quantification of the data obtained in ELISA 
studies was performed by Dr Forrest. 
3.3.3 Antibodies 
All antibodies used in this study were commercially available and have been 
used previously to detect NR2A, NR2B, EphA4, PSD95, NFkB, COX2, SHH, SOX2 
and PCNA in numerous regions of the human or rat brain as well as in vitro 
studies. Rabbit polyclonal antibodies were used to label NMDA receptor subunits 
NR2A and NR2B (1:5000; PPS 012 and PPS 013 , R&D System, Abingdon UK), 
Ephrin type-A receptor (EphA4) (1 : 5000; sc-921, Santa Cruz, Insight 
  92 
 
Biotechnology, Wembley, UK), Nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFkB) (1 : 5000; sc-372, Santa Cruz, Insight Biotechnology, 
Wembley, UK) and rabbit monoclonal antibody for Post synaptic density protein 
95 (PSD95) (1 : 10,000; 3450, Cell Signalling, New England Biolabs, Hitchin, UK). 
Goat polyclonal antibodies were used to label Cyclooxygenase 2 (COX2) (1:1000; 
sc-1745, Santa Cruz, Insight Biotechnology, Wembley, UK), Sonic hedgehog (SHH) 
(1 : 1000; sc-1194, Santa Cruz, Insight Biotechnology, Wembley, UK) and  [Sex-
determining region of Y-chromosome (SRY) related –high mobility group (HMG) 
box]SOX2 (1:250 or 1:1000; sc-17320, Santa Cruz, Insight Biotechnology, 
Wembley, UK). Proliferating cell nuclear antigen (PCNA) was labelled using 
mouse monoclonal antibodies diluted at 1:1000 (sc-56, Santa Cruz, Insight 
Biotechnology, Wembley, UK). As a control for transfer and loading, actin was 
detected on blots using anti-actin (goat polyclonal, 1:10,000; sc-1615 Santa 
Cruz, Insight Biotechnology, Wembley, UK).   
The following secondary HRP-conjugated antibodies were used at a 1: 5000 
dilution: goat anti-rabbit HRP (12-348) (Millipore, Watford, UK), donkey anti-
goat HRP (sc-2020) and goat anti-mouse (sc-2005) (Santa Cruz, Insight 
Biotechnology, Wembley, UK). The concentrations of primary and secondary 
antibodies, along with the exposure time to the X-ray film were optimized to 
provide optical density values that fell within the linear range.  
3.3.4 Data analysis and statistics 
Quantification of all neurochemical markers was achieved by means of optical 
densitometry using ImageJ software (ImageJ, NIH, MD, USA). To control for 
variations and differences in protein loading, each membrane was stained with 
Ponceau S solution (Sigma, Poole, UK) after proteins were electrophoretically 
transferred onto a hydrophobic Invitrolon poly(vinylidene difluoride) (PVDF) 
membrane. Each membrane was reprobed and examined for actin expression 
and the relative optical density measurements for the respective target proteins 
were normalized to the relative optical density of the actin signal intensity 
within each lane. Actin served as an internal standard control and was not 
affected by treatments in this study. For all experiments, three pregnant rats 
were injected in each of the treatment groups and two pups from each litter 
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were randomly selected for western blot analysis (n=6). To assess the long term 
effects of prenatal poly(I:C) exposure  on the P21 offspring, comparisons of each 
treatment group with their respective control group was analysed using unpaired 
t-tests. In the second set of experiments, the acute effects of a single injection 
of saline and poly(I:C) on neurochemical alterations in foetal brain were 
determined by performing unpaired t-tests. Analyses were conducted using 
statistical software GraphPad Instat (version 3.0). Statistical significance was set 
at 0.05 for all analyses. 
3.4 Results 
3.4.1 Cytokine expression 
Measurement of cytokine responses were also assessed in maternal plasma and 
the amount of pro-inflammatory cytokines interleukin-1 (IL-1), tumour 
necrosis factor- (TNF-), the chemokines monocyte chemoattractant protein-1 
(MCP-1) and macrophage inflammatory protein-1 (MIP-1) were analysed using 
ELISA. Poly(I:C) is recognized primarily by toll-like receptor-3 (TLR-3), in which 
upon recognition of dsRNA, induces an inflammatory cascade that results in the 
production of antiviral cytokines and chemokines (Alexopolou et al., 2001, 
Matsumoto and Seya, 2008). We examined the levels of several 
cytokines/chemokines in the maternal serum after 5 hours post administration of 
poly(I:C) so as to capture early changes of inflammatory responses.   Activation 
of the maternal immune response by poly(I:C) caused a significant increase of 
chemokines MCP-1  5 hours after treatment compared with saline-treated 
animals, whilst the proinflammatory cytokines IL-1 and TNF- were not 
substantially affected 5 hours after poly (I:C) injection (data for IL-1β and TNF-α 
not shown). Analysis of these results was performed by one of our colleagues and 
data for MCP-1  was indicated to highlight the effectiveness of the drug dosage 
used in this model (Forrest et al. 2012). The levels of this compound in the 
maternal blood is shown in Figure 3-2 which indicate a significant increase in 
concentration.  
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Figure 3-2 Effect of prenatal administration of poly(I:C) on maternal plasma levels of 
MCP-1 
Bar chart showing the maternal blood levels of monocyte chemoattractant protein-1 (MCP-1) 
measured 5 h following the administration of poly(I:C) 10mg/kg. Values are shown as the 
mean ± SEM (n=3) in arbitrary units of optical density (OD).  
 
3.4.2 Protein expression 
3.4.2.1 Maternal infection induced by poly(I:C) alters protein expression in 
the embryo brain after 5 h administration. 
In a set of an experiment to assess protein expression following poly(I:C)-induced 
immune stimulation, pregnant dams were administered with poly(I:C) 10 mg/kg 
or vehicle treatment (sterile 0.9% NaCl) on embryonic day  (E18) and sacrificed 5 
h post treatment. Expression levels of several neurodevelopmental proteins in 
the exposed embryo were examined using western blotting. These 
neuroregulatory molecules are known to be critically involved in several aspects 
of neuron development such as synaptic formation and plasticity, axonal 
guidance, and neurogenesis processes amongst many others. This included 
analysis of components of the NMDA receptor subunits complex (NR2A, NR2B and 
postsynaptic molecule PSD95), tyrosine kinase receptor EphA4 that are 
associated with axogenesis and formation of synaptic contact, and also included 
inductive signalling factor sonic hedgehog (SHH). In addition we examined the 
inflammatory regulated molecules (COX2 and NFB) as well as general marker 
for neurogenesis in the brain, PCNA together with SOX2 in the exposed progeny. 
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As indicated in the previous section, acute poly(I:C) treatment in pregnant dams  
induced an elevation in one of the most important chemokines, MCP-1 in the 
maternal blood, thus confirming the the efficacy of the dose used in the animal 
set up. Western blot analysis of the level of β-actin, a house keeping protein, 
showed no difference between Ro61-treated rat and control. Both NMDA 
receptor subunits, its postsynaptic membrane proteins (PSD95) and axonal 
guidance molecule EphA4 from immunoblot anayses resulted in a strong signal at 
180 kDa,95 kDa and 120 kDa, respectively. In the foetal brain significant changes 
in the levels of NMDA receptor subunits were observed 5 h after maternal 
poly(I:C) injection,  which showed a highly  significant decrease of NR2A 
(expression level as compared with maternal control treatment Figure 3-3 (A), 
p=0.04). In contrast, expression of the NR2B subunit was increased in the brains 
of foetuses derived from poly(I:C)-treated mothers at 5 h post treatment (Figure 
3-3(B), p=0.03). The expression of the NMDA receptor associated protein, PSD95 
and one member of tyrosine kinase receptor, EphA4 were not significantly 
affected by maternal immunological manipulation at E18 (for PSD95: Figure 3-4 
(A),  p=0.06; for EphA4: Figure 3-4Figure 3-4 (B), p=0.30).  
In addition, we also examined several molecules with generic roles in neuronal 
proliferation,migration and maturation. Immunoblot analysis of the inductive 
signaling protein (SHH), neuronal proliferation marker (PCNA) and  transcription 
factor in early stages of cell maintenance and survival (SOX2) resulted in a signal 
with a molecular weight of 45 kDa, 36 kDa and 34 kDa, respectively. In the 
foetal brain, acute poly(I:C) exposure had no effect on the expression of SHH 
(Figure 3-5 (A), p=0.19),  PCNA (Figure 3-5 (B), p=0.37) and also SOX2 proteins 
(Figure 3-5 (C), p=0.35). Finally, we evaluated the effects of prenatal exposure 
to viral challenge on the expression of molecules involved in the inflammatory 
pathway which include transcription factor (TF) NFB and the inducible type of 
rate-limiting enzyme of  PGs sysnthesis, COX2.  In WB analysis, immunoreactivity 
for polyclonal p65 anti- NFB was found as a 65 kDa protein whereas anti-COX2 
showed at 70 kDa. Single administration of poly(I:C) during late gestation at E18 
revealed no significant difference in the level of relative amount of NFB p65 
subunit (Figure 3-6 (A), p= 0.90) and COX2 protein levels (Figure 3-6 (B), p=0.25) 
in the foetal brain from poly(I:C) exposed versus control dams.  
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Figure 3-3 Expression of NMDA receptor proteins in the embryo brains at 5h post-
administration. 
The graphs show immunoreactivity optical density values of NR2A (M.W. 180 kDa) and 
NR2B (M.W. 180 kDa)  after normalization with corresponding actin on the same gel. 
Intraperitoneal injection of poly(I:C) 10mg/kg was administered on E18 and samples were 
collected 5 hour later. Prenatal poly(I:C) administration decreased the levels of NR2A 
protein expression while displayed an increase in NR2B immunoreactivity relative to 
prenatal control animals. Actin was served as an internal standard control and was not 
significantly different across lanes. All data were expressed as mean ± standard error of the 
mean (SEM). Representative western blots illustrate the data obtained from animals 
exposed to the saline (S) [n=6] or poly(I:C) (P) [n=6] and show the relevant protein and the 
corresponding actin (M.W. 42 kDa). *P<0.05 unpaired t-test. 
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Figure 3-4 Expression of PSD95 and EphA4 proteins in the embryo brains at 5h post 
administration. 
The graphs show immunoreactivity optical density values of PSD95 (M.W. 95 kDa) and 
EphA4 (M.W. 120 kDa) after normalization with corresponding actin on the same gel. 
Intraperitoneal injection of poly(I:C) 10mg/kg was administered on E18 and samples were 
collected 5 hour later.  Actin was served as an internal standard control and was not 
significantly different across lanes. All data were expressed as mean ± standard error of the 
mean (SEM). Representative western blots illustrate the data obtained from animals 
exposed to the saline (S) [n=6] or poly(I:C) (P) [n=6] and show the relevant protein and the 
corresponding actin (M.W.42kDa). 
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Figure 3-5 Expression of neurodevelopmental proteins in the embryo brains at 5h post-
administration. 
All the graphs show immunoreactivity optical density values of SHH (M.W. 45 kDa), PCNA 
(M.W. 36 kDa) and SOX2 (M.W. 34 kDa) with corresponding actin on the same gel. 
Intraperitoneal injection of poly(I:C) 10mg/kg was administered on E18 and samples were 
collected 5 hour later.Actin was served as an internal standard control and was not 
significantly different across lanes. All data were expressed as mean ± standard error of the 
mean (SEM). Representative western blots illustrate the data obtained from animals 
exposed to the saline (S) [n=6] or poly(I:C) (P) [n=6] and show the relevant protein and the 
corresponding actin (M.W. 42 kDa). 
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Figure 3-6 Expression of inflammatory proteins in the embryo brain at 5h post-
administration. 
The graphs show immunoreactivity optical density values of NFB (M.W. 65 kDa) and COX2 
(M.W. 72 kDa) afternormalizationwith corresponding actin on the same gel. Intraperitoneal 
injection of poly(I:C) 10mg/kg was administered on E18 and samples were collected 5 hour 
later Actin was served as an internal standard control and was not significantly different 
across lanes. All data were expressed as mean ± standard error of the mean (SEM). 
Representative western blots illustrate the data obtained from animals exposed to the saline 
(S) [n=6] or poly(I:C) (P) [n=6]  and show the relevant protein and the corresponding actin 
(M.W. 42 kDa). 
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3.4.2.2 Maternal infection induced by poly(I:C) alters protein expression in 
the postnatal day (P) 21 offsprings. 
Maternal viral mimicked infection was modelled in timed-pregnant rats at 
embryonic days (E) 14, 16 and 18 by administering injections of poly(I:C) at 
(10mg/kg, i.p.) to study the impact of the maternal inflammatory response on 
the brain development of the resulting offspring at post natal day 21. Although 
not significantly altered in comparison to the 5 h treatment, the level of NR2A 
remained low, when observed in pups exposed to poly(I:C) at the later age of 
postnatal day 21 (Figure 3-7 (A), p=0.12). Similarly  with NR2A, expression of 
NR2B subunit was not altered in poly(I:C)-pups at postnatal day 21 (Figure 3-7 
(B), p=0.64). The expression of neither PSD95 (Figure 3-8 (A), p= 0.51) nor EphA4 
(Figure 3-8 (B), p= 0.12) showed any significant difference from control pups 
from saline-treated dams.   
As indicated in the section 3.4.2.1, acute poly(I:C) exposure had no effect on the 
expression of SHH, however repeated in utero viral challenges led to significant 
changes among this neurogenesis factor only at P21. As shown in Figure 3-9 (A) 
and Figure 3-5 (A), antibodies used against the SHH precursor protein (45 kDa) 
was clearly detected in the embryonic and postnatal brain tissues. Although 
there was no change in the level of expression of the SHH precursor protein at 5 
h after poly(I:C) injection compared with that in age-matched uninfected 
controls, a statistically significant reduction was shown in the brain of postnatal 
day 21 (p= 0.03). Similar situation was observed when poly(I:C) was administered 
during the mid and late gestation in the rodent model, long term effects of 
prenatal viral challenge on survival and maintenance of cells in the brain as 
indicated by the expression of SOX2 was clearly demonstrated. Prenatal poly(I:C) 
exposure significantly increased the relative amount of SOX2 protein in the P21 
pups  compared with control pups (Figure 3-9 (C), p= 0.009). Although strong 
signals were seen in the postnatal brain, PCNA protein levels of P21 offspring  
were not statictically different  as compared with control rats (Figure 3-9 (B), p= 
0.64). Results of western blot analysis with this developmental markers showed 
strong signals suggesting conserved levels of endogenous expression  during 
relatively early developmental period. Bands were also observed at moderate 
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intensities in the postnatal brain at the same position with molecular weight of 
36 kDa. 
Finally, we examined the levels of the inflammation transcription factor (TF) 
NFB and the inducible type of rate-limiting enzyme of  PGs sysnthesis, COX2, 
whose expression is linked to inflammation-induced oxidative stress. In the 
brains from P21 pups exposed to poly(I:C), the expression of neither NFB 
(Figure 3-10 (A), p= 0.97) nor COX2 (Figure 3-10 (B), p= 0.35) showed any 
significant difference from control treatment. Thus, prenatal viral challenge at 
either E18 or three time points during mid-late gestation showed no apparent 
difference between treatments on the levels of protein expression of selected 
inflammatory markers. 
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Figure 3-7 NMDA receptor protein levels in the P21 offsprings after the maternal 
injection of poly(I:C). 
Quantified protein expression of (A) NR2A and (B) NR2B in the brains of P21 rat offspring. 
Poly(I:C)-exposed groups consisted of offspring rats whose mothers were subjected to 
administration of a dose 10 mg/kg (i.p.) of poly(I:C) (P) on days E14,16 and 18 of gestation. 
Control groups consisted of offspring rats whose mothers were submitted to the same 
treatment schedule with saline (S). Exposed and control rats display no difference in the 
levels of protein. Results are expressed as mean ± SEM. Representative western blots 
illustrate the data obtained from both groups and show the relevant protein and the 
corresponding actin. There was no significant difference between control (n=6) and 
poly(I:C)-treated groups (n=6). 
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Figure 3-8 PSD95 and EphA4 protein levels in the P21 offsprings after the maternal 
injection of poly(I:C). 
Quantified protein expression of (A) PSD95 and (B) EphA4 in the brains of P21 rat offspring. 
Poly(I:C)-exposed groups consisted of offspring rats whose mothers were subjected to 
administration of a dose 10 mg/kg (i.p.) of poly(I:C) (P) on days E14,16 and 18 of gestation. 
Control groups consisted of offspring rats whose mothers were submitted to the same 
treatment schedule with saline (S). Exposed and control rats display no difference in the 
levels of protein. Results are expressed as mean ± SEM. Representative western blots 
illustrate the data obtained from both groups and show the relevant protein and the 
corresponding actin. There was no significant difference between control (n=6) and 
poly(I:C)-treated groups (n=6).  
 PSD95 
  Actin 
  S        S         P         P 
  S        S         P         P 
  EphA4 
   Actin 
  104 
 
A 
SHH
0.0
0.5
1.0
1.5
Saline                         Poly(I:C)
O
p
ti
c
a
l 
d
e
n
s
it
y
 (
O
D
)
O
D
 p
ro
te
in
/O
D
 a
c
ti
n
 
 
 
    
    
 
 
 
 
         
    
 
 
 
B 
  PCNA
0.0
0.5
1.0
1.5
Saline                         Poly(I:C)
O
p
ti
c
a
l 
d
e
n
s
it
y
 (
O
D
)
O
D
 p
ro
te
in
/O
D
 a
c
ti
n
 
 
 
         
         
   
 
 
    
    
 
 
C 
SOX2
0.0
0.2
0.4
0.6
0.8
1.0
Saline                         Poly(I:C)
O
p
ti
ca
l d
en
si
ty
 (
O
D
)
O
D
 p
ro
te
in
/O
D
 a
ct
in
 
 
 
                
 
 
       
        
        
 
Figure 3-9 Neurodevelopmental protein levels in the P21 offsprings after the maternal 
injection of poly(I:C). 
Quantified protein expression of (A) SHH, (B) PCNA and (C) SOX2 in the brains of P21 rat 
offspring. Poly(I:C)-exposed groups consisted of offspring rats whose mothers were 
subjected to administration of a dose 10 mg/kg (i.p.) of poly(I:C)(P) on days E14,16 and 18 of 
gestation. Control groups consisted of offspring rats whose mothers were submitted to the 
same treatment schedule with saline (S). SHH level was decreased in the poly(I:C)-exposed 
group compared to control rats. SOX2 was upregulated when observed at P21. Results are 
expressed as mean ± SEM. Representative western blots illustrate the data obtained from 
both groups and show the relevant protein and the corresponding actin. *p<0.05, **p<0.01 
by unpaired student t-test.  
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Figure 3-10 Expression of inflammtory proteins in the P21 offsprings after the maternal 
injection of poly(I:C). 
Quantified protein expression of (A) NFB and (B) COX2 in the brains of P21 rat offspring. 
Poly(I:C)-exposed groups consisted of offspring rats whose mothers were subjected to 
administration of a dose 10 mg/kg (i.p.) of poly(I:C) (P)on days E14,16 and 18 of gestation. 
Control groups consisted of offspring rats whose mothers were submitted to the same 
treatment schedule with saline (S). Exposed and control rats display no difference in the 
levels of protein. Results are expressed as mean ± SEM. There was no significant difference 
between control (n=6) and poly(I:C)-treated groups (n=6). 
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3.5 Discussion 
3.5.1 Maternal immune activation 
In line with cases of infection during pregnancy, several lines of evidence 
indicate that the maternal immune response rather than direct infection of the 
foetus is responsible for the increased incidence of schizophrenia and also 
autism in the offspring of mothers who suffer infections during pregnancy 
(Patterson, 2002, Gilmore and Jarskog, 1997). This evidence is supported by 
studies that show behavioural and histological abnormalities in the adult 
offspring following exposure to either bacterial lipopolysaccharide (LPS) or 
doublestranded RNA, poly(I:C) similar to those seen in the offspring of infected 
mothers. The variability of immunological and neurological responses from using 
active viral agents help rationalize the use of non-replicating viral mimetics like 
poly(I:C) that act through the same toll-like receptor 3(TLR3) as all other viral 
infections. Intravenous (i.v.) and i.p. administration of poly(I:C) are widely used 
as inducers of the innate immune response, which mimics the first phase of 
defensive mechanisms against viral infections. Systemic administration of viral 
mimetic is a widely accepted model of immune activation, resulting in TLR3 
stimulation which then induces a robust anti-viral response including type 1 
interferons α and β and also other inflammatory cytokines (Matsumoto and Seya, 
2008, Alexopolou et al., 2001). For the purpose of prenatal immune activation 
models, the use of poly(I:C) instead of live pathogens has the advantages of 
avoiding the use of infectious agents within the working environment and 
treatments can be standardized which provides a predictable intensity and 
duration by appropriate dosage. This aspect facilitates an evaluation of the 
influence of the timing of maternal poly(I:C)-induced immune challenge on the 
emergence of brain and behavioural dysfunctions in the resulting offspring 
(Meyer et al., 2006, Meyer and Feldon, 2011). 
To shed more light on the potential involvement of viruses in the etiological role 
during certain stages of brain development, models of early life exposure to the 
viral mimetic poly(I:C) was studied with regard to the long and short term 
effects on protein expression in the brain. We choose to mimic a viral infection 
instead of the most frequently used bacterial mimic agent, because viral 
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infections during pregnancy are common during the influenza season and appear 
to predispose the offspring to develop psychiatric illness (Brown et al., 2004).  
By using the synthetic double-stranded RNA poly(I:C) to induce maternal immune 
activation (MIA), we are able to study the effects of MIA on the embryo, and 
explore the impact and association between prenatal immune challenge and 
postnatal brain dysfunction. We noted no obvious malformations in the pups of 
poly(I:C) treated dams and no differences in body weight between the poly(I:C)-
rats and control rats. Early reports from our laboratory has confirmed the 
efficiency of the poly(I:C) used in the study to activate maternal immune system 
since the expression of MCP-1 is increased 5 h after its injection, indicating that 
the maternal is eliciting an inflammatory chemokine response which may then 
enhance the recruitment of mast cells. Mast cells express TLR-3 and are known 
to be strongly activated upon treatment with poly(I:C) (Kulka et al., 2004). The 
chemokine MCP-1 is reported to function in CNS inflammation and injury as it 
has been found expressed rapidly following brain injury by both microglia and 
astrocytes. Apart from that, chemokines contribute to normal brain 
development by providing cues for the migration of newly generated neurons 
and glial cells and also modulate axon path-finding. In addition, MCP-1 enhances 
neuronal excitability and synaptic transmission in hippocampal neurons (Zhou et 
al., 2011).  
A correlation between higher expression of MCP-1 and colonization of activated 
mast cells remains to be determined. Mast cells form close interactions with 
neurons and transfer intracellular content by transgranulation, which may 
modulate neuronal functions and affect CNS development (Wilhelm et al., 2005, 
Conti et al., 1997). However, we did not observe any changes in the level of 
other cytokines such as IL-1β and TNF-α in the maternal plasma (Forrest et al. 
2012). The basis for the observed changes and lack of changes in the other 
cytokines at 5 h following the administration of poly(I:C) is in agreement with 
the other studies that showed a robust increase of TNF-α protein level in the 
maternal plasma at 2 h after exposure, decreased thereafter and below the level 
of detection by 6 h post injection, while plasma concentration of IL-1β did not 
change after poly(I:C) injection. It also has been observed at a protein and 
mRNA level that the concentration of IL-1β may vary during development 
(Fortier et al., 2004). Analysis of i.p. administration of poly(I:C) indicates the 
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triggering of a broad antiviral maternal innate immune activation and represents 
a unique response of the maternal environment and would have a variety of 
effects on the developing brain (Gilmore et al., 2005a). The mechanisms 
whereby viral infection can lead to neurodevelopmental disorders remain poorly 
understood. Currently it is believed that the virus can act either directly or 
indirectly to affect neurodevelopment. Following viral infection, the immune 
system becomes activated and cytokines are released, which can in turn 
interfere with proper neurodevelopment as already mentioned. It should be 
noted that although the physiological function of cytokines might be to preserve 
or restore homoeostasis, sustained or excessive production of cytokines could 
cause damage. Expression levels of a subset of cytokines and chemokines in the 
foetal brains somehow do not reflect the changes in concentration levels 
observed in maternal serum. Since only maternal serum was assessed in this 
study and we have not assessed the cytokine levels in the foetal and placenta, 
measurement of foetal brain cytokines following a similar set up of prenatal 
infection would provide additional information with respect to the association 
between their role in inflammatory responses and effects on CNS development, 
including effects on neuronal survival, differentiation and also excitotoxicity in 
developing brain (Rothwell and Hopkins, 1995, Boksa, 2010).  
It should be emphasized that the effect of maternal infection on the 
measurement of foetal brain cytokines was complex, and is dependent on the 
gestational age at which poly(I:C) was administered and the time of the 
evaluation after administration.  Findings with regard to the changes in protein 
levels of these cytokines in foetal brain have shown inconsistency and do not 
provide compelling evidence as to suggest the exact mechanism of how 
cytokines changes in fetal brain could have altered the function of foetal 
neurodevelopment (Meyer et al., 2006). However, causal links between maternal 
infection and the emergence of a wide spectrum of behavioural and 
pharmacological abnormalities in the offspring have been observed in rodent 
models (Boksa and Luheshi, 2003). This has led to speculation that the idea that 
the perturbations caused by the prenatal immunological manipulation are 
widespread, indicative of multiple structural brain abnormalities and also 
dependent on a range of normal neuropsychological functions. Therefore, it 
remains to be experimentally confirmed whether cytokines are the mediators 
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responsible for long term effects on CNS function in offspring (Shi et al., 2003, 
Meyer and Feldon, 2009). 
3.5.2 Protein expression 
Results from this study also indicate the ability of inflammatory challenges by 
poly(I:C) to produce neuroadaptive changes that might alter neuronal properties 
and function including  changes in the magnitude of NMDA receptor  subunit 
expression. This receptor is known to be an important regulator in neuronal 
development and function, therefore alterations in the levels of its neuronal 
properties could have important consequences for synaptic responses (Hunt and 
Castillo, 2012). To further address this issue, we have examined the effect of 
poly(I:C) exposure during gestation on the level of two major subunits of the 
NMDA receptor in the brain obtained from the embryo and also from postnatal 
age 21 day. The NR2A and NR2B subunits were chosen for examination in this 
study because they are the most predominant NMDA receptor subtypes in their 
respective subunit families and underlie functional excitatory synaptic 
transmission and activity-dependent synaptic plasticity (Cull-Candy et al., 2001, 
Cull-Candy and Klein, 2007). Both subunits show greater excitotoxicity than the 
other subunits and brain regions enriched in NMDA receptor composed of NR2A 
and NR2B subunits (such as hippocampus and forebrain) are commonly injured in 
excitotoxic insults such as ischemia, brain injury and HIV-1 infection (Waxman 
and Lynch, 2005, O'Donnel et al., 2006, Schumann et al., 2008). The expression 
of NMDA receptor subunit subtypes were significantly altered following 5 h post-
exposure with poly(I:C). However, the differential changes of the subunit levels 
induced by poly(I:C) then reached expression levels comparable to those 
observed in control offspring at postnatal day 21. Our findings suggest that both 
NR2A- and NR2B-containing receptors would be particularly susceptible to 
poly(I:C)-induced damage in the embryo brains. The demonstrable low level of 
NR2A and robust expression of NR2B subunit suggests the likely expression of 
functional NR2B, since it has been shown that this subunit predominates in early 
development (Waxman and Lynch, 2005, Babb et al., 2005). The resulting 
increase in the amount of this subunit may be due to new protein synthesis in 
the total brain homogenates. It thus seems that the early changes to NMDA 
receptor subunit expression in the foetus derived from immune-challenged 
mothers may not have been sufficient to impair the subsequent expression of 
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NMDA receptor associated molecules in the brain at a later stage of postnatal 
development (i.e on P21). However, it should be pointed out that infection-
induced disruption of early prenatal brain development may lead to long-lasting 
structural and functional brain abnormalities leading to the emergence of 
behavioural dysfunctions in later life (Fatemi et al., 2002, Meyer et al., 2008b). 
Although questions remain to be answered regarding the specific mechanisms of 
action for synaptic protein, their involvement in the regulation of patterns of 
synaptic connectivity has been established and suggestive evidence implicates 
them in schizophrenia (Cull-Candy et al., 2001, Gladding and Raymond, 2011).  
Another interesting finding emerging from the present results was the expression 
of SHH and SOX2. The relative protein level of inductive signal SHH was initially 
unchanged in the brains of foetuses derived from poly(I:C)-treated mothers 5 h 
post-treatment, but then decreased significantly at 21 days. This effect was  
found in the young offspring 21 day after they were born, demonstrating that 
prenatal exposure to poly(I:C) can produce long-term neurochemical alterations. 
A related study of maternal poly(I:C) exposure on a different time point, during 
early/middle pregnancy (E9) found reduced foetal brain gene expression of SHH 
at 2, 4 and 8 days after maternal immune activation. This study provides 
evidence on the involvement of SHH and other related genes in the foetal 
dopaminergic development(Meyer et al., 2008a). SHH signalling is required 
during embryonic development in the regulation of cell proliferation, migration 
and survival and in the maintenance of cell in the adult (Bale, 2002). Evidence 
that strengthen the pivotal role of SHH signalling during early developmental 
period demonstrate the regulation of cellular proliferation for precise 
morphogenesis of embryonic tissue  and also in the early expansion of developing 
midbrain and proliferation of granular cell precursors in cerebellum(Wechsler-
Reya and Scott, 1999, Britto et al., 2002, Ruiz i Altaba et al., 2002). The 
influence of SHH signalling activation in response to other types of infection also 
has been noted. Expression of SHH and its downstream signalling molecules, GLi1 
and its receptor Patched (Ptc) were upregulated in Helicobacter pylori infection 
and the level of SHH is elevated in gastric cancer cells. This suggests that SHH 
signalling pathway is one of the host signals related to cancer growth and 
metastasis and changes in the level of SHH expression may provide a marker for 
chemo preventive measures(Kim et al., 2010). In vivo studies showed that 
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prolonging infection with H.pylori resulted in a different pattern of SHH protein 
expression in the gastric mucosa of the gerbils 51 weeks after bacterial 
inoculation (Suzuki et al., 2005).  Both studies demonstrate that H.pylori 
infection modified the expression of morphogens involved in the regulation of 
gastric mucosal homoeostasis. In addition, a number of researchers have shown 
that dysregulated activation of SHH signalling predispose cells to the 
development of tumours, in which overexpression of SHH have been found in 
many types of cancers including medullolastoma, basal cell carcinoma, lung 
carcinoma, adenocarcinoma of digestive tract and oral squamus cancer cell 
(Dahmane et al., 2001, Wechsler-Reya and Scott, 1999, Stecca and Ruiz i Altaba, 
2005, Lupi, 2007, Watkins et al., 2003, Nishimaki et al., 2004). Apart from its 
role in patterning and the proliferation of embryonic tissue, SHH has been shown 
to influence the differentiation of various cell types, including dopaminergic 
neurons and lymphocytes (Hynes and Rosenthal, 1999). The present finding 
showed that maternal poly(I:C) during late gestation decreased the level of the 
inductive signal SHH in the P21 offspring as compared with maternal control 
treatment. Since the emergence of changes was demonstrated only at a 
postnatal age, this leads to the possibility that SHH signalling pathway 
abnormalities emerging after prenatal immune challenge are likely to be of 
developmental origin starting early in foetal life (at the time of injections) and 
that the pathway is influenced following maternal immune activation. 
The high-mobility group transcription factor SOX2 is expressed in embryonic 
neural epithelial stem cells and represent the unique expression of multipotent 
stem and progenitor cells in neurogenic regions of the brain of the central 
nervous system (CNS) throughout adulthood (Brazel et al., 2005, Lefebvre et al., 
2007). In this study, we showed that SOX2 protein levels was not affected by 
maternal poly(I:C) exposure during embryonic development, however an 
upregulation of SOX2 protein product in the brain of day 21 progeny of virally 
exposed rat was observed. SOX2 expression has been most commonly associated 
with non-committed stem and precursor cells in the developing nervous system. 
It was also being expressed in multipotent cell types which suggest a role for 
SOX2 in preserving developmental potential.  Many SOX genes are expressed in 
the developing and adult brain, their expression patterns overlapping with each 
other since a high degree of identity are shared within the same group (Guth and 
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Wegner, 2008, Brazel et al., 2005). In vitro functional studies showed that the 
collaboration of SOX2 with the other transcriptional factors, particularly Oct4 
and Nanog is required to maintain pluripotency and self-renewal in human 
embryonic stem cell (ESC), thus preserving developmental potential (Fong et al., 
2008). Even though the SOX-B1 members can compensate for each other‟s loss 
during early development, they have distinct roles later in development 
(Graham et al., 2003). Thus proper levels of SOX2 are required for stem cell 
maintenance as either increased or decreased levels of SOX2 are used as cues for 
differentiation. Continuous expression of SOX2 led to an increased number of 
proliferating progenitors and reduction of SOX2 is associated with loss of the 
pluripotent state and a propensity for differentiation and regulation of target 
genes requiring cooperation between other critical transcriptional regulators like 
Oct4 and Nanog (Lefebvre et al., 2007). 
As a cofactor for DNA polymerase delta and DNA replication, PCNA expression is 
a useful marker of cell proliferation under both normal and pathological 
influences. In this study, following the poly(I:C) exposure, PCNA protein levels 
were not significantly different than control levels as observed at E18 and P21. 
As PCNA expression was used to identify the population of proliferating cells and 
involved in the regulation of cell cycle and neurogenesis, any insult such as 
ischemia or infectious agents may serve as triggers to activate the cell cycle. 
Increased density of proliferating cells has been observed in several models of 
experimental CNS injury such stroke and bacterial meningitis, which postulate 
the idea of increased neurogenesis as a general reaction after neuronal injury of 
various etiology (Gerber et al., 2009). Apart from that, it has been regarded as 
one of either diagnostic or prognostic markers in many disease states, which 
include predicting the biological behaviour of different types of tumours. The 
higher content of PCNA positive cells in ameloblastic carcinoma samples perhaps 
could explain the infiltrative growth of ameloblastoma in which PCNA positivity 
reflects cell proliferation (Piattelli et al., 1998). However, conclusions drawn 
from PCNA immunohistochemical studies vary considerably, reflecting 
differences in case selection, sample selection, numbers of cells counted, 
evidence of reproducibility and methods of statistical analysis (Kurki et al., 
1986, Valero et al., 2005).  
  113 
 
We also investigated the impact of maternal immune challenge during pregnancy 
on the foetal and postnatal expression of several genes known to be critically 
involved in inflammatory related process. This included analysing the protein 
expression of COX2 and the transcription factor, NFB. This served to ascertain 
whether putative changes in inflammatory markers might be causally related, in 
part to the known consequences of infection exposure in the human. It should be 
noted that the nature of the predominant cellular response and the 
inflammatory factors involved in immune and inflammatory process is extensive, 
thus the presence of enhanced expression of MCP-1 reflects a general pro-
inflammatory status in the maternal environment following poly(I:C). However, 
poly(I:C)-induced immunological challenges in rodents are short lived, ranging 
from 24 to 48 h depending on the dose (Meyer and Feldon, 2011). As the peak of 
detection of protein and mRNA levels of cytokines may vary following 
stimulation and our results showed no changes to other inflammatory cytokines 
such as IL-1β and TNF-α in maternal compartment. We suggest that there was no 
ongoing inflammatory activity that could exaggerate inflammatory responses in 
which we have noted no evidence of changes in the levels of expression for 
NFB and COX-2 in the embryo brain or young adult offspring P21. Although 
there was no demonstrable difference in immunoreactive of both markers in the 
fetal and postnatal brain, low steady state levels of COX2 and NFB are 
observed throughout the brain. Steady state of COX2 appears to be regulated by 
normal glutamatergic synaptic activity in the adult brain (Kaufmann et al., 
1997). In this regard, endogenous synaptic transmission also might be capable of 
regulating NFB activity (Meffert and Baltimore, 2005).  
The widespread distribution in the CNS indicates that NFB may be sensitive to 
synaptic activation as expression of this gene is increased in hippocampal 
granule cells after LTP (Meberg et al., 1996). The presence of extracellular 
signals such cytokines, bacteria, viral proteins or mitogen causes the activation 
of NFB with rapid translocation to the nucleus and the transcriptional 
activation of target genes. A common sign of NFB-activating conditions is that 
they either represent a direct threat to the cells or that they are endogenous 
signals produced in response to pathogens (Baeuerle and Henkel, 1994). The 
activation of inflammatory transcription factors within the brain is a step that 
occurs before the expression of target genes, which trigger brain-intrinsic 
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responses. This phenomenon can be assessed by measuring the expression of 
markers and their activation. It is well known that NFB is one of the early 
markers of  inflammatory activation in the brain, and their nuclear translocation 
can be induced by TNF/IL-1and IL-6 as shown in previous studies (Dharane et al., 
2010). Corresponding to the rather negligible levels of this pro-inflammatory 
cytokine in the maternal plasma, no clear changes in the expression levels of 
NFB was observed either at 5 h post treatment (embryo brain) or at later 
developmental age of P21.   
Although COX2 has limited constitutive neuronal distribution in the CNS, it can 
be induced in the mammalian brain under a variety of physiological and 
pathological conditions (Yamagata et al., 1993).  For example, a marked 
elevation of COX2 mRNA levels by kainic acid-induced seizure was detected in 
the hippocampal CA1-1 pyramidal cell layers, granule layers of DG, cortex and 
amygdale. Pronounced increases in brain derived neurotrophic factor (BDNF) 
mRNA has also been noted in the dentate granule cell layer and pyramidal 
layers. It has been suggested that marked expression of BDNF in rat brain may 
occur as a trophic response to the neuronal injury caused by kainic acid-induced 
seizures (Hashimoto et al., 1998). Injuries to the brain activate multiple cellular 
pathways, some of which are adaptive, while others may persist and become 
harmful. The severity of neural injury appears to correlate to the degree and 
duration of some of these inflammatory markers. In agreement with this, 
increased COX2 expression has been observed with several neurodegenerative 
disorders such as AD, ALS and PD and also in traumatic brain injury and seizures 
(Nogawa et al., 2003, Almer et al., 2001, Teisman et al., 2003, Joseph et al., 
2006). The present results show no marked changes in the expression of pro-
inflammatory cytokines (TNF-α and IL-1β), the inducible form of enzymes for 
PGE2 (COX2) and the transcription factor (NFB) following maternal poly(I:C) 
treatment. Thus, our study showed that repeated challenges do not appear to 
induce an inflammatory response distinct from that induced by a single 
challenge and are insufficient to produce any lasting impairment in the 
inflammatory pathway. 
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3.6 Conclusion 
Changes in behaviours relevant to psychiatric disorders such as schizophrenia 
and autism are consistently reported following maternal challenge in the mouse 
or rat, and the MIA model to study prenatal risk factors for these disorders is the 
focus of much scientific research (Boksa, 2010, Smith et al., 2010). The 
mechanisms by which MIA disrupts foetal development and sets into motion an 
atypical trajectory of brain and behavioral development and maturation are 
largely unknown. It is therefore possible that the induction of cytokines and 
downstream effects of such activation in the foetal brain following MIA 
interferes with neurodevelopmental processes or functioning within the brain 
regions essential to social behaviours (Meyer, 2013, Meyer et al., 2009). It should 
be pointed out that the current study did not examine the anatomical and 
behavioural consequences of maternal poly(I:C). Based on the current findings, 
it is not possible to draw any conclusions as to relate the mechanisms by which 
poly(I:C)-induced MIA leads to subsequent behavioral changes.  In this aspect, a 
more complete behavioural phenotype of offspring born to poly(I:C)-exposed 
dams is required to determine the specific behavioural effects of MIA. 
Additionally, the mechanism by which MIA results in atypical performance on 
behavioural tasks is unclear and may be addressed by the inclusion of 
neuroanatomical studies. It is important to note that regulation of expression of 
molecules used both during early development and in other processes later in 
life is likely to play a major role in the correct processing of the molecule‟s 
functions. Differential regulation, possibly involving different regulatory 
molecules or mechanisms, occurs at different stages of life and could be 
responsible for different phenotypes in different developmental periods. The 
present study was conducted with the aim to characterize the effects of the 
infection on CNS function in the offspring at two points of developmental stages 
(embryo and P21). Assessing acute neurochemical changes in foetal brain are of 
importance in understanding mechanisms that underlie persistent or longer term 
CNS changes in the offspring following maternal infection. 
 In summary, the study carried out showed some evidence that disturbances 
caused by viral infection during prenatal period of life can produce some 
neuroadaptive changes that alter neuronal function and development. Some of 
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the developmental markers showed changes during the period of the insult and 
disappeared or diminished as animal grew up. This may be an outcome of the 
compensatory capacity of the CNS to alleviate such changes. In relation to this, 
changes seen in the expression of the NMDA receptor subunits, NR2A and NR2B 
could imply that alterations in the receptor number and function may impinge 
on the formation and establishment of neuronal circuits and connections. The 
present study demonstrates that poly(I:C) challenge in pregnant dams results in 
transient alterations in  the levels of NMDA receptor subunit NR2A and NR2B in 
the fetal brain, representing a potential mechanism for altering synaptic 
development and may contribute to abnormal brain development and risk for 
neurodevelopmental disorders.  On the other hand it is also possible that 
prenatal poly(I:C) treatment manifested its effects on the postnatal brain 
independently from its effect at the time of exposure. The acute inflammatory 
response induced by prenatal poly(I:C) administration somehow induced further 
long term changes in factors regulating cell proliferation and migration, in order 
to produce altered neurogenesis in offspring later in development at P21. We 
show that changes in markers that are involved in neurogenesis (SOX2 and SHH) 
were observed at a later stage of postnatal development (P21). This could imply 
that prenatal immune activation elicited by poly(I:C) in rodents may have long 
term effects on neurogenesis in young postnatal offspring. Although we did not 
include behavioural assessment and immunolabelling studies, previous data 
together with current findings suggest such deficits or changes in neurogenesis 
could conceivably contribute to the alterations in hippocampal-mediated 
function that have been observed in juvenile or adult rodents following prenatal 
exposure to poly(I:C) (Meyer et al., 2008b). However the results presented here 
support the association between immunological manipulation at a specific 
gestational age and postnatal brain dysfunctions. Unravelling the mechanisms 
that mediate immunologically sensitive developmental periods that allow for 
programming of adults‟ responses deserves further attention in which it permits 
possibility for intervention. Taken together, our animal models indicate that 
distinct neurochemical abnormalities are manifested at different stages of 
postnatal development after prenatal exposure to viral-like immune challenge 
during late gestation in rats.  
 
 
 
4 The effect of prenatal inhibition of the 
kynurenine metabolism pathway on the 
expression of proteins in the rat brains 
4.1 Introduction 
It has been suggested that changes in the endogenous levels of neuroactive 
metabolites of the kynurenine pathway are implicated in the pathogenesis of 
several brain disorders, for instance Parkinson‟s disease and schizophrenia.  
These neuroactive metabolites include KYNA, 3-hydroxykynurenine (3-HK) and 
quinolinic acid (QUIN). The basis for kynurenine pathway up-regulation as seen 
in psychotic disorders may not reside within one particular enzyme but rather 
with one of many factors that control the expression of the initiating enzymes 
involved in the pathway. There is evidence that emphasize the unique 
antagonistic properties of KYNA as an endogenous factor which is capable of 
blocking the neurotoxic and seizures caused by QUIN which support the fact that 
manipulation favouring its accumulation in the brain extracellular space may be 
beneficial against endogenous excitotoxic abnormalities (Foster et al., 1984). 
Pharmacological blockade of the enzyme kynurenine-3-monooxygenase (KMO) 
which is responsible for the formation of 3-hydroxykynurenine is one of the ways 
of influencing the level of kynurenine in the brain (Stone and Addae, 2002). 
For the purpose of this study, a novel compound 3,4-dimethoxy-N-[4-(3-
nitrophenyl)thizol-2-yl]benzenesulfomide or better known as Ro61-8048 which 
exerts high activity as a selective inhibitor of enzyme KMO was used. The aim 
was to provide a better understanding of the actions of this inhibitor in the 
central nervous system and to assess the possible mechanism of action. We 
examined protein expression of selected markers in brain homogenates of 
offspring whose mother had been administered at 3 time points (E14, 16 and 18) 
with compound Ro61-8048 at 100 mg/kg. These markers included the NMDA 
receptor subunits NR2A and NR2B, NMDA receptor post synaptic density protein 
PSD95, type A ephrin receptor EphA4, inflammatory markers NFB and COX2, 
sonic hedgehog (SHH), stem cell marker SOX2 and proliferation marker PCNA. 
The protein level of these markers was examined by using western blots and 
relative protein levels are shown after normalization to corresponding actin 
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levels on each lane. We explored differential protein expression profiles in the 
rat brain at different stages of postnatal development, whole brain at postnatal 
day 21 (P21) and regional expression in hippocampus, cerebellum, cortex and 
midbrain in postnatal day 60 (P60) rat. Protein expression in the embryo brains 
following administration of KMO inhibitor, Ro61-8048 was also examined at 5 h 
and 24 h after treatment. Apart from that, the ability of the administration of 
the novel compound 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-
yl]benzenesulfomide or known as Ro61-8048 during gestation in altering the 
balance of kynurenine pathway through reducing kynurenine pathway flux to 
QUIN, either to cause a rise in brain KYNA levels or decreased formation of QUIN 
has been previously determined by our colleague, Dr Forrest C.M. (HPLC results 
shown in (Forrest et al., 2013a). 
4.2 Research aims 
What is the influence of early modulations to the kynurenine metabolism 
pathway on the functional expression of proteins important to brain 
development and to what extent does kynurenine-3-monooxygenase inhibitor 
(Ro61-8048) play a role in reducing kynurenine pathway flux? To address this 
issue we set out our aim to study the role of compound Ro61-8048 in influencing 
the regulation of normal neuronal development through modulation of the 
kynurenine pathway on the level of protein expressions in the embryo and 
subsequent changes in the brain development of offspring at P21 and P60. The 
aim was also to characterize the effects of the KP inhibition on CNS function in 
the offspring at various stages of development. 
 
4.3 Experimental approaches 
Our experimental strategy is to use an animal model similar to the protocol 
established for maternal immune activation by employing the western blotting 
technique to examine protein expression of selected markers that play a key 
role in neuronal development, synaptic plasticity, axon guidance and neurite 
outgrowth. For the first phase of the study, investigations into the effect of 
administration of compound Ro61-8048 during gestation on selected molecular 
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targets of neurodevelopmental relevance was carried out in the embryo brains 
at two time points, 5 hour and 24 hour post-injection of Ro61-8048 on embryonic 
day 18. A later phase of the project involved an examination of the effect of  
prenatal inhibition of kynurenine pathway on E14/16/18 in terms of changes to 
the protein expressions of a selected panel of neurodevelopmental targets in the 
offspring at postnatal day 21 and 60. It is important to determine whether any 
alterations in protein expression at an early stage of development either in 
embryo or at young age P21 would persist into adulthood.  
4.3.1 Animal treatment regimens 
4.3.1.1 Acute administration of Ro61-8048 
This experiment was set up for the purpose of assessing the immediate effects of 
gestational modulation of the kynurenine pathway on the levels of protein 
expression in the embryo brains measured 5 h and 24 h post administration. For 
this purpose, gestational day 18 timed-pregnant rats were assigned to receive 
i.p. injections of the following treatment regimens: (1) 5 h group: saline (0.9% 
NaCl) and (2) 5 h group: 100mg/kg Ro61-8048.  After the injections the animals 
were left undisturbed for 5 hours and then anesthetized with an overdose of 
sodium pentobarbital and decapitated after blood was obtained by cardiac 
puncture. The blood was collected in a heparinised vacutainer tube and kept ice 
cold. The animals were dissected and the uterine horn containing embryonic day 
18 pups were surgically removed. Foetal whole brains were dissected and 
immediately frozen on dry ice.  In another set of experiment, two groups of 
pregnant rats were injected at gestational day 18 with single injection of vehicle 
solution and compound Ro61-8048 (100mg/kg), respectively. Twenty- four hours 
later, the animals were sacrificed and dissected to obtain foetal whole brains 
along with the mother‟s brain. In addition, this set up was partly to demonstrate 
the effect of selected dosages in producing changes in the levels of several 
metabolites of the kynurenine pathway through HPLC analysis. The levels of 
kynurenine and kynurenic acid were measured by high performance liquid 
chromatography (HPLC) with electrochemical detection as previously described 
(HPLC data not shown). HPLC analysis was  performed by Dr Forrest C.M. 
(Forrest et al., 2013a).  
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4.3.1.2 Postnatal day 21 and 60 
For gestational treatment, groups of pregnant dams were  administered 
intraperitoneally (i.p.) with compound Ro61-8048 (100mg/kg) at the dose 
indicated on days E14, E16 and E18 in order to extend the temporal impact of 
kynurenine pathway modulation on the embryos, with no apparent ill effects on 
the dam or her behaviour towards her litter after birth. Group of pregnant dams 
were injected on E14, 16 and 18 between 9am and 11am to minimise variation in 
responses. Control females were injected with the same volume of 0.9% NaCl. 
Gestation was allowed to proceed normally and the offspring were undisturbed 
until weaning on P21 when they were taken from the home cage for euthanasia 
followed by removal of the brain. Each brain was divided into the two cerebral 
hemispheres and frozen immediately on dry ice before being transferred to 
storage at -80ºC until required for analysis.  
In a separate experiment to evaluate the extended effect of prenatal exposure 
of compound Ro61-8048 in more mature animal, the neonates were allowed to 
survive until around 60 days of age (young adult) at which time all litters were 
euthanized and their brains were removed. The brain was then sectioned into 
four main regions i.e. hippocampus, cerebellum, cortex and midbrain and 
preserved for further western blot (WB) analysis. 
4.3.2 Western blot analysis 
Tissue samples were prepared as described in the chapter 2. Briefly, samples 
were homogenized in RIPA buffer containing protease inhibitors and total protein 
concentration was determined in the resulting supernatant using the Bio-Rad 
Coomassie Blue Protein assay. Samples were normalised to 10-20µg per lane and 
subjected to 4-12% Bis-Tris gel electrophoresis and run at 150V for 80 min with 
SeeBlue pre-stained as standard. Each gel contained samples from three 
separate litters (two pups from each litter), n=6. Proteins were separated  
according to their molecular weight and transferred onto PVDF membrane and 
blocked in 5% non-fat milk/TBST and then incubated (overnight at 4oC) with the 
primary antibodies (see Antibodies section in chapter 2, Table 2-5). Membranes 
were then washed 3 times for 15 min in TBST and incubated for 1 h at room 
temperature with the appropriate secondary antibody (prepared in 5% 
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milk/TBST). After incubation, blots were washed 3 times for 15 min and 
developed using enhanced chemiluminescence plus detection kit and 
immediately exposed to film.  
The measurement of protein level for the selected molecular targets for western 
blot analysis includes NMDA receptor subunits NR2A and NR2B, an ephrin 
receptor EphA4, NMDA receptor anchoring protein post synaptic density (PSD95), 
inflammatory markers NFkB and COX2, the key signalling molecule for 
organogenesis sonic hedgehog (SHH), proliferating cell nuclear antigen (PCNA) as 
a proliferation marker and stem cell marker SOX2. Actin was used as a control for 
transfer and loading and was unchanged throughout the experiment.  
4.3.3 Data analysis and statistics 
Immunoreactive bands for all the markers were analysed using ImageJ software. 
To control for accuracy of tissue loading and efficiency of transfer, all sample 
bands were examined after staining with Ponceau S stain. Data were normalised 
to actin detected on the same blots. The final data are expressed in standard 
protein unit and presented as a ratio of [intensity of target protein]/[intensity 
actin]. The data were analysed statistically using unpaired t tests to examine 
differences between groups of pups born to mothers treated with Ro61-8048 and 
groups born to mothers injected with saline. A p value<0.05 was considered 
significant and actual P values are indicated when >0.0001.   All data are 
presented as means ± SEM.  
4.4 Results 
Studies on the effects of inhibitors of enzymes particularly enzyme kynurenine-
3-monooxygenase (KMO) in the kynurenine pathway are interesting, since such 
molecules could on the one hand increase kynurenine availability and kynurenic 
acid (KYNA) production and on the other, decrease the synthesis of 3-
hydroxykynurenine and of QUIN, 2 toxic compounds which originates from a 
different pathway of kynurenine metabolism.  
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To examine whether a single or triple injections of Ro61-8048 during the late 
gestational period influenced the level of expressions of several proteins 
important to brain development, either acutely or chronically in young and adult 
animals, we performed semi-quantitative western blot on brain tissue collected 
either at 5 h and 24 h after injection (acute) or on P21 whole brain (chronic). 
Another set of animals using much older animals at P60 is important to 
determine whether any changes seen in developing brains would be extended to 
a later age. The effect of each marker might be masked in the whole brain, thus 
we hope to able to pick up any subtle changes in regional samples of P60 which 
includes hippocampus, cerebellum, cortex and midbrain.  
4.4.1 Effects of prenatal modulation of kynurenine pathway on 
embryonic brains following prenatal exposure to Ro61-8048 
In order to provide a better understanding of the actions of this inhibitor in the 
central nervous system and to assess the possible mechanism of action, we  
examined the protein expression of selected markers, namely NMDA receptor 
subunits NR2A and NR2B, NMDA receptor post synaptic density protein PSD95, 
type A ephrin receptor EphA4, inflammatory markers NFkB and COX2, sonic 
hedgehog (SHH), stem cell marker SOX2 and proliferation marker PCNA in the 
embryo brains measured after 5 h and 24 h. The levels of the protein expression 
in all the markers were determined by immunoblot analysis with the specific 
antibody as listed in the chapter 2 (Table 2-5). The protein level of these 
markers was examined by using western blot and relative protein levels are 
shown after normalization to corresponding actin on each lane. Levels of other 
proteins, in this case, actin were not significantly modified for the duration of 
the treatment.  
4.4.1.1 Effects of prenatal Ro61-8048 on embryonic brains after 5 h 
exposure. 
The protein expression profile of NR2A-and NR2B-containing NMDA receptor 
subtypes and one of the NMDA receptor-interacting proteins, PSD95 following 
maternal administration of Ro61-8048 was examined in the embryo brains. For 
both NMDA receptor subunits and PSD95, immunoreactive bands corresponding to 
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molecular masses of 180kda and 95kDa, respectively, were observed in brain 
homogenates. In the embryo brains, an obvious reduction in the expression of 
NR2A subunit (Figure 4-1 (A), p=0.005), and a significant increase in expression 
of the other subunit NR2B (Figure 4-1 (B), p<0.0001) were observed at the early 
stage following 5 hour post administration of Ro61-8048.There were no 
significant changes in the level of expression for PSD95 (Figure 4-2 (A), p=0.10), 
a major postsynaptic protein interacting with the C-terminal domains of the NR2 
subunits. 
Antibodies directed against the ephrin receptor type A (EphA4), sonic hedgehog 
(SHH), proliferating cell nuclear antigen (PCNA) and sex determining region of Y-
chromosome related-HMG box 2 (SOX2) all detected single prominent bands at 
the appropriate molecular weights (120kDa for EphA4, 45  kDa for SHH, 36 kDa 
for PCNA and 34 kDa for SOX2). We have performed western blot analysis to 
determine whether protein expression of the molecules that have important 
roles in several aspect of neuronal development particularly neurogenesis 
processes, guidance of migrating cells and neuronal growth cones to specific 
destinations and synapse formation. Involvement of EphA4, one of the Eph 
receptor tyrosine kinases is seen as a key player in controlling cell movements in 
many tissues and at multiple stages of patterning that underlie the 
establishment, maintenance and remodelling of cellular organisation. However, 
level of EphA4 protein revealed no changes (Figure 4-2 (B), p= 0.34) after 5 h 
prenatal administration of Ro61-8048. The groups treated with Ro61-8048 also 
produced no significant changes in the levels of the rest of these proteins. As 
shown in Figure 4-3 (A), western blot analysis of the embryo brain lysate by using 
anti-SHH antibody showed that regulation of precursor form of SHH protein was 
not affected by single administration of Ro61-8048 during late gestation (p= 
0.57). PCNA is an auxiliary protein of DNA polymerase delta necessary for DNA 
replication and its expression has been shown to elevated during G1/S cell cycle 
phase (Kurki et al., 1986). As shown in Figure 4-3 (B), strong signals were seen in 
whole embryo lysates. Our immunoblot analysis showed that PCNA expression 
was not changed following 5 h of Ro61-8048 treatment (Figure 4-3 (B), p= 0.73). 
Five hour after treatment with KMO inhibitor also made no differences in the 
levels of SOX2 protein although this protein was found to be strongly expressed 
in the brain homegenates prepared from foetal brain (Figure 4-3 (C), p=0.48). 
  124 
 
We detected immunoreactive NFB p65 subunit and COX2 expression in embryo 
as shown in Figure 4-4 (A & B). However, no changes in immunoreactive levels of 
both markers were observed after 5 h injection with the enzyme inhibitor, Ro61-
8048 (NFB: p= 0.53; COX2: p= 0.51).  
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Figure 4-1 Expression of NMDA receptor subunits NR2A and NR2B proteins in the 
embryo brains after prenatal Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on embryonic day 18 (E18) and 5 h 
later, embryo brains were obtained. Homogenized tissues of the brains from 6 embryos in 
each group were used for analysis. Blots were probed for NR2A and NR2B as marked, 
showing the presence of NR2A/NR2B containing complexes in the whole brain tissue. 
Representative immunoblots showing protein expression levels of NR2A (M.W. 180 kDa) 
and NR2B (M.W. 180 kDa)  in the embryo brains, with actin (M.W. 42 kDa) shown as a 
loading control. Histogram showing relative NR2A and NR2B protein expression normalized 
to actin expression. Data were expressed as mean ± SEM. (A) Compared with saline-treated 
animals(S) (n=6), there was a signifcant decrease in NR2A protein expression in Ro61-8048 
(R) (n=6)(**p<0.01). (B) Prenatal treatment with 100mg/kg Ro61-8048 showed significant 
increase in NR2B expression compared to control animals (n=6)(***p<0.001). 
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Figure 4-2 Expression of PSD95 and EphA4 proteins in the embryo brains after prenatal 
Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on embryonic day 18 (E18) and 5 h 
later, embryo brains were obtained. Homogenized tissues of the brains from 6 embryos in 
each group were used for analysis. Blots were probed for PSD95 and EphA4 as marked, 
showing the presence of PSD95 and EphA4 containing complexes in the whole brain tissue. 
Representative immunoblots showing protein expression levels of PSD95 (M.W. 95 kDa) and 
EphA4 (M.W. 120 kDa)  in the embryo brains, with actin (M.W. 42 kDa) shown as a loading 
control. Histogram showing relative PSD95 and EphA4 protein expression normalized to 
actin expression. Data were expressed as mean ± SEM. The effect of the treatments were 
determined by performing student t-test and the differences between mean values were 
defined as significant when p<0.05.  
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Figure 4-3 Expression of neurodevelopmental proteins in the embryo brains after 
prenatal Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on embryonic day 18 (E18) and 5 h 
later, embryo brains were obtained. Homogenized tissues of the brains from 6 embryos in 
each group were used for analysis. Representative immunoblots showing protein 
expression levels of SHH (M.W.45 kDa), PCNA (M.W. 36 kDa) and SOX2 (M.W. 34 kDa)  in the 
embryo brains, with actin (M.W. 42 kDa) shown as a loading control. Histogram showing 
relative SHH,PCNA and SOX2 protein expression normalized to actin expression. Data were 
expressed as mean ± SEM. The effect of the treatments were determined by performing 
student t-test and the differences between mean values were defined as significant when 
p<0.05. 
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Figure 4-4 Expression of inflammatory proteins in the embryo brains after prenatal 
Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on embryonic day 18 (E18) and 5 h 
later, embryo brains were obtained. Homogenized tissues of the brains from 6 embryos in 
each group were used for analysis. Representative immunoblots showing protein 
expression levels of NFB (M.W.65 kDa) and COX2 (M.W. 72 kDa) in the embryo brains, with 
actin (M.W. 42 kDa) shown as a loading control. Histogram showing relative NFB and 
COX2 protein expression normalized to actin expression. Data were expressed as mean ± 
SEM. The effect of the treatments were determined by performing student t-test and the 
differences between mean values were defined as significant when p<0.05. 
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4.4.1.2 Effects of prenatal Ro61-8048 on embryonic brains after 24 h 
exposure. 
It has been shown previously that single administration of Ro61-8048 at E18 was 
enough to significantly affect both subunits by a 43% reduction (NR2A) and an 
almost 400% increase in the level of NR2B protein expression following 5 h post 
injection. These changes were no longer observed by 24 h of treatment. It can 
be seen that after the first time point, the expression remained slightly lower 
compared to controls for the NR2A subunit (Figure 4-5 (A), p=0.49) while the 
NR2B content returned to almost control levels after 24 h of treatment (Figure 
4-5 (B),p=0.09). Twenty four hour after treatment also had no effect on the 
level of PSD95, a major postsynaptic protein which interacts with the C-terminal 
domain of the NR2 subunits (Figure 4-6 (A), p=0.93). Similar effect was also 
observed in the level of EphA4 protein in the whole cell extracts from the brain 
at 24 h (Figure 4-6 (B), p= 0.60). 
The activity of SHH as a morphogen during CNS development involved regulating 
the patterning of cellular responses that is controlled by the concentration and 
duration of SHH exposure. The expression pattern of SHH is the result of the 
combined activity of enhancers that control SHH transcription and regulate SHH 
expression in different tissue (Traiffort et al., 1998). In order to further analyze 
the potential roles exerted by SHH signalling in the nervous system of foetal 
following gestational inhibition of kynurenine pathway, we investigated 
developmental characteristic of SHH expression in whole cell lysates prepared 
from embryo brain. As shown preciously in Figure 4-3 (A) we show that the time 
course of Ro61-8048 mediated regulation of SHH protein expression revealed no 
alteration  5 h following single administration of the compound. Interestingly, 
when we examined the level of SHH protein 24 h after Ro61-8048 treatment,  a 
significant increase of the protein level was observed (Figure 4-7 (A), p= 0.04).  
To further assess  whether inhibition of the kynurenine pathway during gestation 
affects expression of intrinsic proliferation marker, the levels of PCNA protein in 
the Ro61-8048-treated group was compared with controls. Our immunoblot 
analysis showed that PCNA expression was not changed following 24 h of Ro61-
8048 treatment (Figure 4-7 (B), p= 0.18). As SOX2 might represent a useful in 
vivo marker for neural progenitor cells in the CNS, we eexmined the expression 
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patterns of SOX2  protein in the embryo 24 h after maternal administration  of 
KMO inhibitor. Western blot analysis with goat anti-SOX2 antibody of total 
protein in the brain homogenate resulted in a single band of 34 kDa. The 
antibody  did not cross react with other SOX-B1 subfamily members i.e. SOX1 
and SOX3. Thus the detection capability of this antibody allowed us to carefully 
examine SOX2 expression in the subsequent sets of experiments. As can be seen 
in Figure 4-7 (C), SOX2 was found to be strongly expressed, although no change 
was seen in the expression of this protein after 24 h post treatment with Ro61-
8048 (p= 0.60). Five hour after treatment with Ro61-8048 had no significant 
effect on the level of inflammtory markers used in this study. However, prenatal 
Ro61-8048 treatment induced strong immunoreactivity for NFB in the embryo 
brain 24 h post injection (Figure 4-8 (A), p=0.01) with no differences in COX2 
protein level (Figure 4-8 (B), p= 0.55). 
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Figure 4-5 Expression of NMDA receptor subunits NR2A and NR2B proteins in the 
embryo brains 24 hour after prenatal Ro61-8048 
Pregnant dams were administered with Ro61-8048 i.p. on embryonic day 18 (E18) and 24 h 
later, embryo brains were obtained. Homogenized tissues of the brains from 6 embryos in 
each group were used for analysis. Representative immunoblots showing protein 
expression levels of NR2A (M.W.180 kDa) and NR2B (M.W. 180 kDa) in the embryo brains, 
with actin (M.W. 42 kDa) shown as a loading control. Histogram showing relative NR2A and 
NR2B protein expression normalized to actin expression. Data were expressed as mean ± 
SEM. The effect of the treatments were determined by performing student t-test and the 
differences between mean values were defined as significant when p<0.05. 
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Figure 4-6 Expression of PSD95 and EphA4 proteins in the embryo brains 24 hour  after 
prenatal Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on embryonic day 18 (E18) and 24 h 
later, embryo brains were obtained. Homogenized tissues of the brains from 6 embryos in 
each group were used for analysis. Blots were probed for PSD95 and EphA4 as marked, 
showing the presence of PSD95 and EphA4 containing complexes in the whole brain tissue. 
Representative immunoblots showing protein expression levels of PSD95 (M.W. 95 kDa) and 
EphA4 (M.W. 120 kDa)  in the embryo brains, with actin (M.W. 42 kDa) shown as a loading 
control. Histogram showing relative PSD95 and EphA4 protein expression normalized to 
actin expression. Data were expressed as mean ± SEM. The effect of the treatments were 
determined by performing student t-test and the differences between mean values were 
defined as significant when p<0.05. 
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Figure 4-7 Expression of neurodevelopmental proteins in the embryo brains 24 hour 
after prenatal Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on embryonic day 18 (E18) and 24 h 
later, embryo brains were obtained. Homogenized tissues of the brains from 6 embryos in 
each group were used for analysis. Blots were probed for SHH, PCNA and SOX2 as marked, 
showing the presence of SHH, PCNA and SOX2 containing complexes in the whole brain 
tissue. Representative immunoblots showing protein expression levels of SHH (M.W. 45 
kDa),PCNA (M.W. 36 kDa) and SOX2 (M.W. 34 kDa)  in the embryo brains, with actin (M.W. 42 
kDa) shown as a loading control. Histogram showing relative protein expression  of these 
proteins normalized to actin expression. Data were expressed as mean ± SEM. (A) Prenatal 
treatment with 100mg/kg Ro61-8048 (R) showed significant increase in SHH expression 
compared to control animals (S) (n=6)(*p<0.05). 
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Figure 4-8 Expression of inflammatory proteins in the embryo brains 24 hour after 
prenatal Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on embryonic day 18 (E18) and 24 h 
later, embryo brains were obtained. Homogenized tissues of the brains from 6 embryos in 
each group were used for analysis. Blots were probed for NFB and COX2 as marked, 
showing the presence of NFB and COX2 containing complexes in the whole brain tissue. 
Representative immunoblots showing protein expression levels of NFB (M.W. 65 kDa) and 
COX2 (M.W. 72 kDa)  in the embryo brains, with actin (M.W. 42 kDa) shown as a loading 
control. Histogram showing relative protein expression  of these proteins normalized to 
actin expression. Data were expressed as mean ± SEM. (A) Prenatal treatment with 
100mg/kg Ro61-8048 (R) showed significant increase in NFB expression compared to 
control animals (S) (n=6) (*p<0.05). 
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4.4.2 Effects of prenatal Ro61-8048 in P21 neonates 
In addition to the expression of proteins studied for the acute response to Ro61-
8048 in embryos, the levels of expression were also examined at P21. In the 
brains from P21 pups exposed to Ro61-8048, the greatest changes noted in these 
animals were of the NMDA receptor subunits, NR2A and NR2B. The expression of 
both subunits NR2A and NR2B showed a highly significant upregulation producing 
approximately 16% (Figure 4-9 (A), p= 0.0045) and 27% (Figure 4-9 (B), p= 0.03) 
increases, respectively. Analysis of the levels of both subunits showed a 
progressive increase in the full- length proteins, indicative of both NR2 subunits 
being regulated in a time-dependent way. We also characterized the expression 
of PSD95, a major postsynaptic protein interacting with the C-terminal domains 
of the NR2 subunits. Five and 24 hours after maternal administration of Ro61-
8048 had no effect on the level of this protein. However, at P21 subsequently 
altered the development of PSD95 protein expression, Ro61-8048-treated 
animals had significantly greater expression than saline controls (Figure 4-10 (A), 
p= 0.03). This finding altogether suggests an influence on the kynurenine 
pathway and involvement of NMDA receptor function to maintaining normal 
regulation during brain development.  During postnatal period as examined at 
P21, expression of  the EphA4  receptor for secreted ephrin molecules  remained 
unchanged in the treated pups (Figure 4-10 (B), p= 0.95).  
The sonic hedgehog protein (SHH), which is intimately involved in the patterning 
and orientation of tissues and cell growth, was reduced to a significant extent 
after exposure to Ro61-8048 (Figure 4-11 (A), p= 0.02). To further assess 
whether inhibition of the kynurenine pathway during gestation affects 
expression of intrinsic proliferation markers at a later developmental age,PCNA 
a protein often studied as a marker of the earliest phases of DNA synthesis, was 
more highly expressed in the treated animals compred with controls (Figure 4-11 
(B), p= 0.02) while levels of the SOX2 protein were unaffected (Figure 4-11 (C), 
p= 0.45). Finally, levels of the inflammation transcription factor, NFB and the 
inducible form of cyclooxygenase (COX2), showed a significant induction of NFB 
reactivity in the total homogenates of P21 brains (Figure 4-12 (A), p= 0.02) with 
no change in COX2 level as observed in treated animals (Figure 4-12 (B), p= 
0.64). 
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Figure 4-9 Expression of NMDA-receptor proteins in the brains of P21 offspring after 
prenatal Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on gestation days E14, E16 and E18, 
after which parturition proceeded naturally and the young were allowed to develop up to the 
time of weaning at postnatal day 21 (P21). The brains were then removed and frozen 
immediately until required for analysis. Homogenized tissues of the brains from 6 pups (two 
pups from 3 litters) were used for analysis. Blots were probed for NR2A and NR2B as 
marked, showing the presence of NR2A/NR2B containing complexes in the whole brain 
tissue. Representative immunoblots showing protein expression levels of NR2A (M.W. 180 
kDa) and NR2B (M.W. 180 kDa)  in the P21 brains, with actin (M.W. 42 kDa) shown as a 
loading control. Histogram showing relative NR2A and NR2B protein expression normalized 
to actin expression. Data were expressed as mean ± SEM. (A) Compared with saline-treated 
animals (n=6), there was a signifcant decrease in NR2A protein expression in Ro61-8048 
(n=6)(**p<0.01). (B) Prenatal treatment with 100mg/kg Ro61-8048 (R) showed significant 
increase in NR2B expression compared to control animals (S) (n=6)(*p<0.05). 
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Figure 4-10 Expression of PSD95 and EphA4 in the brains of P21 offspring after prenatal 
Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on gestation days E14, E16 and E18, 
after which parturition proceeded naturally and the young were allowed to develop up to the 
time of weaning at postnatal day 21 (P21). The brains were then removed and frozen 
immediately until required for analysis. Homogenized tissues of the brains from 6 pups (two 
pups from 3 litters) were used for analysis. Blots were probed for PSD95 and EphA4 as 
marked, showing the presence of PSD95 and EphA4 containing complexes in the whole 
brain tissue. Representative immunoblots showing protein expression levels of PSD95 
(M.W. 95 kDa) and EphA4 (M.W. 120 kDa)  in the P21 brains, with actin (M.W. 42 kDa) shown 
as a loading control. Histogram showing relative PSD95 and EphA4 protein expression 
normalized to actin expression. Data were expressed as mean ± SEM. (A) Compared with 
saline-treated animals (S) (n=6), there was a signifcant increase in PSD95 protein 
expression in Ro61-8048 (R) (n=6)(*p<0.05).  
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Figure 4-11 Expression of neurodevelopmental proteins in the brains of P21 offspring 
after prenatal Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on gestation days E14, E16 and E18, 
after which parturition proceeded naturally and the young were allowed to develop up to the 
time of weaning at postnatal day 21 (P21). Homogenized tissues of the brains from 6 pups 
(two pups from 3 litters) were used for analysis. Representative immunoblots showing 
protein expression levels of SHH (M.W. 45 kDa), PCNA (M.W. 36 kDa) and SOX2 (M.W. 34 
kDa)  in the P21 brains, with actin (M.W. 42 kDa) shown as a loading control. Histogram 
showing relative neurodevelopmental protein expressions normalized to actin expression. 
Data were expressed as mean ± SEM. (A) Compared with saline-treated animals (n=6), there 
was a signifcant decrease in SHH protein expression in Ro61-8048 (n=6)(*p<0.05). (B) 
Prenatal treatment with 100mg/kg Ro61-8048(R) showed significant increase in PCNA 
expression compared to control animals(S) (n=6)(*p<0.05). 
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Figure 4-12 Expression of inflammatory proteins in the brains of P21 offspring after 
prenatal Ro61-8048. 
Pregnant dams were administered with Ro61-8048 i.p. on gestation days E14, E16 and E18, 
after which parturition proceeded naturally and the young were allowed to develop up to the 
time of weaning at postnatal day 21 (P21). The brains were then removed and frozen 
immediately until required for analysis. Homogenized tissues of the brains from 6 pups (two 
pups from 3 litters) were used for analysis. Blots were probed for NFB and COX2 as 
marked, showing the presence of NFB and COX2 containing complexes in the whole brain 
tissue. Representative immunoblots showing protein expression levels of NFB (M.W. 65 
kDa) and COX2 (M.W. 72 kDa)  in the P21 brains, with actin (M.W. 42 kDa) shown as a 
loading control. Histogram showing relative NFB and COX2 protein expression normalized 
to actin expression. Data were expressed as mean ± SEM. (A) Compared with saline-treated 
animals(S) (n=6), there was a signifcant increase in NFB protein expression in Ro61-
8048(R) (n=6)(*p<0.05).  
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4.4.3 Effects of prenatal Ro61-8048 in P60 offpsrings 
Another set of animals using much older animals at postnatal day 60 is important 
to determine whether any changes seen in developing brains would be extended 
to a later age. The effect of each marker might be masked in the whole brain in 
which the juvenile study was erformed on whole cerebral hemispheres, thus we 
hope to be able to pick up any subtle changes in regional samples of P60 that 
includes hippocampus, cerebelum, cortex and midbrain. The range of proteins 
examined in this aspect was similar to that targetted in the previous set up of 
animals at P21 days of age.  
4.4.3.1 Protein expression in the hippocampus 
In the P60-treated groups the effect of maternal administration of Ro61-8048 on 
the level of NR2A subunit protein expression was markedly reduced (Figure 
4-13(A), p=0.003) whereas NR2B level was not affected (Figure 4-13 (B), p= 
0.69). By adulthood as measured regionally in hippocampus, there was no longer 
effect on PSD95 protein expression  as seen in Figure 4-14 (A) (p=0.14). In view 
of the role of NMDA receptors for both synaptic development and function, the 
expression of both subunits, NR2A and NR2B and one of its post synatic protein 
complex, PSD95 also had been observed  to be significantly affected at P21. This 
suggest that the levels of several proteins that are influential to NMDA receptor 
function are dynamically influenced  by the kynurenine pathway. Similarly, no 
significant difference was evident by the age of P60 by the the proinflammatory 
transcription factor, NFB (Figure 4-16 (A), p= 0.25) and PCNA (Figure 4-15(B), 
p= 0.19) in which changes seen at P21 had been resolved or compensated by 
adulthood. While in other cases, proteins which had shown no change at  P21 
remained unchanged at P60. These included the axon guidance and synapse 
formation receptor, EphA4 (Figure 4-14(B), p=0.70)  and one of the importany 
enzyme that accompanies tissue inflammation, COX2 (Figure 4-16(B), p= 0.43). 
There was eminently differences in the expession of SHH, a  protein concerned 
with cell differentiation and maturation, which had shown modified expression 
in animals at the time of weaning (P21). Expression of this molecule was 
decreased significantly in the Ro61-8048-treated animals compared with controls 
(Figure 4-15 (A), p= 0.05). The changes  seen during adulthood in the expression 
level of SHH hippocampus region was comparable to that seen at P21.  
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We found very negligible expression of SOX2 in the hippocampus (data not 
calculated). The absence of SOX2 expression in this study is intriguing. It might 
be due to the processing of the sample during laboratory preparation. Since 
there have been a number of studies that indicate the presence of SOX2 in the 
hippocampus by using immunoflourescent techniques and indicate the expression 
was largely due to proliferating neural progenitors in the neurogenic region of 
hippocampus (Brazel et al., 2005, Komitova and Eriksson, 2004). Therefore, 
repeating the experimental approach in a similar settting is important to 
characterize the expresion level of this marker, or re-examining using another 
source of commercially available antibody for SOX2, though we cannt exclude 
the possibility of differential expression pattern as each commercial antibody 
has its own specific localization expression. 
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Figure 4-13 Expression of NMDA receptor subunits in the hippocampus of control and 
Ro61-8048-treated animals.  
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed and whole 
hippocampi was snap frozen until required for analysis. Homogenized tissues of the brains 
were used for analysis. Blots were probed for NR2A and NR2B as marked, showing the 
presence of NR2A/NR2B containing complexes in the whole hippocampi tissue. 
Representative immunoblots showing protein expression levels of NR2A (M.W. 180 kDa) 
and NR2B (M.W. 180 kDa)  in the hippocampus, with actin (M.W. 42 kDa) shown as a loading 
control. Histogram showing relative NR2A and NR2B protein expression normalized to actin 
expression. Data were expressed as mean ± SEM (n=6) for Ro61-8048, n=4 for control). (A) 
Compared with saline-treated animals(S), there was a signifcant decrease in NR2A protein 
expression in Ro61-8048(R) (**p<0.01).  
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Figure 4-14  Expression of PSD95 and EphA4 in the hippocampus of control and Ro61-
8048-treated animals. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed and whole 
hippocampi was snap frozen until required for analysis. Homogenized tissues of the brains 
were used for analysis. Blots were probed for PSD95 and EphA4 as marked, showing the 
presence of PSD95 and EphA4 containing complexes in the whole hippocampi tissue. 
Representative immunoblots showing protein expression levels of PSD95 (M.W. 95 kDa) and 
EphA4 (M.W. 120 kDa)  in the hippocampus, with actin (M.W. 42 kDa) shown as a loading 
control. Histogram showing relative PSD95 and EphA4 protein expression normalized to 
actin expression. Data were expressed as mean ± SEM (n=6 for Ro61-8048, n=4 for control).   
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Figure 4-15  Expression of neurodevelopmental proteins in the hippocampus of control 
and Ro61-8048-treated animals 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed and whole 
hippocampi was snap frozen until required for analysis. Homogenized tissues of the brains 
were used for analysis. Blots were probed for SHH and PCNA as marked, showing the 
presence of SHH and PCNA containing complexes in the whole hippocampi tissue. 
Representative immunoblots showing protein expression levels of SHH (M.W. 45 kDa) and 
PCNA (M.W. 36 kDa)  in the hippocampus, with actin (M.W. 42 kDa) shown as a loading 
control. Histogram showing relative SHH and PCNA protein expression normalized to actin 
expression. Data were expressed as mean ± SEM (n=6) for Ro61-8048, n=4 for control). (A)  
Prenatal treatment with 100mg/kg Ro61-8048(R) showed significant reduction in SHH 
expression compared to control animals(S) (*p<0.05). 
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Figure 4-16  Expression of inflammatory proteins in the hippocampus of control and 
Ro61-8048-treated animals. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed and whole 
hippocampi was snap frozen until required for analysis. Homogenized tissues of the brains 
were used for analysis. Blots were probed for NFB and COX2 as marked, showing the 
presence of NFB and COX2 containing complexes in the whole hippocampi tissue. 
Representative immunoblots showing protein expression levels of NFB (M.W. 65 kDa) and 
COX2 (M.W. 72 kDa)  in the hippocampus, with actin (M.W. 42 kDa) shown as a loading 
control. Histogram showing relative NFB and COX2 protein expression normalized to actin 
expression. Data were expressed as mean ± SEM (n=6 for Ro61-8048, n=4 for control).  .  
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4.4.3.2 Protein expression in the cerebellum 
The cerebellum exhibited fewer changes of protein expression than either the 
hippocampus or cortex, with only one protein examined showing significant 
modification.  Of all the proteins examined, the majority showed no difference 
between control and drug-exposed animals. Levels of the NR2A and NR2B 
subunits and PSD95 of the NMDA receptor were not significantly different in 
animals exposed in utero to Ro61-8048 compared with controls [NR2A: Figure 
4-17(A), p= 0.42, NR2B: Figure 4-17(B), p= 0.40, PSD95: Figure 4-18 (A), p= 
0.61]. Similarly, there was also no evidence of change for EphA4 receptor for 
secreted ephrin molecules in the treated pups (Figure 4-18(B), p= 0.45). The 
Most striking was the finding of very significant changes in one of the proteins 
involved in neurogenesis. Significant difference was noted in the expression of 
SHH, which is intimately associated with cell growth and maturation. In the 
nervous system of young and adult animals, SHH is known to stimulate the 
proliferation of neuronal precursor cells in the cerebellum and other brain 
regions, such as the hippocampus and forebrain (Fuccillo et al., 2006). Prenatal 
Ro61-8048 exposure resulted in significant decreases in the protein level in the 
cerebellum (Figure 4-19(A), p= 0.02), a result again in a similar pattern to that 
of hippocampus.  The other proteins that are linked with neurogenesis,PCNA  
binds to a nuclear protein in mature cells and transcription factor SOX2, which 
regulates and maintains the undifferentiated state of progenitor cells, were both 
unchanged following prenatal treatment with Ro61-8048 (PCNA: Figure 4-19(B), 
p=0.61, SOX2: Figure 4-19(C), p=0.26). In another case, two proteins intimately 
reflecting inflammatory processes were also examined, with no changes were 
noted in the expression of NFB and COX2 in the treated animals (Figure 4-20). 
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Figure 4-17  Expression of NMDA receptor subunits in the cerebellum of control and 
Ro61-8048-treated animals. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed and whole 
cerebellum was snap frozen until required for analysis. Homogenized tissues of the brains 
from 6 pups (two pups from 3 litters) were used for analysis. Blots were probed for NR2A 
and NR2B as marked, showing the presence of NR2A/NR2B containing complexes in the 
whole cerebellum tissue. Representative immunoblots showing protein expression levels of 
NR2A (M.W. 180 kDa) and NR2B (M.W. 180 kDa)  in the cerebellum, with actin (M.W. 42 kDa) 
shown as a loading control. Histogram showing relative NR2A and NR2B protein expression 
normalized to actin expression. Data were expressed as mean ± SEM.   
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Figure 4-18  Expression of PSD95 and EphA4 in the cerebellum of control and Ro61-8048-
treated animals. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed and whole 
cerebellum was snap frozen until required for analysis. Homogenized tissues of the brains 
from 6 pups (two pups from 3 litters) were used for analysis. Blots were probed for PSD95 
and EphA4 as marked, showing the presence of PSD95 and EphA4 containing complexes in 
the whole cerebellum tissue. Representative immunoblots showing protein expression 
levels of PSD95 (M.W. 95 kDa) and EphA4 (M.W. 120 kDa)  in the cerebellum, with actin 
(M.W. 42 kDa) shown as a loading control. Histogram showing relative PSD95 and EphA4 
protein expression normalized to actin expression. Data were expressed as mean ± SEM.  
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Figure 4-19 Expression of neurodevelopmental proteins in the cerebellum  
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed and whole 
cerebellum was snap frozen until required for analysis. Homogenized tissues of the brains 
from 6 pups (two pups from 3 litters) were used for analysis. Blots were probed for SHH and 
PCNA as marked, showing the presence of SHH, PCNA and SOX2 containing complexes in 
the whole cerebellum tissue. Representative immunoblots showing protein expression 
levels of SHH (M.W. 45 kDa),PCNA (M.W. 36 kDa) and SOX2 (M.W. 34 kDa)  in the cerebellum, 
with actin (M.W. 42 kDa) shown as a loading control. Histogram showing relative SHH and 
PCNA protein expression normalized to actin expression. Data were expressed as mean ± 
SEM. (A)  Prenatal treatment with 100mg/kg Ro61-8048(R) showed significant reduction in 
SHH expression compared to control animals(S) (n=6)(*p<0.05). 
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Figure 4-20 Expression of inflammatory proteins in the cerebellum of control and Ro61-
8048-treated animals. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed and whole 
cerebellum was snap frozen until required for analysis. Homogenized tissues of the brains 
from 6 pups (two pups from 3 litters) were used for analysis. Blots were probed for NFB 
and COX2 as marked, showing the presence of NFB and COX2 containing complexes in 
the whole cerebellum tissue. Representative immunoblots showing protein expression 
levels of NFB (M.W. 65 kDa) and COX2 (M.W. 72 kDa)  in the cerebellum, with actin (M.W. 
42 kDa) shown as a loading control. Histogram showing relative NFB and COX2 protein 
expression normalized to actin expression. Data were expressed as mean ± SEM.  
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4.4.3.3 Protein expression in the cortex 
In order to compare the changes occurring in the cortex with those observed 
previously in the hippocampus nd cerebellum, a similar range of proteins was 
examined in this study, including proteins involved in neuronal migration, axon 
guidance, neurogenesis and dendrite formation. Most of the proteins included in 
this analysis showed no difference between control and drug-exposed animals. 
However, a significant difference was noted in the expression of the NR2A 
subunit for which expression was increased 20% (Figure 4-21(A), p = 0.008) 
although there were no changes detected in the GluN2B subunits (Figure 4-21(B), 
p= 0.74), or in the NMDA receptor-associated post-synaptic density protein PSD-
95 (Figure 4-22(A), p= 0.73). In addition, no significant differences were 
detected in the expression of PCNA (Figure 4-23(B), p=  0.31) and SOX2 (Figure 
4-23(C), p= 0.15) in brains from Ro61-8048-exposed compared to controls at P60. 
On the other hand, expression of the morphogenetic protein SHH, was found to 
be substantially decreased by about 24% (Figure 4-23(A), p= 0.0003). This 
pattern of expression was similar to that observed in the cerebellum and also in 
the hippocampus. Axon guidance and synapse formation receptor, EphA4 
exhibited a significant alteration in the pups exposed to Ro61-8048, with about 
13% increase in expression compared to saline treated animals (Figure 4-22(B), 
p= 0.05).Two proteins intimately reflecting inflammatory processes were 
examined, with a highly significant, 30% decrease observed in COX2 expression 
(Figure 4-24(B),p= 0.01) but no change in NFB (Figure 4-24 (A), p= 0.38).  
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Figure 4-21 Protein expression of NMDA receptor subunits in P60 cortex after prenatal 
Ro61-8048. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed, sectioned and snap 
frozen until required for analysis. Homogenized tissues of the brains were used for analysis. 
Blots were probed for NR2A and NR2B as marked, showing the presence of NR2A/NR2B 
containing complexes in the cortex tissue. Representative immunoblots showing protein 
expression levels of NR2A (M.W. 180 kDa) and NR2B (M.W. 180 kDa)  in the cortex, with 
actin (M.W. 42 kDa) shown as a loading control. Histogram showing relative NR2A and 
NR2B protein expression normalized to actin expression. Data were expressed as mean ± 
SEM (n=6 for Ro61-8048, n=6 for control). (A) Compared with saline-treated animals(S), there 
was a signifcant increase in NR2A protein expression in Ro61-8048(R) (**p<0.01).  
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Figure 4-22 Protein expression of PSD95 and EphA4 in P60 cortex after prenatal Ro61-
8048. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed, sectioned and snap 
frozen until required for analysis. Homogenized tissues of the brains from 6 pups (two pups 
from 3 litters) were used for analysis. Blots were probed for PSD95 and EphA4 as marked, 
showing the presence of PSD95 and EphA4 containing complexes in the cortex tissue. 
Representative immunoblots showing protein expression levels of PSD95 (M.W. 95 kDa) and 
EphA4 (M.W. 120 kDa)  in the cortex, with actin (M.W. 42 kDa) shown as a loading control. 
Histogram showing relative PSD95 and EphA4 protein expression normalized to actin 
expression. Data were expressed as mean ± SEM (n=6 for Ro61-8048, n=6 for control). (B) 
Compared with saline-treated animals(S), there was a signifcant decrease in EphA4 protein 
expression in Ro61-8048(R) (*p<0.05).  
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Figure 4-23 Protein expression of neurodevelopmental proteins in P60 cortex after 
prenatal Ro61-8048. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed, sectioned and snap 
frozen until required for analysis. Homogenized tissues of the brains from 6 pups (two pups 
from 3 litters) were used for analysis. Representative immunoblots showing protein 
expression levels of SHH (M.W. 45 kDa), PCNA (M.W. 36 kDa) and SOX2 (M.W. 34 kDa)  in the 
cortex, with actin (M.W. 42 kDa) shown as a loading control. Histogram showing relative 
SHH,PCNA and SOX2 protein expression normalized to actin expression. Data were 
expressed as mean ± SEM. (A)  Prenatal treatment with 100mg/kg Ro61-8048(R) showed 
significant reduction in SHH expression compared to control animals(S) (n=6)(**p<0.01). 
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Figure 4-24 Protein expression of inflammatory protein in P60 cortex after prenatal Ro61-
8048. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). After euthanasia the brains were then removed, sectioned and snap 
frozen until required for analysis. Homogenized tissues of the brains from 6 pups (two pups 
from 3 litters) were used for analysis. Blots were probed for NFB and COX2 as marked, 
showing the presence of NFB and COX2 containing complexes in the cortex tissue. 
Representative immunoblots showing protein expression levels of NFB (M.W. 65 kDa) and 
COX2 (M.W. 72 kDa)  in the cortex, with actin (M.W. 42 kDa) shown as a loading control. 
Histogram showing relative NFB and COX2 protein expression normalized to actin 
expression. Data were expressed as mean ± SEM. (B)  Prenatal treatment with 100mg/kg 
Ro61-8048(R) showed significant reduction in COX2 expression compared to control 
animals(S) (n=6)(**p<0.01). 
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4.4.3.4 Protein expression in the midbrain 
Maternal exposure to 100mg/kg Ro61-8048 had no effect on the level of proteins 
in the midbrain regions which included the striatum and caudal regions 
projecting to it. The majority of the markers examined in this study showed no 
difference between control and drug-exposed animals. No significant differences 
in the expression of proteins  between control and Ro61-8048-treted animals 
were noted for NMDA receptor subunit  in this region (NR2A: Figure 4-25(A), p= 
0.24;  NR2B: Figure 4-25(B), p= 0.98). Similar expressions were seen in PSD95 
(Figure 4-26(A),p= 0.30) and  EphA4 (Figure 4-26(B), p= 0.14). Three of the 
proteins linked  to neurogenesis, namely SHH (Figure 4-27(A), p= 0.39) , PCNA 
(Figure 4-27(B), p= 0.83) and SOX2 (Figure 4-27(C), p= 0.88) remained unchanged 
after prenatal Ro61-8048. While no change was seen in the levels of NFB 
(Figure 4-28 (A), p= 0.15) or COX2 (Figure 4-28(B), p= 0.45). 
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Figure 4-25 Expression of NMDA receptor subunit proteins in the midbrain of control and 
Ro61-8048-treated animals. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). Offspring were subsequently euthanized for the removal of brains. 
Homogenized tissues of the brains were used for analysis. Blots were probed for NR2A and 
NR2B as marked, showing the presence of NR2A/NR2B containing complexes in the 
midbrain tissue. Representative immunoblots showing protein expression levels of NR2A 
(M.W. 180 kDa) and NR2B (M.W. 180 kDa)  in the midbrain with actin (M.W. 42 kDa) shown as 
a loading control. Histogram showing relative NR2A and NR2B protein expression 
normalized to actin expression. Data were expressed as mean ± SEM (n=6 for Ro61-8048, 
n=6 for control).  
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Figure 4-26 Expression of PSD95 and EphA4 receptor proteins in the midbrain of control 
and Ro61-8048-treated animals. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). Offspring were subsequently euthanized for the removal of brains. 
Homogenized tissues of the brains were used for analysis. Blots were probed for PSD95 
and EphA4 as marked, showing the presence of PSD95 and EphA4 containing complexes in 
the midbrain tissue. Representative immunoblots showing protein expression levels of 
PSD95 (M.W. 95 kDa) and EphA4 (M.W. 120 kDa)  in the midbrain with actin (M.W. 42 kDa) 
shown as a loading control. Histogram showing relative PSD95 and EphA4 protein 
expression normalized to actin expression. Data were expressed as mean ± SEM (n=6 for 
Ro61-8048, n=6 for control).  
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Figure 4-27 Expression of neurodevelopmental proteins in the midbrain of control and 
Ro61-8048-treated animals. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). Offspring were subsequently euthanized for the removal of brains. 
Homogenized tissues of the brains were used for analysis. Blots were probed for 
SHH,PCNA and SOX2 as marked, showing the presence of SHH,PCNA and SOX2 containing 
complexes in the midbrain tissue. Representative immunoblots showing protein expression 
levels of SHH (M.W. 45 kDa),PCNA (M.W. 36) and SOX2 (M.W. 34 kDa)  in the midbrain with 
actin (M.W. 42 kDa) shown as a loading control. Histogram showing relative SHH,PCNA and 
SOX2 protein expression normalized to actin expression. Data were expressed as mean ± 
SEM (n=6 for Ro61-8048, n=6 for control).  
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Figure 4-28 Expression of inflammatory proteins in the midbrain of control and Ro61-
8048-treated animals. 
Compound Ro61-8048 was administered  i.p.  to the pregnant dam at days E14, E16 and E18 
of gestation while groups of control animals were injected with tha saline vehicle. 
Parturition was allowed to proceed naturally and the young were allowed to develop up to  
postnatal day 60 (P60). Offspring were subsequently euthanized for the removal of brains. 
Homogenized tissues of the brains were used for analysis. Blots were probed for NFB and 
COX2 as marked, showing the presence of NFB and COX2 containing complexes in the 
midbrain tissue. Representative immunoblots showing protein expression levels of NFB 
(M.W. 65 kDa) and COX2 (M.W. 72 kDa)  in the midbrain with actin (M.W. 42 kDa) shown as a 
loading control. Histogram showing relative NFB and COX2 protein expression normalized 
to actin expression. Data were expressed as mean ± SEM (n=6 for Ro61-8048, n=6 for 
control).  
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4.5 Discussion 
In the current study, we have demonstrated that the protein expression of some 
of the important molecules involved during neurodevelopmental events in the 
brain undergoes a differential pattern of regulation. We investigated possible 
alterations in the inhibitory activity of compound Ro61-8048 on acute and long 
term changes in the expression of proteins in the brain as well as regional areas 
of the brain (P60) of animals at various stages of development. Evaluation of 
region-specific protein expression presented in P60 animal allows us to make 
some speculations on the involvement of relevant brain regions that provide a 
guide for further investigation. Several findings are of interest in this study and 
will be discussed further. 
We demonstrate that pharmacological manipulation of the kynurenine pathway 
during the prenatal period can be accomplished by treating pregnant dams 
during late gestation. Our previous data indicate that the levels of KYNA in 
maternal plasma and embryo brain can be elevated by the systemic 
administration of KMO inhibitor, Ro61-8048 which deflects kynurenine 
degradation towards enhanced KYNA formation. Administration of this compound 
to pregnant rats at three time points during late gestation caused comparable 
substantial increases in maternal plasma and embryo brain of KYNA level 
(Forrest et al. 2013b). In accordance with this, increases in the concentrations of 
brain KYNA has been reported following administration of the KMO inhibitor, 
Ro61-8048 to immune-stimulated mice and this was accompanied by reduced 
concentrations of 3-hydroxykynurenine and QUIN, suggesting that in pathological 
situations, KMO is a rate limiting enzyme for both 3-hydroxykynurenine and also 
QUIN (Chiarugi et al., 2001). Administration of Ro61-8048 also provoke an 
increase in brain KYNA concentrations and reduced the severity of dystonia 
(Richter and Hamann, 2003). Beneficial effects of KMO inhibition have been 
shown in a murine model of cerebral malaria, where an increase in KYNA and 
anthranilic acid in R061-8048-treated infected mice would protect against the 
activation of NMDAR. However, when Ro61-8048 was given to the controls, no 
alteration in QUIN concentrations was observed(Clark et al., 2005). The effect of 
maternal KMO inhibition on embryo brain KYNA and neurochemical alterations 
seen in later stages of developmental suggests evidence for acute endogenous 
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changes in KP metabolism which might be potentially responsible for the 
changes seen in this study.  
4.5.1 Protein expression of NMDA receptor subunits and 
associated protein  
To date, no study has examined the influence of maternal administration of KMO 
inhibitor on NMDA receptor subunits expression in the embryo and also in the 
postnatal brains. To examine the possibility that NMDA receptors contribute to 
the kynurenine –mediated regulation of NMDA subunits level in the brain, the 
influence of Ro61-8048 on the inhibition of the kynurenine pathway was 
addressed.  The present study demonstrates that prenatal modulation of the 
kynurenine pathway during pregnancy is associated with alterations in NMDA 
receptor subunits protein levels as early as 5 hour following single injection. In 
addition, we found that both NMDA receptor subunits and PSD95 followed a 
different profile of expressions during postnatal development in the brain.  
The NMDA receptors modulate glutamate postsynaptic neurotransmission by 
generating long lasting calcium channel opening for calcium influx through the 
channel and causing longer depolarizations. This process is responsible for 
mediating synaptic plasticity changes such as LTP and LTD that underpins many 
higher functions including learning and memory. Activation of the receptor in 
the mechanism of LTP is considered and understood to be the synaptic model of 
learning and memory (Bliss and Collingridge, 1993, Gladding and Raymond, 
2011). The subunits NR2A and NR2B were chosen for examination in this study 
because they are the most predominant NMDA receptor subunit subtypes in their 
respective subunit families and would therefore be the most likely receptor 
subunits responsible for changes. Our results demonstrate that both these major 
subunits of the NMDA receptor, NR2A and NR2B, are differentially expressed 
during pre-and postnatal development in the rat brain. Both NMDA receptor 
subunit proteins were already expressed in the embryo brains as observed at E18 
(following 5 hour post injection). Developmental expression using immunoblot 
analysis showed that the NR2B proteins were detectable as early as E14, 
continued increasing at P10, P20 and into late adulthood P60. It also pointed out 
that environmental insults during prenatal development may result in 
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morphological abnormalities in which aberrant co assembly of the NMDA 
receptor complex may reflect the differentiation of synaptic rearrangement  and 
receptor affinities (Babb et al., 2005). Five hours of Ro61-8048 administration to 
the pregnant dams had different effects on two major NR2 subunits of NMDA 
receptor, with reduced protein expression for NR2A and increased levels of NR2B 
protein at embryonic day 18. A consistent set of chronic changes in the protein 
levels of both subunits was observed in young animals at P21. It is important to 
note that a change in the NR2A expression in the hippocampus and cortex after 
Ro61 treatment was maintained into adulthood and likely to have influenced 
structural and functional aspects of synaptic plasticity at the receptor. The 
observed increase in NR2A subunits in the 21 day postnatal offspring produced by 
prenatal Ro61 exposure may therefore be a compensatory mechanism for a 
potential decrease in the receptor subunit function at earlier time points in 
development. This may also hold a similar explanation for the differential 
pattern of NR2A expression observed in mature animals. There may be brain 
regional and developmental age selectivity for the effects of prenatal 
kynurenine inhibition on NMDA receptors. For PSD95, we showed that acute 
exposure to the enzyme inhibitor produced no alteration in the level of protein 
expression in the whole brain lysate. However, the level of protein detected was 
progressively increased at P21. In accordance with this, we did observe 
significant differences in the level of NR2A and NR2B proteins in the same age 
group of postnatal rats. Concerning the expression of the major subunit NR1 
(results presented in (Forrest et al., 2013a), no significant alteration was 
observed in all ages of development. The present study demonstrates that there 
are differential long term-effects of prenatal modulation of the kynurenine 
pathway on the NMDA receptor complex in the offspring. This implies that a 
change in NMDA receptor number or function could underlie altered 
neurotransmission and receptor pharmacology both during normal physiological 
activity and in response to neuroactive metabolites. The fact that we observed 
reduced NR2A subunit, but not NR1 and NR2B protein levels in homogenates 
prepared from hippocampus isolated from P60 rat in the presence of unaltered 
mRNA expression of the subunits (data presented in (Forrest et al., 2013a) 
indicates that the reduction in NR2A protein may be the result of differential 
post-transcriptional processing of the protein in the Ro61-treated animal. This 
observation is consistent with other studies showing that, in some cases, NMDA 
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receptor subunit mRNA levels do not correlate with protein levels (Gazzaley et 
al., 1996). The exact mechanisms for how NR2A expression is decreased in the 
hippocampus was not formally addressed in our study, thus reduced translation 
or increased degradation of the NR2A protein in the hippocampus of exposed 
animals should be evaluated in future studies. Up regulation of NR2A subunits in 
the cortex has been noted suggesting that prenatal kynurenine inhibition 
enhanced neural activity in the cortex. Therefore, changes in NR2A protein 
levels seen in only two regions could be a compensatory response to prolonged 
NMDA receptor inhibition in utero that persist into adulthood.  As our western 
blot analysis indicates, protein expression of NMDA subunits NR2A and NR2B and 
also PSD95 is enriched in the hippocampus compared with other regions. This is 
supported by the evidence demonstrating that in the hippocampal region, the 
expression of NR2A, NR2B and PSD95 increased with age. During the 
development of the hippocampus, the pyramidal cells in CA1 and CA3 grow 
rapidly after birth and are gradually stabilized after postnatal week 3. Since the 
granule cells had self-renewal capacities for their lifetime, the number of 
granule cells in the dentate gyrus gradually increases with age and maintain the 
ability to proliferate in adulthood. The obviously different expression patterns of 
the subunits implicated their distinct roles in the postnatal development of 
hippocampus (Al-Hallaq et al., 2007). NMDA receptor function is regulated 
mainly through association with many signalling proteins that are concentrated 
with the postsynaptic density (PSD) compartment. Of the many PSD proteins that 
can potentially modulate NMDA receptor properties, PSD95 has gained the most 
attention because this molecule associates with various signalling protein and 
exerted its effect by recruiting  kinases or phosphatases to the NMDA receptor 
complex (Li et al., 2003, Tezuka et al., 1999). However, the present study could 
not justify the exact functional composition and localization of NMDA subunits 
since we used a total pool of proteins that included intracellular pools of 
assembled and unassembled NMDA receptors expressed at the cell membrane. 
The homogenates are heterogeneous, containing a percentage from the synaptic 
region itself, as well as from extrasynaptic membranes, the soma and the axons. 
Apart from that, interaction between the major subunits with its associated 
protein, like PSD95 using immunoprecipitation studies was not examined in this 
study. Although the distribution of NMDA receptor compositions across brain 
region were not addressed in this study, these data indirectly support a 
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regulated  mechanism of subunit assembly because NMDA receptor subunit 
composition differs across regions in which NR2A and NR2B are the predominant 
NR2 subunits, such as in hippocampus and cortex (Wenzel et al., 1997). In 
addition, physical interaction between NR2 subunits and PSD proteins have been 
shown to play an important role in regulating the localization of the NMDA 
receptor and this interaction is mediated by the cytoplasmic tail of NR2 subunits 
(Al-Hallaq et al., 2007, Delint-ramirez et al., 2010). 
The present studies add to a growing body of evidence that environmental 
insults during pregnancy are associated with alterations in NMDA receptor 
subunit levels. Our results report changes in the protein levels of NMDA receptor 
subunits in different developmental ages as a result of either acute or persistent 
effects of kynurenine modulation during pregnancy. The persistence of these 
alterations into adulthood indicates that modifications of glutamatergic 
neurotransmission is highly involved in the adaptive responses that underlie 
homoeostatic and compensatory changes in the function of the receptor complex 
that contribute to the neurochemical imbalance associated with learning and 
memory deficits that are observed in adult animals that were exposed prenatally 
to KMO inhibitor. 
4.5.2 Differential expression of developmental molecules 
following prenatal Ro61-8048 administration 
We have examined the expression level of developmental molecules responsible 
for some important processes including neuronal proliferation and migration, 
axon guidance and synapse formation in the embryo and postnatal brains. The 
increasing number of developmental events associated with these molecules has 
generated considerable interest in studies regarding their molecular mechanisms 
as well as putative involvement in a range of neurodegenerative diseases. Our 
study showed that EphA4 was expressed in the developing brain from embryonic 
day 18 with reduced levels detected 24 hour after Ro61 administration and also 
at P21. In P60 brain, there was a dynamic pattern of expression, with a 
persistent but differential pattern of expression in the several regions of the 
mature brain. Although no significant changes was seen in the hippocampal level 
of EphA4 as compared to control levels, this molecule has been found to be 
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highly expressed in the hippocampus and involved partly in synaptic plasticity 
events such as long term potentiation. While many of the molecular mechanisms 
regulating the induction of LTP remain unclear, Ephs receptor protein kinase 
activity is known to be involved in this process (Pasquele, 2008). We 
demonstrate here that the regional pattern of EphA4 expression changes 
markedly during postnatal development as shown at P60, with the observation of 
lowered expression in the cortex suggesting that prenatal modulation of the 
kynunerine pathway may preferentially affect particular regions of the brain. 
These data suggest that EphA4 expression is regulated in a NMDA-dependent 
synaptic response through regulation of kynurenine metabolites in the brain and 
that EphA4 kinase activity may play a functional role in maintaining the 
organization of dendritic spines postnatally.  The fact that EphA4 regulates axon 
guidance during embryonic development and postnatal synaptic function 
emphasizes the varied and complex roles for this receptor family in regulating 
cell-cell interactions within the CNS. The molecular mechanisms of many Ephs 
and ephrin related synaptic functions are still largely unknown, thus a more 
elaborate examination of the roles and mechanisms of this receptor complex will 
be needed to further establish them as important synaptogenic molecules in the 
nervous system (Lai and Ip, 2009). 
The physiological function of PCNA is well described, being necessary for DNA 
replication and repair in proliferating cells. Changes in cell proliferation 
dynamics in response to various insults have been assessed previously using 
multiple cell cycle markers, in which the pattern of changes was reflected in 
double/triple immunolabelling using a combination of PCNA with other 
proliferation markers including 5-bromo-2‟-deoxyuridine (BrdU) and/or Ki-67. 
The combination of different cell cycle regulators permits study of the 
proliferative, migratory and survival characteristics of neuronal progenitors cells 
in the developing and adult rodent brain (Halbach, 2011, Valero et al., 2005).We 
showed that in the early developmental period, kynurenine pathway modulation 
during gestation caused no changes in the proliferative event, as demonstrated 
by PCNA expression in the embryo. However, it progressively appeared that the 
resistance of the immature brain has its limitations, in which we noted an 
elevated extent of proliferation as shown by PCNA expression at later stage of 
development only at P21 and regionally unaffected when examined at P60.  
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Upon binding to its receptor Patched (Ptc), SHH activates the highly conserved 
hedgehog (HH) signalling cascade, resulting in activation of the Gli family of 
transcription factors. The SHH signalling cascade is involved in the development 
and patterning of several vertebrate embryonic structures, anteroposterior 
patterning of the limbs and dorsoventral patterning of the neural tube (Ruiz i 
Altaba et al., 2002, Palma et al., 2005). Analysis of SHH protein expression after 
administration of enzyme inhibitor Ro61-8048 has paved a way for the 
characterization of the potential roles for this molecule in the normal and 
treated brain. Robust SHH expression was found in the embryo, suggesting 
localized signalling in the developing brain. Interestingly, the expression is high 
before birth and markedly reduced at postnatal day 21. Application of antibodies 
specific for SHH led to a pattern of regional protein expression in the adult rat 
brain. In protein extracts isolated from animals exposed to Ro61-8048, western 
blot analysis indicated that a 45kDa SHH protein SHH was broadly expressed in 
all brain areas examined with reduced expression found in three main areas of 
cerebellum, cortex and hippocampus. Such a pattern of expression was found 
conserved for the SHH mRNA, albeit a low expression was detected  within these 
brain regions, suggesting that this molecule may be implicated in local signalling 
circuitry (Forrest et al., 2013b).  Although in this study, we did not focus on the 
regulation of neural stem cells, a number of reports have demonstrated that in 
the nervous system of young and adult animals, SHH is known to regulate the 
proliferation of the cerebellar granule cell precursors, neural progenitors lining 
the subventricular zone of the forebrain and in the dentate gyrus of the 
hippocampus. These studies partly demonstrate that concerted cell 
proliferation, migration and differentiation in response to SHH protein are 
important for normal embryonic developmental and postnatal homeostasis 
(Palma et al., 2005, Lai et al., 2003, Machold et al., 2003, Bertrand and 
Dahmane, 2006). Expression studies of SHH and other genes involved in 
hedgehog signal- transduction have indicated a function of hedgehog signalling in 
the adult brain in addition to its roles during early development (Traiffort et al., 
1999, Charytoniuk et al., 2002). A number  approaches including in vitro cell 
culture and animal model have been used to unravel the SHH signalling pathways 
linking relationship between various perturbations or exposure to the regulation 
of the expression  of SHH signalling cascade  in the embryonic and adult rodent 
brain. It has been shown that this powerful developmental morphogen is 
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upregulated in adult organisms after injury and involved in a repair mechanism 
in which it enhances adult hippocampal neurogenesis following electroconvulsive 
seizure (Banarjee and Rajendran, 2005). It appears that the expression of SHH 
also increased during ischemia (Sims et al., 2009) and under oxidative stress 
induced by hydrogen peroxide (H2O2) (Dai et al., 2011). Other molecular events 
that has influence on the modulation of the SHH pathway includes exposure to 
caffeine in primary neuronal and astroglial cultures (Sahir et al., 2004) and in 
the presence of teratogen valproic acid (VPA), which altered the expression of 
some regulatory genes reported to be involved in the serotonergic neuronal 
development, and that SHH and its components expression were all decreased in 
the VPA-treated cells compared to the control (Miyazaki et al., 2005).  Exposure 
of zebrafish embryos to alcohol during gastrulation impaired SHH signal 
transduction and suggesting a role for defective SHH signalling in the 
pathogenesis of alcohol-induced birth defects (Li et al., 2007). Our results 
demonstrate that in the adult brain, this pathway remains active and has a 
continuous role in the adult neural stem cells, and mature neurons are likely to 
be the source of SHH (Ihrie et al., 2011).We show that the SHH pathway, one of 
a key developmental signals in the brain, may be differentially regulated 
following kynurenine modulation. At present we are not entirely certain of the 
exact mechanisms that underlie the effects seen in this study. There remains 
room for further exploration to gain a greater understanding of the processes of 
SHH signalling mechanism.  
We analysed the expression of SOX2 in brain homogenates prepared from foetal 
and also from rat offspring at P21 and regional areas at P60 to determine 
whether this transcription factor was affected after modulation of kynurenine 
pathway during gestation. The biological roles of SOX2 have been thoroughly 
studied in the context of embryonic developmental regulation as it is known as 
one of the key factors in the regulation of embryonic stem cell self-renewal and 
is associated with neural stem cell (NSC) populations in the mature rodent brain 
(Brazel et al., 2005, Komitova and Eriksson, 2004). It is worth mentioning that 
all proteins of the SOX-B1 group (SOX1,SOX2,SOX3) are expressed in the 
developing brain to a different extent during development and many of the SOX 
proteins coexist throughout the CNS (Bylund et al., 2003). Our study shows that 
expression of SOX2 is abundant in the control embryonic brains, during a time 
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window in which the pool of neural progenitors expands extensively which in 
agreement with a previous study that indicate an essential role for SOX2 in early 
development (Avilion et al., 2003). Acute treatment with Ro61-8048 caused no 
alteration in the SOX2 levels suggesting the important role of SOX2 in neural 
stem cell maintenance in the developing brain. The prominent expression of 
SOXB1 protein in general, in the neurogenic regions of adult brain has prompted 
many researchers to analyse the expression pattern of these markers in the 
neurogenic lineage using a culture model of different types of dividing precursor 
cells with the aim of comparing the expression level of the markers that are 
expressed at different stages of adult neurogenesis. The reason for the lack of 
expression in the hippocampus of P60 animal, even in a control setting might 
arise from the hippocampal sections used in this study. The sections were 
obtained after it had been exposed to electrophysiological procedures. Thus, it 
is likely to reflect the overall cellular contents of the homogenates. As SOX2 
proteins bind to specific DNA sequences via their HMG box domains and 
synergizing with other transcription factors to fulfil variable roles, their mode of 
action may depend both on the cellular context and on the target gene 
functionally regulating active transcriptional complexes (Lefebvre et al., 2007). 
It has been shown that SOX2 is expressed mainly in dividing neural stem cells and 
transient amplifying progenitor cells in the hippocampus which indicates that 
SOX2 is expressed stage-specifically in cells of the adult neurogenic lineage (Suh 
et al., 2007, Ellis et al., 2004).  In another series of experiments, studies have 
shown that SOX2 continues to be expressed in specific populations of adult cells 
of other brain regions including cerebellum, where SOX2 positive cells have been 
observed in Bergmann glia which is not considered as a stem cell 
population(Alcock et al. 2009). Our results show a differential expression pattern 
in the adult brain regions after kynurenine pathway regulation as we 
demonstrate that endogenous concentrations of SOX2 varies between distinct 
classes of neural progenitor cells in those regions. The present findings only 
indicate that SOX2 is differentially expressed between regions. It is worth 
mentioning that isolated populations of these types of progenitor cells based on 
their SOX2 expression and subsequent gene expression profile of each sorted 
population can be used to accurately ascertain distinct neural progenitors 
(Hutton and Pevny, 2011), though at this stage we cannot identify the stem cell 
population pool in vivo as the antibody used in this study resulted in both 
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cytoplasmic and nuclear localization. As SOX2 represents a molecular signature 
for neural stem cells, this finding is particularly interesting and highlights the 
need to fully characterize the cell populations that express this marker in the 
adult brain.   
These observations suggest that prenatal modulation of the kynurenine pathway 
might lead to changes in the expression levels of several molecules that are 
involved in the regulation of cell cycle, proliferation as well as the neurogenesis 
process in developing and adult brains. An increased expression of the 
transduction molecule SHH was observed 24 h after treatment with enzyme 
inhibitor during late gestation. However, when repeated challenges of the 
inhibitor were given, a different pattern of expression was seen with reduced 
levels of expression demonstrated at developmental age P21 and it remained 
repressed in some regional areas of the brain including the hippocampus, 
cerebellum and cortex. Substantial studies have gathered evidence supporting 
the idea that dysregulation of the cell cycle in neural cells plays an important 
role in diverse pathological processes in the CNS. Further study on the 
characterization of cell cycle properties in this process and comparative studies 
on the expression of individual members of each related proteins under 
physiological conditions, including various developmental stages and in exposure 
to pathological stimuli may provide better and conclusive explanations.  
4.5.3 Expression profiles of inflammatory associated proteins 
As both NFB and COX2 are critical to host defense to various pathological 
stimuli, their common activating conditions represent either a direct threat to 
cells or that they are endogenous signals produced in response to pathogens. In 
this respect, administration of foreign substances might induce an inflammatory 
response; we explored the expression profiles of relevant inflammatory markers 
following administration of an enzyme inhibitor of the kynurenine pathway, 
Ro61-8048. The impetus of the present study was to test the hypothesis that 
prenatal inhibition of KP by Ro61-8048 would have impacts on the transcriptional 
activity of NFB and COX2 expression in the offspring. The ability of Ro61-8048 
to shift the production of kynurenine metabolites towards greater levels of KYNA 
has been reported and we show a substantial increase of KYNA in the maternal 
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plasma and in the brains of the embryos after 5 h of Ro61 administration. Level 
of KYNA remained significantly elevated in the embryonic brains after 24 h post 
administration (Forrest et al. 2013b). This effect was accompanied by increased 
NFB activity in the embryo brains 24 h post treatment, indicating a role for this 
TF in inducing activity of other relevant target genes in the presence of the 
kynurenine pathway metabolite, KYNA. The effect of Ro61-8048 in shifting the 
balance of KP as seen in the embryonic brains also suggests that there is some 
constitutive NFB activity that normally influences activity of KP during 
embryonic development. Increased activity of NFB in gestational tissue has 
been thought to be an integral part of the final phase of pregnancy and involved 
in the biochemical changes associated with labor (Choi et al., 2007). 
 It has been reported that NFB mediates the increased expression of both IDO 
and TDO in the human placenta following infection (Dharane et al., 2010). IDO is 
considered to be an important immunoregulator, where its induction during 
pregnancy has led to the suggestion that it has as essential role in suppressing 
the maternal immune response to the presence of the fetus (Munn et al., 1998). 
NFB is a primary transcription factor specialized in cytoplasmic-nuclear 
signaling and coordinate the activation of various genes following extracellular 
stimulation (O'Neill and Kaltschmidt, 1997). Extracellular signals, in particular 
neurotransmitters might regulate gene expression through activation of NFB. In 
this regard, glutamate and NMDA caused an induction of NFB binding activity in 
the nucleus of mouse cerebellar cells through activation of NMDAR. It seems that 
NFB appears to be a good candidate as a mediator for glutamate induced 
immediate early gene transcription in the CNS (Guerrini et al., 1995). Sustained 
expression with significant increased of the level of NFB protein level was 
observable in the total brain homogenates from P21 offspring whose mother had 
been injected with Ro61-8048. However, the levels of this TF were detectable 
with no apparent changes in term of protein levels when observed in the 
hippocampus, cerebellum, cortex and midbrain of P60 brains. Nuclear 
translocation of activated NFB must be demonstrated in order to determine its 
DNA binding activity. However, current findings applied to the quantification of 
expression levels generated from whole extracts of whole brain or selected 
regional areas i.e. hippocampus, cortex, cerebellum and midbrain. 
Demonstration of an activation of transcription factors (described before in the 
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text) within these specialized brain sites is therefore a useful tool to evaluate 
inflammatory activation of the brain to a given insult. Owing to the fact that 
these transcription factors are constitutively present in the cytoplasm and 
migrate and accumulate in the nucleus of a stimulated cell, the activation of 
NFB within specific brain sites can be further analyzed by means of 
immunohistochemistry.   Given that the TF also appear to be expressed 
throughout CNS in both neurons and in non-neuronal cells, we sought to 
demonstrate the presence of NFB complexes within brain areas following 
maternal administration of Ro61-8048. It has been found that the majority of 
NFB present in whole cell extracts (not separated into subcellular fractions of 
nuclear and cytosolic fractions) is bound to its inhibitory unit IB, thus, specific 
DNA binding activity was not determined in this study.   It warrants further 
investigation for the functional consequences of differential subcellular 
localization of NFB following KP modulation. In conclusion, the presence of a 
well-known primary transcription factor in the brains throughout developmental 
ages and its induction at different times during development in response to 
prenatal KP modulation by enzyme inhibitor suggests a possible involvement of 
NFB in the regulation of gene expression during CNS development and also 
represents possible physiological consequences from stimulation. 
Different reports have demonstrated the involvement of NFB in the 
transcriptional regulation of COX2 expression after stimulation with LPS or 
cytokines i.e. TNF-α. Coordinated increases in COX2 expression were associated 
with enhanced PGE2 production.  Functional relevance of NFB activation in this 
aspect was seen using NFB inhibitors in the transfected macrophages prior to 
stimulation with agent (Diaz-Munoz et al., 2010). In addition, rapid activation of 
NFB upon stimulation with IL-1 has been demonstrated in human myocyte 
tissue from term pregnant women and this factor is functionally linked to the 
expression of COX2 mRNA and protein that NFB can induce COX2 enzyme (Choi 
et al., 2007). Our results show that the expression of COX2 protein in the 
embryonic brain was not affected following acute stimulation of Ro61-8048. 
Increased expression of NFB in the total protein from embryo brain after 24 h 
treatment (correspond to E19) and P21 offspring was not accompanied by any 
apparent changes in COX2 levels. Differential expression of COX2 was presented 
in the P60 animals while a relatively strong repressive effect of COX2 were 
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observed in the cortex of Ro61-reated rats than control animals. Neurons of 
various regions including the hippocampus, cerebral cortex and hypothalamus 
express COX2 which is thought to play a role in fundamental brain functions, 
such as synaptic activity and memory formation. COX2 expression has been 
shown to be rapidly upregulated in neurons in response to excitatory synaptic 
transmission mediated by NMDAR activation or neurotoxic stimuli (Yamagata et 
al., 1993).Taken together with our findings, these characteristic  localizations 
suggest regional and tissue-specific roles for COX2 in cellular signaling.  
4.6 Conclusion 
A number of mechanisms modulating kynurenine metabolism in the brain during 
early life can be envisioned. In this respect, we noted that the in vivo use of 
Ro61-8048, not only caused KYNA levels to be pharmacologically enhanced, but 
also confirmed the ability of this compound to inhibit KMO, thus demonstrating 
the intimate relationship between maternal and foetal KP metabolism. 
Administration of Ro61-8048 to pregnant rats during the late gestation period 
caused comparable increases in maternal environments (plasma and brain) and 
fetal brain KYNA, demonstrating that the endogenous changes in KP metabolism 
were compromised by this pharmacological intervention. In the context of the 
study, we provided evidence of how variations in brain development mechanisms 
are affected by regulation of the kynurenine pathway during pregnancy. The 
brain is very sensitive to noxious environmental influences, in particular during 
early stages of life. Severity and duration of the insults/agents are of critical 
importance for the brain outcome of any detectable lesions. One implication of 
this finding is that exposure to high levels of KYNA may begin early in life, as we 
have previously shown an increased endogenous KYNA concentration in the 
maternal plasma and foetal brain, and that increases in KYNA concentration and 
the resulting inhibition of NMDAR during early developmental stages could have 
lasting impacts on brain development.  
 
 
5 Molecular effects in the adult rat brain following 
prenatal inhibition of the kynurenine pathway 
5.1 Introduction 
Kynurenine pathway metabolites, particularly the pivotal QUIN and KYNA (Zhao 
et al., 2008) concentrations in the foetal brain are controlled locally and are 
also responsive to maternal infections and pharmacological manipulations. 
Moreover, the pathway is intimately associated with excitatory amino acid 
neurotransmission systems that play central roles in neuronal growth, 
differentiation and synapse formation. It has been shown that various anomalies 
of glutamate-mediated synaptic transmission can lead to excessive activation of 
neurons (excitotoxicity), which may in turn initiate their death or compromise 
their survival in some neurological disorders.  Considering that the plasticity of 
glutamate-mediated receptors could be affected by changes in the balance 
between endogenous levels of KP metabolites, several pharmacological agents 
have been successfully used to probe the physiological and pathological roles of 
kynurenines (Schwarcz et al., 2012, Schwarcz and Pellicciari, 2002, Carlsson et 
al., 2001). It is well know that NMDA subtypes of glutamate receptors are 
involved in plasticity processes during brain development and excessive 
activation of this receptor during early stages of brain development may 
manifest its effects only later in life. It is therefore important to consider the 
possibility that pharmacologically induced prenatal increases in brain KYNA 
levels might induce neurochemical alterations which could interfere with 
developmentally essential glutamatergic neuronal function in the offspring.  
Generation of new neurons (known as neurogenesis), that persists lifelong 
postnatally in the subventricular zone of the lateral ventricle and subgranular 
zone of the dentate gyrus in the hippocampus forms crucial neuronal networks 
responsible for cognitive, emotional and memory function. The brain regions 
that are capable of producing new neurons contain pools of neural progenitor 
cells (NPC) which are functionally integrated into the existing neuronal circuitry 
and regulate hippocampus-dependent learning and memory processes. These 
tightly regulated processes takes place within an appropriate time frame and 
sequence and consists a balance between NPC proliferation, migration, 
differentiation and survival. Any defect along these processes could have some 
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implications and lead to neurological and psychiatric disorders (Zhao et al., 
2008). Study on the regulation of these processes are continually researched as 
they represent  prominent forms of brain plasticity, potentially involved in 
learning and memory and partly associated with cognitive deficits of many 
neurodevelopmental disorders. Various neuropsychiatric disorders such as 
depression, schizophrenia, Huntington‟s disease and also in stroke and drug 
addiction patients are characterized by alterations in neurogenesis in the 
hippocampus as indicated by the increased cell proliferation and the presence of 
newly generated neuron in the neurogenic regions of the brain (Curtis et al., 
2003b, Curtis et al., 2003a, Jin et al., 2004). There is also growing interest on 
the evidence that neurodevelopmental disorders are associated with cerebellar 
deficits and learning impairments. Thus, the cerebellum is likely one of the 
structures of choice to investigate the relationship between regional 
development defects and learning. Its main role not only has been primarily 
associated with motor control, but also in motor learning and cognition. The 
presence of cognitive deficits and structural changes together with functional 
cerebellar alterations have also occasionally been implicated in neuropsychiatric 
pathology (Hoppenbrouwers et al., 2008).  
In the present study, to elucidate the effects of developmental exposure to an 
enzyme inhibitor of the KP on neurogenesis, the distribution of granule cell 
lineages in the hippocampus formation were analysed in the offspring of rats 
exposed to Ro61-8048 during pregnancy. The hippocampus represents a unique 
structure for ongoing neurogenesis throughout postnatal life and is crucial for 
higher brain functions such as learning and memory. Moreover, NMDA receptors 
are abundant in this region and it is suggested that hippocampal NMDA receptors 
are closely related to the cause of various psychiatric disorders such as anxiety 
and depression as well as the functions of learning and memory. Apart from the 
hippocampus, the cerebellum with its well-defined cell types positioned in a 
layered fashion also makes the region particularly amenable for the study of 
morphogenesis. An increase in cerebellar volume during development is due to 
the expansion and proliferation of the granule cell precursor (GCP) during early 
postnatal periods. Various stimuli are involved in the regulation and induction of 
granule cell proliferation. Among these SHH, a secreted factor expressed in 
Purkinje cells from the embryonic period is the most efficacious endogenous 
  176 
 
mitogen known to be involved in the regulation of GCP in the cerebellum in 
which inhibition of SHH signalling has been shown to reduce GCP proliferation 
(Dahmane and Ruiz i Altaba, 1999, Lewis et al., 2004).  
5.2 Research aims 
In the present study, to detect a key molecular event reflecting permanent 
disruptions of neuronal development due to modulation of the kynurenine 
pathway during gestation that can interfere with NMDA receptor signalling and 
function, we examined cellular distribution and localization of several markers 
that have been implicated in neurogenesis process of adult rats. We 
hypothesized that early modulation on NMDA receptor function via kynurenine 
pathway metabolites may affect ongoing neurodevelopmental processes 
including postnatal hippocampal neurogenesis in the offspring. The aim was to 
address whether prenatal inhibition of the kynurenine pathway regulates the 
expression of key components of the cell genesis in the hippocampus and also in 
the cerebellar cortex and to demonstrate whether the patterns of morphological 
findings were consistent with those of protein expression levels. Moreover, we 
also sought to corroborate if the changes described in these regions are 
representative of the whole brain or whether prenatal exposure to Ro61-8048 
induced region-specific changes in the adult offspring. 
5.3 Experimental approaches 
5.3.1 Prenatal treatment and operative procedures 
Timed pregnant Wistar rats were injected intraperitoneally (i.p.) with 100mg/kg 
of Ro61-8048, a compound inhibiting a key enzyme in the kynurenine pathway 
which shifts the balance of tryptophan metabolism towards the production of 
kynurenic acid (Forrest et al., 2013a), or saline (0.9% NaCl) at E14, 16 and 18 
(n=3 per group). Then, gestation was allowed to proceed normally and at 
postnatal day 60 (adult) their brains were perfusion-fixed for 
immunocytochemical processing (Figure 5-1). Animals were deeply anesthesized 
with Euthatal and intracardially perfused with mammalian Ringer solution 
followed by 4% paraformaldehyde in 0.2M PB.  
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Figure 5-1 Timeline for prenatal treatment of Ro61-8048 for immunocytochemical 
experiments. 
 
 
5.3.2 Tissue processing and immunocytochemistry 
The brains were then dissected, post-fixed for 4 h in the same fixative at 4oC 
and transferred to a 30% sucrose solution until equilibrium was reached. The 
brain fixative contained 30% sucrose as a cryoprotectant, preventing large ice 
crystal formation. The regions of the brains were embedded in 5%  agarose gel 
and coronal sections were cut with a vibratome at  60 m in 0.1M PBS. Free 
floating sections through the entire rostral to caudal hippocampal axis were 
serially collected in bottles filled with the same buffer with 5-6 sections/bottle.  
For analyses of hippocampal  neurogenesis, serial free-floating sections from one 
bottle of coronally cut sections  were first washed in 0.3M phosphate buffered 
saline (PBS) before being incubated with optimally diluted primary antibodies in 
0.1% Triton in PBS (PBST; pH 7.4) for 72 h at 4oC under continuous shaking 
conditions. Primary antibodies used in our study were monoclonal mouse anti-
NeuN (1:500), polyclonal goat anti-Doublecortin (DCX) (1:250) and polyclonal 
rabbit anti-SHH (1:100). In this study, immature and developing neurons in the 
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dentate gyrus of the hippocampus were identified with a goat antiserum 
(Sc8066, Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1:250) directed 
against a synthetic  doublecortin peptide corresponding to amino acids 385-402 
at the C-terminus of human doublecortin and specific for DCX of mouse, rat and 
human origin. Postmitotic mature neurons were identified by using a mouse 
monoclonal antibody that recognizes the neuron-specific nuclear protein 
(MAB377 Millipore, Temecula CA92590, USA; diluted 1:500). It reacts with most 
neuronal cell types throughout the nervous system of rats and is primarily 
localized in the nucleus of neurons with lighter staining in the cytoplasm. In this 
study, the NeuN antibody provided specific labelling of neurons throughout the 
hippocampal formation and the staining pattern was very similar to that seen in 
other studies in which this antibody was used.  Rinses were performed between 
all steps using 0.3M PBS before or after the primary and secondary antibody 
incubation. Following primary antibody treatment, sections were subsequently 
incubated overnight at 4oC in species specific Alexa Flour-tagged secondary 
antibodies: Alexa 488, Alexa 647 and Rhodamine-conjugated secondary antibody.  
Sections were mounted and cover-slipped with an aqueous mounting medium for 
fluorescence H-1000: Vectashield. This application of method is dependent on 
antibody specificity and is not a direct measurement of protein amount. 
However, it has the advantage of cellular localization within cell bodies and 
neuronal processes.  
5.3.3 Confocal microscopy and data analysis 
All analyses were conducted by the researcher blind to experimental condition. 
Sections were initially examined with a 20× objective lens using a fluorescent 
microscope. The regional areas  of CA1, CA3 and dentate gyrus of hippocampal  
sections (from bregma -2.50 mm to –3.50mm) were delimited by morphological 
criteria and only immunopositive cells showing a stained unit area sufficient to 
ensure that the majority of their volume was contained within the selected area 
were scored. For the cerebellum, at least 3 coronal sections were 
immunolabelled and in every section, two to four images were taken followed by 
image processing to optimally visualize the staining area. These sections were 
scanned with a Bio-Rad Radiance 2100 confocal system through a 40×oil-
immersion lens to produce image stacks with a 1 μm z-separation. The counting 
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of the DCX, SHH  and NeuN positive cells were conducted in a total of 15 grids of 
area (50µm x 50µm) for the dentate gyrus and CA1 regions and grids of 5x5 
(50x50µm each grid size) for the CA3 region per section. Cell staining was 
assessed in the granule cell layer (GCL) including the germinative SGZ and 
molecular layer of the DG within the grid area. While the number of NeuN 
immunoreactive neurons in the internal granular layer of the cerebellum were 
quantified in one hemisphere at approximately the middle region of the 
cerebellum in a total grid size of 4x4 (50µm x 50µm). Three dimensional 
reconstructions of the z-series were performed to assess the overlap between 
cell bodies. The cell number analysis was done on a total of 3 sections per 
animal with at least 2-3 observations per section using ImageJ software (Version 
1.43M; National Institute of Health). Immunopositive cell counts of 3 sections 
were averaged to obtain a single value for the number of positive-stained cells 
per section. Quantification of immunopositive cells were analysed using data 
generated from individual animal as the experimental unit. A mean ± standard 
error (SE) was calculated from the data in each group (n= 7-9 animals). Images 
were generated as projections of z-stacks to illustrate the extent of all the 
markers staining (DCX+ve cells, NeuN+ve cells and SHH+ve cells) within a 60m 
section. Representative images were not altered except for overall brightness 
and contrast. For statistical analysis, a student‟s t test was performed to 
examine the differences in the mean number of cells per region per animal 
between treatment groups. P<0.05 was deemed significant.  
5.4 Results 
To determine the cell fate of the hippocampal cells, we did triple 
immunoflourescent labelling using cell specific markers, including DCX, a marker 
of immature and developing neurons, SHH and one of the neuronal markers, 
NeuN.  
5.4.1 DCX-expressing cells in hippocampus 
Doublecortin is a microtubule binding protein that is transiently expressed in 
proliferating progenitor cells of adult neural progenitor cells (Francis et al., 
1999). On tissue sections of the adult hippocampus dentate gyrus overviews 
(Figure 5-3) showed the band of DCX-positive cells in the granule cell layer 
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proper. Labelling in both groups were generally in cell bodies aligned in a single 
row along the base of the granule cell layer while its dendrites of various lengths 
were visible and reach into the molecular layer. In both blades of the DG, we 
observed some DCX-positive neurons with extensive and orientated vertical 
dendrites which extended into the molecular layer. There were also a number of 
cells having horizontally orientated dendrites. The nucleus appears usually 
devoid of immunoreactions and it looks like an envelope. The immature neurons 
in the control group are more often found clustered and extending as rows in to 
granule cell layer. In addition, the absence of basal dendrites was another 
feature that we noticed in our study.  
The number of DCX-positive cells representing newborn granule cells in both 
control and Ro61-8048-treated brains appeared to progress through similar 
pattern of expression with no difference in term of general localization which 
were more abundant in the granule cell layer as seen in the dentate gyrus. DCX 
immunopositive cells in the DG were mostly dispersed with few clustered cells 
(Figure 5-3). DCX expression can be visualised within the soma and dendrites 
suggesting that the newly born cells differentiate into neurons. The average 
number of DCX-positive cells located in the SGZ of dentate gyrus was not 
statistically different between control and Ro61-8048- treated group. Ro61-8048 
treatment had no effect on the number of cells staining for DCX (p=0.93) when 
compared to their control offspring. We then compared the overall dendritic 
maturation of newly generated neurons between the groups during the DCX 
expression phase which was based on the complexity and orientation of 
dendrites. The DCX positive neurons with vertical dendrites emanating from the 
soma and extending into the GCL were counted. Quantification of neurons with 
dendritic projections that are relatively more mature showed significantly fewer 
neurons bearing these longer dendrites in tissue from animals exposed prenatally 
with Ro61-8048 (Ro61: 8.29 ± 1.19 vs Saline: 14.30 ± 1.19, p=0.0029, Figure 
5-3(F)).  Furthermore, most of the newly generated neurons with vertically 
orientated dendrites in Ro61-8048-treated sections exhibited short terminal 
branches and the spread of the dendritic tree in these newly generated granule 
cells appeared narrower. This modification of DCX immunoreactivities were 
restricted to the dentate gyrus and not observed in any other hippocampal 
subfield. In the hippocampal formation area, CA1 and CA3, we observed 
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essentially no DCX-expressing dividing cells in both areas following exposure to 
Ro61-8048.  
 
Figure 5-2 Coronal section through the rat brain indicating the position and extend of 
the hippocampal formation. 
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Figure 5-3 Arrangement of newly generated neuron (DCX+ve immunoreactivity) in the 
dentate gyrus of P60 rat.  
Expression of DCX positive newly generated neurons were visualized with green 
fluorescence (A-D). Overview pictomicrograph showing the hilus, molecular layer (ML) and 
subgranular zone (SGZ) which shows the distribution of newly born neurons with dendrites 
in the two blades of the control dentate gyrus (10x magnification)(A). A higher power (40x 
magnification) representation of DCX expression in control dentate gyrus which shows DCX 
labelling of dendrites around the apex of dentate gyrus reaching into molecular layer (C). 
Representative image of DCX expression in the dentate gyrus of P60 offspring after prenatal 
administration of Ro61-8048 (10x) (B). A higher power (40x) DCX expression in Ro61-8048 
treated rats which shows relatively fewer and simple unbranching processes (D). Note that 
the distribution of new neurons is heterogeneous and dendrites from many newly generated 
neurons cross the inner and middle molecular layer and reach the outer molecular layer. 
Arrows indicate examples of DCX+ve cells which appeared to envelope the somata and 
dendrites. The number of DCX expressing cells was unchanged following prenatal treatment 
with Ro61-8048 when compared to control saline(E), whereas the proportion of DCX+ve 
cells with dendritic projections in the dentate gyrus were greatly reduced in Ro61-8048 
animals [n=8] when compared to control [n=8-9 from each group] (F). Astericks indicate 
statistical significance between experimental groups (**P<0.01; Student’s test). Data are 
presented as mean ± SEM. SGZ, subgranular zone; GCL, granule cell layer; ML, molecular 
layer. Scale bar= 100µm (A and B), 10µm (C and D). 
GCL 
SGZ 
ML 
Hilus 
Hilus 
 ** 
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5.4.2 Immunoreactivity of NeuN in the hippocampal formation at 
P60 
Using NeuN-immunoreactivity as a neuron-speciﬁc marker, we examined whether 
neuronal density in the hippocampus was affected by in utero exposure to Ro61-
8048. The distribution of NeuN-immunoreactive cells in the hippocampal 
formation that included the DG, CA1 and CA3 regions is shown in Figure 5-4 and 
Figure 5-5Error! Reference source not found., respectively. To see whether 
early modulation of the kynurenine pathway during pregnancy affects the late 
neuronal differentiation process and the survival of neuronal lineage committed 
cells during the late stage of adult hippocampal neurogenesis, a mature neuronal 
marker, NeuN was immunolabelled.  Generally, the NeuN antibody labels the 
nucleus and cytoplasm of most neuronal cell types in all regions of the adult 
brain with no reactivity seen in astrocytes. The most cytoplasmic 
immunopositive staining was concentrated in the soma, rarely extending at a 
short distance into the dendritic processes. In all the regions, this extranuclear 
staining appeared finely granular and somewhat diffuse. We also noted with 
closer inspection of less well-stained dot-like subnuclear structure staining 
within cells. In this study the expression of NeuN was clearly observed in all 
subfields of the hippocampus.  In the hippocampal dentate gyrus, the entire 
section of both control and treated animals were intensely stained with NeuN-
immunoreactivity while some granule neurons of the hilar region were also 
immunoreactive as shown in Figure 5-4(A & B). Animals exposed to the 
kynurenine inhibitor exhibited a high survival rate of newly born neurons.  
The maturity of newly born neurons indicated by NeuN were affected at P60, 
where NeuN reactivity was found to be more intense in the granular cells of 
dentate gyrus and the number of NeuN positive cells increased significantly 
when compared with controls (Ro61: 206.07 ± 7.65 vs Saline: 179.07 ± 4.00, 
p=0.0049, Figure 5-4 (E)). In the CA1 region, the expression of nuclear 
immunoreactivity to NeuN was predominantly seen in the pyramidal cells both in 
the nuclei and cytoplasm Figure 5-5 (A & B). At P60, a significant increase was 
observed in the number of NeuN positive cells in the CA1 region (Ro61: 140.71 ± 
17.31 vs Saline: 94.91 ± 6.57, p=0.0168, Figure 5-5 (E)), whereas there were no 
statistically significant differences in the number of immunoreactive cells to 
NeuN between the control and treatment groups in the CA3 which indicate that 
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existing mature neurons are not affected (Figure 5-5 (F); p=0.8071). These 
results provide evidence that Ro61-8048 administration during pregnancy has a 
stimulatory effect on the development of new neurons and also demonstrate 
that this effect is long lasting, being evident in pubertal offspring 9 weeks after 
their first exposure to the compound. 
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Figure 5-4  Prenatal Ro61-8048 exposure increases the number of NeuN immunoreactive 
neurons in the dentate gyrus of P60 rats. 
Representative photomicrographs showing morphology of NeuN expression in the saline 
control dentate gyrus (10x magnification) (A) and at higher power (40x magnification) (C).   
Low magnification confocal image of the immunohistochemical localization of NeuN in P60 
dentate gyrus coronal sections after prenatal administration of Ro61-8048 (B). A higher 
power (40x) DCX expression in Ro61-8048 treated rats which shows the granule cell layer is 
slightly thicker than that of control animals (D). Expression of nuclear immunoreactivity to 
NeuN was more intense in the granular cell layer (GCL), and some granule neurons in the 
hilar region were also immunoreactive. The size of the hippocampal formation in the Ro61-
treated rats appears to be larger and the granule cell layer of the dentate gyrus is somewhat 
thicker than that seen in the control animal. Quantification of NeuN immunoreactivity in the 
dentate gyrus in a subset of animals prenatally exposed to Ro61-8048 suggested a 
significant increased of mature neurons [n=7-9 from each group] (E). Astericks indicate 
statistical significance between experimental groups (**P<0.01; Student’s test). Scale 
bar=100µm in A and B and 10m in C and D.  
 
 
GCL 
GCL Hilus 
Hilus 
 ** 
 
  186 
 
 
(E)       (F) 
0
50
100
150
200
    Saline                   Ro61-8048N
e
u
N
+
v
e
 c
e
ll
s
 i
n
 C
A
1
/s
e
c
ti
o
n
       
0
50
100
150
    Saline                   Ro61-8048N
e
u
N
+
v
e
 c
e
ll
s
 i
n
 C
A
3
/s
e
c
ti
o
n
 
Figure 5-5 Immunocytochemical localization of NeuN in hippocampal coronal sections 
of CA1 and CA3 regions  
Representative photomicrographs of NeuN positive neurons from control and Ro61-8048 
animals are shown. NeuN immunopositive pyramidal cells in CA1 region in the control (A) 
and Ro61-8048-treated rats with an apparent neuronal increase in the hippocampal CA1 
region (B). Immunostaining of NeuN in the CA3 region of the hippocampus in the control (C) 
and Ro691-8048-treated sections (D). Bar graphs show the quantified immunopositive cells 
to NeuN in CA1 and CA3 regions. The quantified score based on the number of cells 
showed significantly increased number of NeuN+ve neurons in the CA1 hippocampus of 
Ro61-8048-treated rats while no differences in terms of immunoreactive cells were observed 
in the CA3 region (E & F). Values are expressed as mean  SEM [n=8-9 from each group]. 
Asterick indicates statistical significance between experimental groups (*P<0.05; Student’s 
test). Scale bar= 20m (A,B,C and D). 
 * 
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5.4.3 Immunocytochemical analysis of SHH distribution in the 
adult rat hippocampus 
The present study indicates that early modulation of kynurenine pathway which 
leads to changes in the levels of neuroactive metabolites in the brain could 
impose a long lasting effect on the regulation of expression of one of the cell 
genesis morphogen in the adult hippocampal subfields.  Immunostaining studies 
using anti-SHH antibody revealed cellular localization of SHH which was 
predominantly observed in cells within the subgranular layer of the dentate 
gyrus, the hilar region and CA1 and CA3 regions (Figure 5-6 and Figure 5-7). Our 
immunocytochemical analysis demonstrates that endogenous SHH in the 
hippocampus were distributed in puncta extracellularly and intracellularly at the 
soma of the hippocampal neurons. The Ro61-8048-treated offspring compared 
with control exhibited a marked increase in the number of immunopositive cells 
for SHH in the hippocampal dentate gyrus (Ro61: 84.33 ± 7.49 vs Saline: 52.56 ± 
9.02, p=0.029,Figure 5-6 (E)). This stimulatory effect on the generation of new 
cells was also detected in the CA1 region of the hippocampus of Ro61-8048-
treated animal (Ro61: 90.17 ± 5.58 vs Saline: 51.48 ± 5.92, p=0.0003, Figure 5-7 
(E)).In contrast to these changes in SHH positive cells as seen in DG and CA1, 
prenatal Ro61-8048 treatment failed to produce a significant increase in the 
number of SHH-labeled cells in CA3 region (Ro61: 73.48 ± 7.55 vs Saline: 48.17 ± 
10.08, p=0.0678, Figure 5-7 (F)). We showed that SHH is predominantly 
expressed in cells within the subgranular layer of the dentate and CA1 region. 
These results suggest that neurons upregulate SHH in response to early changes 
in the endogenous levels of kynurenine metabolites. Based on 
immunohistochemistry analysis, neurons within the dentate gyrus and CA1 region 
may be accounted for by the increased SHH.   
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Figure 5-6  Representative pictures of SHH immunoreactivity in the dentate gyrus of P60 
rat. 
SHH expression in the saline control dentate gyrus(DG) at 10x magnification (A). A higher 
power (40x magnification) representation image of SHH expression in control dentate gyrus 
(C). SHH expression in P60 dentate gyrus offspring after prenatal administration of Ro61-
8048 (10x) (B). A higher power (40x) SHH expression in Ro61-8048 treated rat (D). Note that 
the majority of SHH+ve cells were identified within the granular cell layer and hilus regions 
of the DG in both control and Ro61-8048-treated rats. A small fraction of immunopositive 
cells could also be detected in the molecular layer of the hippocampus. Analysis of the 
number of SHH imunoreactive cells in the DG revealed a significant increase in the SHH+ve 
cell number after prenatal inhibition of the kynurenine pathway as depicted in (E). Data is 
represented as mean ± SEM [n=8-9 from each group]. Astericks indicate statistical 
significance between experimental groups (*P<0.05; Student’s test).  Scale bar=50µm (A and 
B), 10µm (C and D). 
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Figure 5-7  Immunocytochemistry for SHH in the CA1 and CA3 region of the 
hippocampus. 
SHH immunolabelling of neurons in coronal sections through the hippocampal formation 
subfield CA1 and CA3 region in P60 animals after prenatal treatment with Ro61-8048. SHH 
immunopositive staining shows increased expression within the CA1 region following 
kynurenine pathway inhibition.  Representative photomicrograph shows distribution of SHH 
at 40x magnification in the CA1 region of saline control animals (A). Representative image 
of SHH expression in Ro61-8048-treated animals in the CA1 (B). SHH expression in the CA3 
region of P60 offspring in control animals (C). A higher power (40x) SHH expression in the 
CA3 region of Ro61-8048-treated animals (D). Analysis of the number of SHH 
immunoreactive cells in CA1 revealed a significant increased in the SHH+ve cell number 
after prenatal inhibition of the kynurenine pathway as depicted in (E)  while no differences 
were observed in the CA3 region (F). Astericks indicate statistical significance between 
experimental groups (***P<0.001; Student’s test).  Data represented as mean ± SEM (n=8-9). 
Scale bar=20µm (A,B,C and D). 
  
 
 *** 
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5.4.4 Cerebellar NeuN-positive cells after prenatal Ro61-8048 
We examined on closely spaced triple-labelling coronal sections of the adult 
cerebellum in an attempt to identify and characterize the expression of these 
developmental markers following Ro61-8048 treatment during the late phase of 
gestation. Inspection of these sections revealed no evidence of staining for DCX 
which marks postmitotic, migrating neurons, while high levels of diffuse staining 
were observed for SHH in the granule cell layer which made it impossible to 
count individual neurons for both markers. Previous studies have demonstrated 
that SHH expression is confined to the purkinje layer, in line with its production 
in the purkinje cells (Traiffort et al., 1998). However, observations in our 
sections exhibited a very faint reactivity for SHH antibody in the purkinje layer, 
which on the basis of its distribution might reflect labelling of purkinje cells. In 
this respect, increased secretion or reduced removal and altered metabolism of 
SHH could possibly be attributable to the indistinct diffuse staining 
intracellularly and on the extracellular surface of the soma. Immunoreactivity 
for NeuN was observed in the small granule neurons located within the granular 
layer, showing cytoplasmic reactivity in addition to nuclear immunolocalization. 
As for the number of NeuN-positive cells in this area, there were no statistically 
significant differences in both control and treatment groups (Ro61: 137.85 ± 4.39 
vs Saline: 148.76 ± 5.29, p=0.1348, Figure 5-8 (E)). 
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Figure 5-8  Immunocytochemistry for NeuN in the IGL region of the cerebellum. 
In the adult cerebellar cortex, most NeuN-positive cells could be seen in the internal granule 
layar (IGL) with only a few stained nuclei could be found in the molecular layer (ML). 
Representative photomicrographs showing morphology of (A) NeuN expression in the 
saline control IGL of the cerebellum (40x magnification). (C) A higher power (40x, zoom3 
magnification).  (B) NeuN expression in  the IGL of P60 offspring after prenatal 
administration of Ro61-8048 (40x). (D) A higher power (40x, Z3) DCX expression in Ro61-
8048-treated rats. Values are expressed as mean ± SEM, and n=8 animals per group. 
Quantification of NeuN immunoreactivity in the IGL in a subset of animals prenatally 
exposed to Ro61-8048 showed no changes between treatments.(E). Scale bar=20µm in A 
and C and 10m in B and D.  
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5.5 Discussion 
Confocal microscopy was used to determine the phenotype of all the 
immunoreactive cells in selected region of interest. Immunolabeling with DCX, 
SHH and NeuN allowed visualization of newly generated cells that were 
developing and maturing according to a neuronal fate in both treatment groups. 
The observation of variable conditions including physiological, pathological and 
pharmacological stimuli could modulate adult neurogenesis. Therefore the 
present study was designed to identify possible changes in granule cell number, 
proliferation and maturation in the hippocampus as to corroborate the molecular 
data at the morphological and protein level. We also sought to examine whether 
the modified expression of these proteins are associated with structural changes 
at the cellular level that might contribute for the modification of neuronal 
structure and development. 
We studied the effects of modulation of NMDA receptor function by 
administering a known enzyme inhibitor, Ro61-8048 on the localisation of 
neuronal structure with respect to neurogenesis processes that includes 
neuroblast differentiation using DCX staining, neuronal migration and orientation 
using SHH and the maturity of neurons using NeuN immunocytochemistry, in the 
hippocampus at P60. During early development of the brain, NMDA subtypes of 
glutamate receptors and α7NCR receptors of glutamatergic and cholinergic 
mechanisms are critically involved and play central roles in neuronal growth, 
differentiation and synapse formation (Bard and Groc, 2011, Cull-Candy et al., 
2001).  It has been established that endogenous KYNA functions as an 
endogenous agent capable of directly affecting both NMDARs and α7NCRs.  
Antagonistic properties of  KYNA  at  the NMDA receptor account for its ability to 
reduce excitation and are responsible for its neuroprotective and anticonvulsant 
properties (Foster et al., 1984). However, these effects may also pose for a 
pathophysiologically relevant function in neuropsychotic diseases such as 
schizophrenia, which includes abnormal brain KYNA levels (Muller and Schwarcz, 
2006). As endogenous KYNA might also be involved in the processes underlying 
learning and more generally synaptic plasticity, fluctuations in KYNA levels can 
be envisioned to influence these processes. As elaborated in previous studies, a 
range of pharmacological agents have been used to probe the physiological and 
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pathological roles of KP metabolites. One approach to influence the levels of KP 
metabolites is based on the pharmacological blockade of KMO, the enzyme 
responsible for the formation of 3-HK and QUIN (Stone et al., 2012, Stone, 
2000). This concept is supported by our previous studies showing that the 
administration of Ro61-8048 during late gestation of rats were reported to alter 
the relative concentrations of endogenous KP metabolites and resulted in 
disordered neuronal development.  
We have demonstrated an increased in the levels of kynurenine and KYNA in the 
maternal plasma and also in the embryo brains 5 hour post-injection. The 
maternal levels of these metabolites  normalize after 24 hour but remain 
elevated in the embryonic brain. It seemed that the outcome of administering 
pharmacological compounds that block KMO  somehow shunted the metabolism 
of KP toward the production of KYNA. It has been suggested that the changes in 
the protein expressions of some of the target molecules observed at 
developmental ages of P21 and P60 were likely to be caused by the increased 
levels of these KP metabolites, particularly KYNA (Forrest et al., 2013a, Forrest 
et al., 2013b). 
5.5.1 Protein localisation in the hippocampus 
To test the hypothesis that an early modulation in the endogenous levels of 
KYNA induced by blocking one of the main enzymes in the KP, would produce 
long lasting changes in the generation and development of neurons, we focused 
on the hippocampus because it possesses a substantial capacity for regeneration 
and presents itself as a unique form of neural circuit plasticity. A substantial 
body of evidence regards a crucial role for hippocampal neurogenesis in 
mediating specific cognitive functions. In line with its well-recognised role in 
cognitive processes, any modification as in decreased or abnormal process is 
strongly correlated with deficits in hippocampal structure and function in various 
neurological disorders including epilepsy, ischemia and schizophrenia(Curtis et 
al., 2003b, Eriksson et al., 1998). 
 The dentate gyrus of the hippocampus is one of the few mammalian brain 
structures that continue to generate new neurons through adulthood. It has been 
demonstrated that adult-generated cells especially in the dentate gyrus of rats 
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develop the morphological characteristics of granule cells, receive synaptic 
input, then extend axons into the mossy fiber pathway and express a number of 
markers of mature neurons. These sequential steps of adult neurogenesis ranging 
from neural precursor proliferation, migration, differentiation to synaptic 
integration of newborn neurons are tightly regulated by a variety of extrinsic 
and intrinsic factors, most of which still remain uncharacterized (Zhao et al., 
2008, Kempermann et al., 2004).The extended period of granule cells genesis 
and the ability for continual restructuring of neurogenic areas according to the 
current environment and involvement of signalling cues, represent a dynamic 
process that could be regulated by natural factors including physical activity, 
hippocampal-dependent tasks, NMDA receptor activity, hormones and growth 
factors. The late-generated neurons in this brain region might render the 
dentate gyrus particularly sensitive to environmental perturbations that may 
adversely alter hippocampal structure and function. In addition, it has been 
brought forward into consideration that treatments which typically enhance or 
normalize the cell generation process could ameliorate the behavioural 
alterations in animal models or humans. This data substantiates a ground cause 
that adult hippocampal neurogenesis may be part of intrinsic requirement of 
therapeutic targets for behavioural of distinct neurological diseases (Eriksson et 
al., 1998, McDonald and Wojtowicz, 2005, Kempermann et al., 2004).  
In most studies to examine morphological details of newborn neurons have been 
made possible by the application of either retrovirus-mediated gene transfer or 
the use of thymidine analogue, 5‟-bromodeoxyurindine (BrdU) which 
incorporates into the DNA of dividing cells during the S-phase of the cell cycle 
(Zhao et al., 2006, Rao and Shetty, 2004).The identification of newly born 
neurons has also been accomplished by  immunostaining with DCX. In animal 
studies of adult rodents, DCX has been identified as a promising candidate for 
the identification of newborn immature neurons in which its expression 
specifically persists in the hippocampus with clear labelling detected in both cell 
bodies and the dendritic processes that extend into the granule cell and 
molecular layers of the dentate gyrus. Previous studies have showed that the 
expression of DCX appears to be persist for a prolonged period and overlapped 
with both immature as well as mature neuronal markers(NeuN), indicating that 
DCX expression in postmitotic granule cells is quite extensive  during the early 
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growth period of the neurons including dendritic and axon growth. Counting of 
neurons that are positive for DCX in hippocampal sections particularly in the 
dentate gyrus gives a good estimate of the newly generated neurons that exhibit 
the phenotype of differentiated granule cells. Thus, transient expression of DCX 
during specific times of cell genesis justifies the ability of DCX as a reliable 
marker of newly generated neurons in the adult hippocampus (Rao and Shetty, 
2004, Rao et al., 2005, Brown et al., 2003).  
 In our study, DCX positive staining exhibits the phenotype of neurons with 
staining around the soma and also in dendrites. DCX immunostaining revealed 
newly formed neurons in the DG and the overall production of new neurons were 
maintained at the same levels as controls. Characterization of DCX-positive cells 
having the phenotype of differentiated granule cells showed that dendritic 
process in the control group showed a comparatively complex branching of 
apical dendrite in the molecular layer which presumably indicate more mature 
new neurons while neurons in Ro61-8048-treated specimens exhibited either no 
or with short processes which did not reach deep into the molecular layer.  
Analysis of the dendrites revealed that the new granule cells in the Ro61-8048-
treated sections exhibit fewer number of cells with a complex dendritic spread. 
The shorter apical dendrites with narrower dendritic spread in newly born 
granule cells of the adult, most likely reflect changes in differentiation of the 
cells having a relatively immature morphology.   Although the precise functions 
that depend on the production of new neurons in the DG throughout life are not 
defined, a range of studies have implied that the cells might be involved in 
aspects of normal hippocampal function, such as learning and memory. Along 
this line, studies reported an age-related decrease in adult neurogenesis and has 
further been proposed as a factor in the age-related decline of cognitive ability  
(Ben Abdallah et al., 2010, McDonald and Wojtowicz, 2005, Farioli-Vecchioli et 
al., 2008).  
Stressful experiences during development may also potentially be involved in 
impaired performance of hippocampal-dependent  learning  in adulthood by 
suppressing the production of granule neurons. Elevation of glucocorticoid 
corticosterone  and stimulation of glutamate release following stress diminishes 
the number of proliferating cells in the DG. This evidences suggested that stress 
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exhibits a suppressive effect of glucocorticoid and NMDA receptor activation 
which decreases the production of granule neurons in the developing brain and 
might possibly have a negative impact on learning and memory in adulthood 
(Gould and Tanapat, 1999). In contrast, several other types of brain injuries such 
as traumatic brain injury, ischemia, epileptic seizure and stroke enhance the 
production of new neurons in the adult DG(Wennstrom et al., 2003, Yu et al., 
2008). Similarly, studies have suggested that the therapeutic mechanisms of 
antipsychotics are related to their stimulatory effect on neurogenesis.The 
effects on proliferation in the neurogenic regions of the adult rat brain have 
been observed by incorporating the proliferation marker BrdU, while 
neurogenesis has been described following an increase in markers of neuronal 
differentiation and survival such DCX and NeuN (Toro and Deakin, 2007). 
The secreted factor SHH is a signalling protein that plays multiple roles in the 
regulation of early patterning of neural tube and subsequently has been found to 
stimulate the production of progenitor cells by actively being involved in the 
regulation of neuronal precursor proliferation, migration, differentiation and cell 
survival. This indicates that SHH is a powerful regulator of stem cell 
maintenance in the developing embryonic  brain (Traiffort et al., 2010).  
Involvement of this morphogen in the control of stem cell properties in the adult 
brain have been studied in vivo and in vitro. SHH has been shown to regulate the 
proliferation of adult hippocampal neural stem cells and represents its function 
in the adult nervous system. This proliferative effect of SHH through activity-
dependent synthesis or secretion within the hippocampal  neurogenic area may 
indicate a mechanism for regulating neurogenesis and could be implied as one of 
the therapeutic potential for the regeneration of neural tissue in 
neurodegenerative disorders (Lai et al., 2003, Palma et al., 2005). Several 
pathological conditions for instance ischemia, hypoxia and seizures have been 
shown to induce a rapid regulation of key genes of the SHH signalling cascade 
and that SHH signalling is required for adult neurogenesis. This implies that 
activation of SHH and its receptor components  through activity-dependent 
neural plasticity may be involved in the regulation of adult brain neurogenesis 
(Banarjee and Rajendran, 2005, Sims et al., 2009).  
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Another major finding of this study was the localization of SHH in the 
hippocampal formation.  In the study described here, we found that prenatal 
modulation of kynurenine pathway by inhibiting KMO enzyme upregulated the 
expression of SHH. Most notable is our finding that the newly generated neurons 
produced by in utero exposure to Ro61-8048 are able to express SHH, as 
demonstrated by a significant increase in the number of cells expressing SHH in 
the hippocampus. This stimulatory effect has been observed in the dentate gyrus 
and CA1 region. Although it is unclear by what mechanism NMDA antagonistic 
properties of KYNA up regulates SHH, the increase may likely involve other 
intermediate regulatory steps that regulate the expression of SHH.  It is possible 
to suggest that SHH produced in the hippocampal subregions particularly the CA3 
and dentate gyrus, might play a role in regulating axonal guidance from the 
newborn granular neurons of the dentate gyrus as the CA3 region receives the 
mossy fiber output from the granular neurons of the dentate gyrus(Charytoniuk 
et al., 2002). 
 Our results show that despite high levels of SHH expression seen in the CA3 
region, it did not reach statistical significance. In addition to that, we also 
observed a diffuse staining of granule cells throughout the hilar region of the 
hippocampus. As the function of secreted protein SHH has generally been 
attributed in relation to cell proliferation and migration, the expression of SHH 
in fully differentiated neurons in this area could be associated with errors or 
modification in cell migration process. These data demonstrate that an in utero 
challenge with Ro61-8048 has a significant, stimulatory effect on the generation 
and development of new neurons in the selected areas of hippocampal 
formation. The increased activation of the SHH pathway in this region could 
potentially increase the growth and survival of newly generated granule cells 
and their developing axons. These findings raise the possibility that the early 
modulation of NMDA receptor function through KYNA on the expression of SHH 
and its unidentified receptor components could contribute to the influence on 
adult neurogenesis. It also suggest that the SHH pathway may continue to have 
an important role in adulthood in regulating structural plasticity. Further studies 
are thus required to address whether the effects of KP inhibition also involve 
other SHH receptor components which could further regulate the response of 
SHH signalling mechanisms.  Unlike our protein expression study (chapter 4) 
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which showed significant decreases of SHH protein in the hippocampus after 
exposure with Ro61-8048 while no changes were seen in mRNA levels may 
suggest a possible explanation for this discrepancy. We assumed that the 
reduced protein level seen in whole hippocampal lysates of adult animals is 
possibly due to decreased translation or altered stability or degradation of the 
protein at the time of examination. 
Of several molecular markers that could be linked to neural development, NeuN 
has gained widespread acceptance as a reliable immunocytochemical marker for 
neurons in neurodevelopmental research.  It is also has been incorporated as a 
useful tool in diagnostic neuropathology where its specific expression in 
postmitotic neurons has made it possible to distinguish and localize neuronally 
differentiated cells. Immunostaining analysis showed that NeuN was primarily 
localized to the nuclei of postmitotic neurons throughout the CNS and the 
immunoreactivity can be detected in multiple vertebrate species suggests a 
considerable conservation of this antigen (Mullen et al., 1992). The present 
findings are consistent with previous studies that indicate preferential nuclear 
localization of the protein, but also show NeuN immunoreactivity in the 
cytoplasm (Lind et al., 2005). The hippocampal granule cells and pyramidal cells 
of the CA1 and CA3 regions are finely stained by this antibody and the dendrites 
emanating from these cells are clearly devoid of staining.   
5.5.2 Protein localisation in the cerebellum 
Numerous studies have confirmed that the process of generating new neurons in 
the adult brain, after the foetal and early postnatal development has ceased is a 
robust and continual step that occurs within specific neurogenic areas of the 
adult brain. Although it remains controversial, recent findings have proposed 
that adult neurogenesis could also occur in brain areas such as the cortex and 
the substantia nigra (Gould et al., 1999, Zhao et al., 2003, Magavi et al., 2000). 
It is conceivable that addition of new neuron to these areas where neurogenesis 
is not normally detected in adulthood play a special role in functions associated 
with cognitive processes. For instance, in one study on adult maraque by using a 
combined technique of BrdU labelling and fluorescent retrograde tracing, the 
research suggested that the SVZ is primarily the source for an additional 
population of new neurons that migrate through fiber tracts to neocortical 
  199 
 
regions (Gould et al., 1999). Moreover, cells with proliferative properties also 
appear to reside in some other adult CNS regions where neurogenesis occurs 
rarely under non-pathological conditions. The neurogenic potential of these cells 
could only be demonstrated after injury, such as stroke and ischemia 
(Lichtenwalner and Parent, 2006). This assumption is based on a finding that 
injuries to the brain accompanied by responses that also include mitogenic 
recruitment of progenitor cells besides other local activation such as astrocytes 
and angiogenic response. Although a low level of neurogenesis in other brain 
regions is detected, appropriate combination of multiple stimulatory exogenous 
and endogenous factors may be necessary for inducing  the regeneration 
potential of neurons at lesions in areas with slow turn-over rates (Yamamoto et 
al., 2001).  
Certainly, elucidation of the molecular nature and mechanisms of the actions of 
these signals will be essential for further understanding the regeneration 
capacity of the adult CNS. In this study, we examined the expression of selected 
developmental markers in relation to cell genesis in the adult cerebellum. We 
demonstrated regional specificity for DCX, SHH and NeuN immunoreactivity in 
the adult brain. Here, no detectable expression of DCX was seen in the 
cerebellar cortex. The lack of expression for this marker could be explained as 
part of adaptation or resistance to change during cerebellar development. 
Another possibility is that, since the DCX expression reflects ongoing 
neurogenesis and migration of immature cells in the adult, the failure for 
staining and no effect in the overall number of mature neurons at this point of 
developmental age might suggest that adult born cells have long past both 
neurogenesis and the neuronal migration stage. Despite no quantification of SHH 
expression in the adult cerebellum, the presence of SHH staining within small 
granule neurons and extracellular area demonstrate that SHH is required for 
granule cell development. In support of this, a number of lines of evidence have 
indicated the role of mitogenic factor SHH in regulating cerebellar growth and 
development. This is based on the findings that SHH control granule neuron 
precursors proliferate during embryogenesis and postnatally, and highlight a 
mechanism responsible for modulating rapid proliferation of GCP in the 
germinative layer, external granular layer (EGL). Inhibition of SHH antibodies 
results in reduced GCP proliferation and caused reduction in the formation and 
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growth of the folia(Wechsler-Reya and Scott, 1999).  SHH, secreted by purkinje 
cells and binds to Ptc, a receptor on GCPs, thereby unleashing the Smo 
transmembrane protein to cause the activation of downstream intracellular 
events. It has been demonstrated that GCP proliferation is dependent on 
interactions with purkinje cells, as demonstrated by the observed decrease in 
granule cell number when purkinje cells are lost because of genetic mutations 
(Charytoniuk et al., 2002, Corrales et al., 2006). In this regard, identification of 
other components of this signalling pathway during postnatal cerebellar 
development may provide some better understanding on the functional 
mechanism and interaction between the Purkinje cell and granule neurons 
development.  
As NeuN has been used widely to identify postmitotic neurons and is found to be 
expressed by neurons throughout the nervous system, we sought to examine the 
developmental progression of the rat cerebellum by including NeuN. Based on 
initial observations which in agreement with previous studies that NeuN is not 
expressed in cerebellar purkinje neurons, it might be useful to include NeuN as a 
marker to contrast developmental expression of cerebellar neurons for example 
excitatory granule cells to that of purkinje neurons (Mullen et al., 1992). We 
observed that expression of this antigen was restricted to granule neurons of the 
adult cerebellum. The heterogeneity of NeuN immunoreactivity among 
cerebellar granule cells, as also evident in our specimens might suggest a 
subpopulation of distinct postmitotic cells which could be related to granule 
cells activity, synaptic input or NMDA receptor subunits(Vallano et al., 1996). We 
have shown earlier that the expression of NMDA receptor subunits in this region 
were not affected by the prenatal inhibition of the KP, thus might explain the 
lack of changes on the number of these neurons seen within the cerebellar 
cortex.   
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5.6 Conclusion 
Our study supports the evidence that cell genesis occurs and retains the 
potential for self renewal throughout life, especially in the adult as part of the 
brain‟s adaptive cellular plasticity to changes. We report here that gestational 
exposure to a compound that is able to modulate the balance of kynurenine 
metabolites, has a long lasting stimulatory effect on the generation and 
development of new neurons in the hippocampal formation, particularly in the 
dentate gyrus. This indicates that these effects of in utero exposure to a 
pharmacological substance induced alterations in protein levels which were 
accompanied by changes in cell numbers and survival that were anatomically 
localized and involved specific subpopulations of neurons. Our results indicate 
that maternal exposure to Ro61-8048 maintained the numbers of proliferative 
progenitors and immature granule cell populations in the hippocampal dentate 
gyrus. As the DCX immunopositive neurons with vertically orientated dendrites 
are relatively more mature among the overall DCX-expressing newly born 
neurons, a smaller fraction of such neurons in the Ro61-8048-treated specimens 
suggests that the early production and dendritic growth of newly born neurons 
happened at a much slower rate and also suggest that developmental exposure 
to Ro61-8048 suppresses the maturation of late stage granule cell lineages. It 
can be assumed at this point of study that the increased activation of growth 
and survival pathways as indicated by SHH, could lead to multiple changes in 
granule cell morphology that might include dendritic as well as axonal growth.  
What is striking is that the regulation of the cell genesis was affected months 
after the animals were initially exposed to Ro61-8048 in utero, suggesting that 
the neural stem cell or progenitor cell populations that give rise to new 
hippocampal granule cells are impaired early on at the time during which the 
injections take place. It remains unclear whether this alteration represents a 
slowing of the cell cycle or maturation process. However, it does appear that 
these effects are at least in part mediated by the KP metabolites imbalance 
produced by administration of Ro61-8048. Future studies will be needed to 
determine the contributions of other SHH signaling molecules and the 
mechanism involved in the increase in metabolism and growth of cells. Such 
studies could prove to be particularly useful in the context of neurogenesis in 
determining the relationship between cellular growth pathway and modulation 
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of NMDA receptor. The possibility that the present changes in the postnatal brain 
could also be interpreted as the brain‟s attempt to compensate for the 
receptor‟s decreased activity must be considered. However, the present findings 
of an increased numbers of postmitotic cells and SHH-labeled granule cells 
suggest that, under certain conditions, increased generation of granule cells can 
occur in the more commonly recognized dentate gyrus of the hippocampus and 
also in other hippocampal subfields of adult animals.  Although our results 
demonstrate that cells in the adult brain undergo cell division and that some of 
the newly generated cells can survive and differentiate into cells with 
morphological and phenotypic characteristics of neurons as indicated by NeuN 
expression, we have not proven that these newly generated cells are functional. 
However, this does provide a basis to investigate the influence of environmental 
stimulation on the fate as well as rate of neurogenesis.  
Our interest was to further examine any alteration in the expression of 
neurogenesis markers in the cerebellum as it has a unique developmental 
profile. The cerebellum plays a pivotal role in motor function including speech, 
muscle tone, posture and coordination of movement. However, there is 
currently growing awareness that neurodevelopmental disorders are also 
associated with cerebellar deficits and learning impairments. Cognitive 
impairments are also occasionally related to cerebellar pathologies and it has 
been suggested that functional connections between the cerebellum and other 
regions of the CNS are linked with its function in emotional processing and 
cognition(Hoppenbrouwers et al., 2008).The results of our immunocytochemical 
analysis showed that Ro61-8048 administration had no effect on the pattern and 
distribution of granule neurons in specimens examined at P60 when compared to 
control. However, these observations were in contrast by our western blot 
results which indicate a significant downregulation of SHH and also DCX at the 
same developmental age in the whole cerebellar tissues. qPCR analysis also 
found that  SHH mRNA levels remained unchanged in these Ro61-8048-prenatally 
exposed groups by comparison to control counterparts.  
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6 Prenatal modulation of the kynurenine pathway 
alters the morphology of neurons in the 
hippocampus of the adult rat brain.  
 
6.1 Introduction 
Relatively modest elevations of extracellular KYNA, caused by the direct 
application of kynurenine or KYNA itself or by systemic kynurenine-3-
monooxygenase (KMO) inhibition have remarkable biological consequences. 
Moreover, KYNA levels are significantly elevated in the brain and the 
cerebrospinal fluid of individuals with schizophrenia and Alzheimer‟s disease 
patients. The most influential evidence of the involvement of NMDA receptors 
stemmed from studies in which blockade of the receptor prevented neuronal 
degeneration, raising the possibility that enhanced inhibition of NMDA receptors 
and also αNCR by KYNA has a causative role in the defining cognitive deficits 
seen in these diseases (Erhardt et al., 2009, Erhardt et al., 2007).  
It is important to note that dendrites are not completely static structures and its 
diversity is a striking characteristic of the brain.  The size and shape of dendrite 
trees determine where it can receive inputs and how it can integrate into 
neuronal networks. Evidences have highlighted continual dynamic changes of the 
dendrites as part of the establishment of neuronal circuitry during development. 
Neuronal activity including membrane depolarization, electrophysiological 
stimulation and NMDA receptor-mediated activity are among potent stimulator 
of dendritic remodelling and stabilization. As dendrite branches are becoming 
more stable in mature neurons and through with combination of neurotrophic 
signalling factor and associated protein, this stability is essential for the proper 
connectivity of neuronal networks. In addition, dendrites can also undergo rapid 
structural changes in response to a variety of stimuli and this plasticity is 
essential to the cellular response of learning and memory. By contrast, any 
alteration in dendrite growth and structure can result in impaired brain function, 
and contributes to the pathology of various illnesses such as schizophrenia and 
Alzheimer‟s disease (Koleske, 2013, Cline and Haas, 2003).  
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The Golgi impregnation method has been utilised in many morphological studies 
that have attempted to describe cellular changes. Structural changes provoked 
by external stimuli later in life are very much related to plasticity. Changes in 
dendritic morphology represent one persisting form of plasticity that is an 
important neural correlate of NMDA-mediated neural activity. Plasticity of 
dendritic morphology has been demonstrated in hippocampal formation as 
implicated in NMDA receptor activity. One key idea is that the hippocampus is 
one of the most plastic regions in the brain and plays an essential role in 
inducing plasticity enabling certain forms of learning and memory consolidation 
(Kempermann et al., 2000, Bannerman et al., 2014). In this regard, the long 
term effects of KMO inhibition were assessed as structural modifications of 
dentate granule cells which include somata size and dendritic segments and 
length, since these anatomic parameters can be correlated with NMDA receptor 
mediated synaptic responses in the hippocampus.  
6.2 Research aims 
The aim of the present study was to assess the consequences of prenatal 
inhibition of the kynurenine pathway on the morphology of dentate granule cells 
in the hippocampus  by performing a quantitative study of dendritic 
arborizations using the Golgi impregnation method. For the quantification of 
neuron morphology, the total length and segments of dendrites in individual 
granule cells were measured, and the complexity of the dendritic branches were 
determined by Sholl analysis.  
6.3 Experimental approaches 
6.3.1 Prenatal treatment 
Pregnant rats were injected with the compound Ro61-8048 (100mg/kg) on 
embryonic days 14, 16 and 18, and gestation was allowed to proceed normally. 
Both male and female pups were included in this study and they remained with 
their mothers until weaning at postnatal day 21 (P21) and were assessed at 
postnatal day 60. Control animals were born from saline-treated mothers and 
were evaluated at the same age. At postnatal day 60, the pups from the 
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respective groups of litters (4 pups per litter, 3 litters per group) were deeply 
anesthetized with sodium pentobarbital before cervical dislocation.  
6.3.2 Golgi-impregnation method 
Golgi staining was performed using the FD Rapid Golgi Stain Kit according to the 
manufacturer‟s instructions. Blocks from experimental and control brains were 
immersed in a freshly prepared solution of equal parts of Solutions A and B, and 
stored at room temperatures for 2 weeks. This solution was replaced with fresh 
solution after the first 24 h of immersion. Then, the brain tissues were immersed 
in Solution C and stored at 4oC for at least 48 h and shielded from light. Solution 
C was also refreshed after the initial 24 h of immersion. Brain blocks were 
blotted dry with tissue paper and sectioned at 200 µm and mounted with 
Solution C on gelation-coated microscope slides. The slides were allowed to dry 
naturally at room temperature while being shielded from light. They were then 
stained with using a solution containing one part of Solution D, one part of 
Solution E and two part of distilled water for 10 min after which the slides were 
rinsed with dH2O twice for four min each. A dehydration process with graded 
concentrations of ethanol were done, and cleared with Histoclear solution. 
Finally, the sections were cover slipped with Histomount.  
6.3.3 Morphometric analysis 
From the time of killing the rats, all histological, drawing and Sholl analysis 
scoring were carried out on rats coded as not to reveal the treatment condition 
in order to preclude bias. Neurons were sampled from the dentate gyrus of the 
hippocampus. The exact localization was registered for the granular cell layer 
with a 40x objective lens. By considering all the morphological criteria for the 
selection of neurons as described earlier, drawings of the Golgi-impregnated 
granule cells from both treatment groups were made manually by hand with the 
aid of a camera at a final magnification of 40x to illustrate the pattern of 
dendritic segments.  Each neuron was therefore examined for soma size, for 
number of primary dendrites, for number of dendritic arborizations (branch 
points) and for number of dendritic intersections crossing each concentric ring. 
The number of impregnated granule cells that fulfilled the morphological 
criteria varied in a given coronal section from any brain, ranging from one to 
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four cells per section.  As a whole, 137 neurons (control: 69 neurons/11 animals, 
Ro61-8048: 68 neurons/9 animals) were drawn individually and used for Sholl 
analysis. The Sholl analysis evaluates the amount and distribution of the 
dendritic material at increasing distances from the cell body. This is 
accomplished by placing a template comprising a series of concentric circles of 
diameters at equidistant farther (20µm) intervals from the soma and quantifying 
the numbers of intersections of the branches with each of the circles (Sholl, 
1953). Morphometric parameters included were the total number of branches 
and total dendrite length and were used to assess the overall magnitude of 
morphological changes following prenatal modulation of the kynurenine 
pathway. An estimate of mean total dendritic length (in µm) was made by 
multiplying the mean total number of intersections by 20. While for branch order 
analysis (to indicate primary and secondary dendrites), branches emerging from 
cell bodies were considered primary segments. After the first bifurcation, 
branches were considered second order of segments.  Sholl analyses were 
conducted on the mean values per animal for the above morphometric 
parameters. Data on mean group differences in soma size, total dendritic length 
and number of branching points were analysed by Student‟s t test. The analysis 
of dendritic complexity was subjected to a two-way analysis of variance (ANOVA) 
followed by Tukey‟s post hoc analysis to examine the contributions of drug 
treatment, sample number and distance from the cell soma. The results were 
expressed as mean ± S.E.M. and significance was set at p<0.05. 
6.4 Results 
6.4.1 Morphology of granule cells in the dentate gyrus 
Our aim was to characterize the possible morphological alterations of granule 
cells in hippocampal slices taken from control animals and from experimental 
rats subjected to prenatal administration of the KMO inhibitor, Ro61-8048. To 
this end, rapid Golgi method was adapted to study the morphology of granule 
cells in these rats and their age-matched controls. We chose to study the 
morphology of granule cells, as this neuron represents the principal neurons of 
the dentate gyrus. In the adult rodent brain, these neurons are arranged in a 
densely packed layer and show a highly uniform morphology of their V-shaped 
apical dendritic trees (Rahimi and Claiborne, 2007). In the Golgi preparations, 
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granule cells in the DG were easily identified according to their characteristic 
soma location and dendritic morphology. Granule cell bodies were round or oval 
shaped with a greater diameter oriented perpendicular to the granule cell layer. 
Typically, a granule cell gave rise to an apical dendrite that extended into and 
arborized within the molecular layer. Whereas the axons of granule cells 
originated from the hilar pole of the soma and projected into the hilus. The 
dendritic trees of impregnated neurons were visualized in photomicrographs of 
the upper and lower blade of the dentate gyrus as seen in Figure 6-1 (A&C). In 
general, the appearance of granule cell bodies and the arborisation pattern of 
their apical dendrites within the molecular layer of the DG in treated animals 
were similar to those of the control group which seemed to be evenly distributed 
and formed a relatively homogenous cell population. Granule cells with well-
branched dendrites could be seen extending into the molecular layers, especially 
in the upper blade of the DG (Figure 6-1 (B&D)). Our observation in the 
specimens showed that granule cells from control and treated adult rats have no 
thick processes arising from the hilar side of their somata that could be 
interpreted as basal dendrites. An example of camera drawings used for Sholl 
analysis of dendritic tree complexity is shown in Figure 6-2. Even though overall 
observations of dendritic tree shapes for granule cells are very much alike and 
similar for both control and treated rats, there is a relatively significant 
decrease in the analysis of the general growth parameters of the dentate 
granule cells (Figure 6-3).  
Several aspects of the dendritic tree including soma size were analysed. The 
area of cell bodies (soma) and branching points of the neurons were not affected 
by prenatal administration of Ro61-8048. We noted that the cell body of an adult 
granule neuron in the rat is approximately in a range between 14-17 µm wide 
and 15-20 µm long. Although in general, the appearance of granule cell bodies 
and the arborisation pattern of their dendritic trees in the control group were 
somewhat similar to those of Ro61-8048, the Sholl analysis on the total dendritic 
number which represents an average dendritic segments in each neuron was 
significantly lower in the Ro61-8048-exposed specimens than in controls (Ro61: 
6.36 ± 0.22 vs Saline: 7.39 ± 0.05, p= 0.01).  The number of dendrite segments of 
each order characterizes the degree of branching arborization. When the data 
were subdivided into distinct parts of the dendritic segment, it was apparent 
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that there were reductions in dendrite number in tissue from Ro61-8048-exposed 
rats only in the secondary dendrites. In this regard, separate measurement on 
the relative contributions of the primary and secondary dendrites in this region 
demonstrates significant differences between the groups, with fewer numbers of  
secondary dendrites in the apical dendritic regions of hippocampal sections from 
rats exposed with Ro61-8048 (Ro61: 3.77 ± 0.06 vs Saline: 4.38 ± 0.17, p=0.029). 
Whereas, there were no differences in the number of primary dendrites in the 
same region (p=0.1019) (Figure 6-3 (C)). Our data indicate between 1-4 primary 
apical dendrites exit from the apical pole of the cell body and branch out 
relatively close to the soma. We noted that most branching occurs within 60-100 
µm of the soma. Based on Golgi-impregnated cells, when the data were 
compared with controls, the estimated overall length of dendrites for the Ro61-
8048- exposed rats was significantly decreased by 14% (Ro61: 904.65 ± 28.0 µm 
vs Saline: 1051.93 ± 33.72, p=0.03). However, the length of the primary and 
secondary dendrites did not differ between treated and control animals (p= 
0.076 for primary and p=0.075 for secondary) (Figure 6-3 (D)). Further analysis 
on overall dendritic branching complexity between the control and Ro61-8048-
exposed animals were made using a two-way ANOVA, taking into account the 
elements of treatment, number of samples and number of intersection levels. 
The analysis revealed no interaction between treatment and dendritic distance 
from the cell body p=0.49 (Figure 6-4) but a highly significant difference 
between the treatments (control vs Ro61-8048) with p<0.0001. However, post-
hoc analysis between individual data points showed no significant differences, 
although the possibility that there are small differences of this analysis cannot 
be excluded. Generally, as the complexity of the dendrites can reflect a 
propensity for neuron connectivity, this might suggest that kynurenine 
modulation as well as NMDA receptor activity appears to be associated with a 
loss of dendrite arbour complexity. 
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Figure 6-1 Morphology of dentate granule cells in the hippocampus at P60 
(A,C) Low magnification of the hippocampus of control and Ro61-8048-treated rats showing 
Golgi-impregnated neurons (4X, scale bar=200µm).  (B,D) Photographs of representative 
dendritic trees of Golgi-impregnated granule cells in the dentate gyrus of control and Ro61-
8048-treated rats in 200µm thick sections. Generally, light microscopic examination of 
Golgi-impregnated tissue from control and experimentally treated brains revealed reliable 
and consistent staining of granule cells. We noted granule cells with well-branched and 
bifurcated dendrites extending into the inner and outer molecular layers of the dentate 
gyrus and almost reaching the hippocampal commissure (10X, scale bar=100µm). 
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Figure 6-2 Reconstructions of Golgi-impregnated granule cells from control and Ro61-
8048-treated rats 
Representative drawings of dendritic trees of a granule neuron traced at P60. Granule cells 
were drawn from the upper and lower limbs of the fascia dentate of the hippocampus with 
approximately equal selection from each of these areas. Overall observation on the 
dendrites shows that the dendrites form a cone-like shape that spread across the molecular 
layer. The appearance of granule cell bodies and the arborisation pattern of their dendritic 
trees in the control group (A&B) were somewhat similar to those of Ro61-8048 (C&D). Scale 
bar =20µm. 
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Figure 6-3  Morphological measurements of dentate granule neurons following prenatal 
modulation of the kynurenine pathway  
Quantitative assessment of neuronal morphology by Sholl analysis showed (A) soma 
diameter (B) mean branching point per neuron, (C) dendritic number, (D) total length of 
apical dendrites and (E) number of intersections of dendrites with concentric spheres 
surrounding the soma. A mean value of each morphometric paramater based on five to 
eight neurons per animal (saline: n=69, Ro61-8048: n=68). t-test comparison with age-
matched controls, * p<0.05.  
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Figure 6-4 Quantitative assessment of dendritic branching complexity 
Quantitative assessment by Sholl analysis revealed prenatal kynurenine modulation 
reduced dendritic complexity in the number of intersections of dendrites with concentric 
spheres surrounding the soma. Data are expressed as mean ± S.E.M. (n= 69 cells/11 animals 
for control, 68 cells/9 animals for Ro61-8048). Sholl analysis revealed reduced dendritic 
branching complexity in Ro61-8048 compared with age-matched littermate controls at Sholl 
radii 20-280 µm from soma.  
 
 
 
 
 
 
     *** 
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6.5 Discussion 
The granule cells are the principal neurons of the dentate gyrus. In the adult 
rodent brain, these neurons are arranged in a densely packed layer and show a 
highly uniform morphology of their V-shaped apical dendritic trees. The 
dendrites which represent the main receptive structures of neurons are 
branched and all dendritic segments are covered with spines. The primary 
contribution of dendrites to a neuron‟s mode of connectivity is through their 
characteristic branching and extension into specific domains. This branch 
ordering schemes wherein dendrites emerging from the cell soma are primary 
and their respective branches are considered secondary and so on, have been 
used to characterize the density of dendritic arborization (Rahimi and Claiborne, 
2007) .  
The use of Golgi method which requires complete impregnation of neurons and 
separation between stained neurons to permit the visualisation of dendrites had 
enabled us to study the general morphological changes of granule neurons in the 
adult rat. The results of the present study have shown that prenatal modulation 
of the kynurenine pathway which alters the balance of its neuroactive 
metabolites regulates the dendritic remodelling and stabilization in the 
developing neuron. The results indicate that the dendritic morphology of the 
selected hippocampal area present important changes in rats prenatally exposed 
to Ro61-8048. Overall observations on the morphological characteristics of the 
granule cells in term of soma size and branch points did not differ between 
saline and Ro61-8048-treated animals. In our study, a simpler scheme of 
counting the number of branch points in the entire dendritic arbour provides a 
sense of how branched a neuron is, but this does not indicate the degree to 
which they fill the space and its functional connectivity. The main changes found 
were reductions in the number of dendritic segments and in the total dendritic 
length of neurons from dentate granule cells. The complexity of the dendritic 
system in the treatment group also appeared to be less robust than that seen in 
the control rats. In this study, we also aimed to determine whether basal 
dendrites appear on granule cells of adult rats as a consequence of KP 
modulation. Such an analysis would provide information about the formation of 
dendrites. The lack of basal dendrites in the dentate granule cells of control 
animals in this study confirmed previous finding that showed the adult rat 
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hippocampal granule cells do not display basal dendrites. In contrast to humans 
and monkeys, hippocampal formation basal dendrites which are studded with 
spines appear to be a functional and integral part of normal granule cells (Seress 
and Mrzljak, 1987). 
 In the treated specimens, no appearance of basal dendriteswere observed. 
However, formation of basal dendrites have been observed in granule cells in 
response to epileptogenic stimuli and this may represent one of the adaptive 
cellular changes of neuroplasticity of granule cells (Spigelman et al., 1998). 
Although we did not measure the spine density for dentate granule neurons, due 
to limited numbers of good impregnated neurons which could produce clear 
identifiable spines or spine heads, the data obtained with this technique could 
indicate that Ro61-8048 produced a reduced number, length and complexity of 
the dendritic system. Based on the increased KYNA concentration in the 
embryonic brain in response to Ro61-8048 administration during late gestation 
(Forrest et al., 2013b), we suggested that NMDA receptor blockade could be a 
possible mechanism underlying these effects. 
 Previous reports have demonstrated that early dendritic arbour growth relies on 
NMDA receptor activation and that this receptor also involved in the refinement 
of synaptic connections during postnatal development, suggesting an intimate 
association between glutamatergic transmission and dendritic arbour 
development. In this regard, NMDA receptor activity might affect dendritic 
arbour development during an early developmental window, in which coincide 
with the occurring of the granule cell genesis in late embryogenesis when they 
started to contribute to the synaptic current (Cline, 2001). The role of this 
receptor might change as the granule neurons in the dentate gyrus undergo 
periods of development and maturation. In the rat, the neurons go through a 
period of maturation during which the dendritic tree is refined and the dendritic 
remodelling  occurs with elongation of some branches and the loss of others 
between days 14 to 60 (Rahimi and Claiborne, 2007). Data from our lab 
demonstrated that granule cells have less dendritic segments which are largely 
attributable to a significant decrease in the number of secondary dendrites and 
in turn have slightly shorter dendritic trees. This indicates that dendritic branch 
loss in response to Ro61-8048 may be affected by incoming neuronal activity. 
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The changes in dendritic structure seen here are likely to have effects on 
neuronal function. To correlate with this finding, our recent findings 
demonstrated a reduction in the amplitude of LTP and paired-pulse inhibition 
which could be in part, a consequence of the altered expression of one of the 
NMDA receptor subunits in the offspring following Ro61-8048 exposure where we 
noted earlier a significant reduction in expression of the NR2A subunit in the 
hippocampus (Forrest et al., 2013a).  
Established roles for NMDARs in dendrite development have been mentioned 
earlier and this suggests specific roles for particular subunits especially NR2A 
and NR2B in determining the functional properties of the NMDAR. In this context, 
subunit composition of synaptic NMDAR controls normal development of synapses 
by regulating the rate of synapse formation and overall dendritic morphological 
outcome (Ewald et al., 2008, Vastagh et al., 2012). Contribution of specific 
NMDAR subunits during synaptogenesis are still not clearly defined, but in vitro 
experiments have showed that reduced glutamatergic synaptic transmission 
following upregulation of NR2A might be associated with a reduction in the 
number of synapse. Whereas expression of NR2B provides greater structural 
plasticity by establishing appropriate synaptic contacts (Gambrill and Barria, 
2010). Following exposure to KP modulation during late gestation, NR2A protein 
level decreased significantly in the foetal brain and remained low in the 
hippocampus at P60. A different observation was noted in NR2B expression, with 
significantly increased expression after 5h and P21 (Forrest et al., 2013a, Forrest 
et al., 2013b). Interestingly, out results also suggest that the observed variation 
of the levels of both subunits expression during development following prenatal 
exposure to Ro61-8048 might underlie the neuronal modification changes seen in 
the hippocampus. Total dendritic branch length and segment numbers provide a 
good indication of the growth behaviour of a neuron. Notably, both indicators in 
the treated group were comparably fewer than those in control. These data 
demonstrate that shift or imbalance in the synaptic NR2A and NR2B levels and 
the persistence of these alterations into adulthood suggests that modification of 
glutamatergic neurotransmission leads to structural changes in the general 
growth parameters of the dentate granule neurons in the hippocampus. Since 
the results emphasize the interdependence of receptor subunits, selectivity 
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effects of Ro61-8048 on synaptic NMDAR transmission by utilising respective 
subunits antagonist is important for future consideration of in vitro assessment.  
It seemed that blockade of the NMDA receptor (in this case, by KYNA) could have 
some implications on the dendritic branch dynamics. It is well established that 
the glutamate receptors of the NMDA subtype play a central role in the process 
of LTP and also synaptic plasticity. The effects of NMDA receptor-mediated 
synaptic plasticity on dendritic arbour growth have been well studied. It has 
been shown that NMDA-mediated responses promote dendritic arbour growth and 
also causes a transient increase in both the size and density of dendritic spines, 
whereas blocking the receptor reduces the growth of dendrites (Lin et al., 
2004a, Wedzony et al., 2005). In congruent with our data which support an 
association between synaptic transmission and dendritic development, it has 
been shown that glutamate receptor antagonists (either competitive or non-
competitive antagonists) decrease dendrite growth and led to a corresponding 
reduction of the number of synaptic contacts, as well as to changes in synaptic 
morphology (Wedzony et al., 2005).  
We showed that prenatal kynurenine pathway inhibition led to long term 
changes in neuronal dendritic morphology of the P60 offspring as a reduction in 
the number and length of apical branches of dentate granule cells. Changes in 
the endogenous levels of KYNA during early development induced dendritic 
retraction, indirectly through NMDA receptor blockade.  
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7 General discussion 
7.1 Neurochemical alterations in rats offspring following 
maternal inflammation during pregnancy  
Epidemiological studies have indicated that exposure to wide range of viruses 
during early development  has been implicated in the pathogenesis of 
neuropsychiatric disorders (Adams et al., 1993, Brown et al., 2004, Mednick et 
al., 1988). The precise mechanisms associating the virus and prenatal 
neurodevelopmental consequences are not yet fully defined. Common mediators 
of maternal immune activation are suspected to be involved in producing a 
range of responses which are likely to contribute to the neuropsychiatric 
disturbances.  In this respect, intrauterine elevations of proinflammatory 
cytokines are thought to play a role. The outcomes on the developing brain 
following the maternal immune activation  includes alteration in gene and 
protein expression relating to various neurodevelopmental  processes, 
excitotoxicity or changes in the molecular pathways involved in the generation 
of cells and also in the neurotransmitter functions (Damman and Leviton, 1997, 
Fatemi et al., 2008, Patterson, 2002). Here, we presented the relative 
contributions of prenatal viral infections to the emergence of neurochemical 
imbalances including glutamate-related pharmacological molecules after 
systemic administration of poly(I:C), a synthetic double-stranded RNA used to 
mimic viral exposure and is known to elicit immune responses by inducing  the 
release of proinflammatory cytokines.  
Pregnant rats were exposed to the inflammatory agent, poly(I:C) (10mg/kg) or 
saline during late pregnancy (E14,16 and 18). Our preliminary experiments 
showed that the indicated dose given to pregnant dams during the last seven 
days of gestation imposed no apparent adverse effects on the dam or her 
behaviour towards her litter after birth. We have demonstrated in previous 
report the ability of poly(I:C) to activate maternal immune system.  The 
associated changes in which we observed  an increase in MCP-1 with the absence 
of other proinflammtory cytokines at 5 h post injection may therefore exhibit 
the specificity of maternal host‟s response to an immunological challenge which 
could modulate  and precipitate related aberrations in the expression of 
selected neurodevelopmental proteins (Forrest et al., 2012) .  
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Our results show a number of significant changes in the expression of several 
proteins important to early brain development following inflammatory challenge 
with poly(I:C). Some of the developmental markers showed changes during the 
time of insult takes place and disappeared or diminished as animal grew up. This 
may be an outcome of the compensatory capacity of the CNS to alleviate such 
changes. In light of fundamental role of NMDA receptor during brain 
development which include neuronal migration and plasticity, we found that 
prenatal poly(I:C) exposure affected the subunits composition of the receptor 5 
h post treatment. Transient changes in the levels of NMDA receptor subunit NR2A 
and NR2B in the fetal brain could signify a potential mechanism of altering 
synaptic development and may impinge on the establishment of neuronal circuits 
and connection.  
On the other hand it is also possible that prenatal poly(I:C) treatment 
manifested its effects on the postnatal brain that are independent from its 
effect at the time of exposure. The acute inflammatory response induce by 
prenatal poly(I:C) administration somehow induce further long term changes in 
factors regulating cell proliferation and migration, in order to produce altered 
neurogenesis in offspring later in development at P21. We show that changes in 
markers involved in neurogenesis,  SOX2 and SHH were observed at later stage of 
postnatal development (P21).This could imply that prenatal immune activation 
elicited by poly(I:C) in rodents may have long term effects on neurogenesis in 
young postnatal offspring. The pattern of changes seen in SOX2 and SHH suggests 
such deficits or changes in neurogenesis could conceivably contribute to the 
alterations in hippocampal-mediated function that could have some implications 
in neuronal development. It seems important to note that activation of the 
immune system during gestation can precipitate brain mal-development, in 
which changes in the NMDA receptor subunits composition appear to be a key 
factor and more likely to be associated with long term developmental brain and 
relevant behavioural outcome in the offspring (Forrest et al., 2012, Khalil et al., 
2013). 
 
  219 
 
7.2 Regulation of kynurenine pathway metabolism in the 
brain after prenatal inhibition with Ro61-8048 
Involvement of the KP occurs in a variety of CNS disorders, infection and 
inflammatory conditions. Moreover, the pathway has been found to be an 
important determinant of immune response which is thought to be related 
primarily to the activation of IDO by IFN- and other immune-active molecules 
and subsequent depletion of tryptophan leading to impairment of protein 
synthesis and modification in the cell proliferation and differentiation by a 
number of downstream KP metabolites such as QUIN. This support  an evidence 
on the importance of the KP as a key link between inflammatory reactions and 
immune response (Stone and Darlington, 2013). The presence of neuroactive KP 
metabolites and their role in regulating excitatory amino acid receptors such as 
NMDA, AMPA and αNCR has been implicated in a number of diseases, thus raising 
out a possible intervention of manipulating the pathway by modulating the 
balance of the metabolites(Stone et al., 2012, Stone and Addae, 2002).  Indirect 
approach to influence the metabolic function of NMDA receptor of glutamate 
subtype by stimulating endogenous KYNA formation may provide advantages 
compared to blocking the receptors indiscriminately with exogenous receptor 
antagonists. In this respect, to probe the physiological roles of KP metabolites 
experimentally, it appear sensible to inhibit enzyme kynurenine 3-
monooxygenase (KMO) by administering known compound Ro61-8048 which 
would affect the synthesis of endogenous KYNA in accordance with changing 
physiological condition and indirectly reduce the degradation of the pathway 
along the QUIN branch(Chiarugi and Moroni, 1999, Richter and Hamann, 2003).  
Our previous study has been carried out to examine the effect of a prenatal 
exposure to the KP enzyme inhibitor on the maternal, fetal and postnatal levels 
of major KP metabolites i.e. kynurenine and KYNA, considering that an 
imbalance in the production of these substances could have profound 
implications in cerebral neurotransmission and brain development. We have 
shown that administration with Ro61-8048 at an early stage of embryonic 
development elevated the levels of kynurenine and KYNA in both maternal 
plasma and brain within a few hours of administration (Forrest et al., 2013a, 
Khalil et al., 2013). The presence of kynurenine, a common parent compound of 
all neuroactive kynurenine metabolites, has shown that the pathway is readily 
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available in the CNS in normal physiological level. In the CNS, this substrate is 
then either transaminated to form KYNA or hydroxylated to produce 3-HK and 
other downstream metabolites including QUIN. Although we did not measure the 
level of QUIN , previous investigations have failed to show changes in QUIN 
concentrations following administration of Ro61-8048 in mice(Clark et al., 2005). 
The  level of KYNA kept rising in the embryonic brain while maternal brain‟s  
KYNA levels had returned to basal levels when observed 24 hour later. When we 
observed the levels of KYNA and kynurenine in the offspring at P21, the levels of 
both substrates had returned to normal control level as evidenced by its effect 
on the brain content. Importantly, the dose of Ro61-8048 caused the expected 
increment in the formation of KYNA in the brain during early period of 
development (Forrest et al., 2013a).Taken together with biochemical data 
showing  alteration in the protein expression levels of various developmentally 
target molecules , these results suggest that the increased level of KYNA in the 
brain caused by the administration of  Ro61-8048 in utero can influence the 
extent of excitability and viability of NMDA receptor function that could be  
partly responsible for the observed  molecular and functional changes we have 
reported earlier. 
We have shown in our previous study that raising brain tissue KYNA 
concentrations has lead to pronounced biochemical and neurochemical 
consequences in the rat offspring. It is noteworthy that the prenatal exposure to 
KP regulator, Ro61-8048 in rodents has been shown to induce a range of 
neurochemical alterations in the offspring detectable at various developmental 
ages. Considering that the plasticity of glutamate receptors could be affected by 
changes in the endogenous ligands  of NMDA  receptors and the role of the 
glutamatergic system in synaptic transmission, neuronal plasticity and also in the 
learning and memory processes, we focussed our attention on this paradigm and 
demonstrated that the exposure in utero to Ro61-8048 during late stage of 
gestation in the rodent was able to influence the level of expression of  NMDA 
receptors and in particular those of NR2 subtype family in the brain. There were 
highly significant changes in the levels of both subunits NR2A and NR2B as 
observed 5 h post injection with Ro61-8048.  
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It is important to note that acute changes in NMDA receptor subunits expression 
in the developing brain immediately after injection were largely transient, the 
levels of both subunits were not different with control levels when observed 24 h 
later. The differential pattern of expression in the embryo brain (around late 
gestational period)   for both subunits might reflect a compensatory adaptation 
of specific balance between these subunits. That is, NR2A expression is generally 
low at birth but increases over several weeks, whereas a relatively high NR2B 
expression at birth and declines slightly through adulthood (Janssen et al., 2005, 
Truman et al., 2002). In this aspect, appropriate NR2A:NR2B ratio and 
fundamental shifts in receptor properties based on subunit representation 
clearly have the capacity to influence neuronal function. We observed long term 
changes in the NR2 subunits when the offspring has reached young adulthood 
(P21). Alteration in the expression level of NR2A was maintained into adulthood 
(P60) as observed in the hippocampus and cortex regions. In fact, changes in the 
hippocampus in particular    appeared to be the opposite of those observed 
earlier which might indicate regional specificity of the ratio between both 
subunits. We have previously shown that in the process of LTP, relative ratio of 
NR2A and NR2B may play a part in the molecular machinery of synaptic plasticity 
and contribute to the functional synaptic changes described in the hippocampus 
(Forrest et al., 2013b).  
Given these differing developmental profiles, early life challenge with KP 
inhibition might be expected to have differential effects on subunit expression 
levels. This continuing change with respect to subunit representation in the 
receptor would impose overall dynamic regulation in NMDA receptor (Janssen et 
al., 2005). Furthermore, it has been shown that NMDA-mediated responses 
promote dendritic arbour growth and also cause a transient increase in both the 
size and density of dendritic spines, whereas blocking the receptor reduces the 
growth of dendrites (Wedzony et al., 2005). We showed that prenatal kynurenine 
pathway inhibition led to long term changes in neuronal dendritic morphology of 
the P60 offspring as a reduction in the number and length of apical branches of 
dentate granule cells. Therefore, changes in the endogenous level of KYNA 
during early development could have some implications on overall neuronal 
structure and the dendritic branch dynamics by antagonistic properties at the 
NMDA receptor. 
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The mechanisms responsible for the Ro61-8048‟s effects on neurogenesis remain 
unclear. It seems probable that the regulation of the neurogenesis was strikingly 
evident months after the initial treatment with KP modulator, suggesting the 
process could be affected early on. Increased KYNA following the inhibition of 
KMO has been expected to cause an effect on the NMDA receptor function. We 
have described changes in term of protein expression of several 
neurodevelopmental markers that are involved in range of developmental 
process including neurogenesis, neuronal plasticity and transmission, 
inflammatory related process among many others (Forrest et al., 2013b, Forrest 
et al., 2013a). Hippocampal neurogenesis in this study was notably affected 
which indicates that this cell genesis process might be influenced by elevated 
levels of one of the kynurenine metabolites, KYNA (Forrest et al., 2013a, Forrest 
et al., 2013b). As SHH is conserved and functions prominently in both developing 
nervous system and the germinal zones of the adult brain. Enhancement effect 
of SHH particularly on the proliferation of neural progenitor cells and neuronal 
differentiation within the entire course of differentiation has been shown in 
vitro. In support with this evidence, the presence of SHH receptor complexes 
including Ptc and Smo within adult neurogenic areas emphasises the role for SHH 
in adult neurogenesis (Traiffort et al., 1998).  
Our results suggest that prenatal modulation of kynurenine pathway might lead 
to changes in the expression levels of several molecules that involved in the 
regulation of cell cycle, proliferation as well as neurogenesis process in 
developing and adult brains. An increased expression of the transduction 
molecule SHH was observed 24 h after treatment with enzyme inhibitor during 
late gestation. However, when repeated challenge of the inhibitor was given, 
different pattern of expression was seen with reduced levels of expression was 
demonstrated at developmental age P21 and remained repressed in some 
regional areas of the brain including hippocampus, cerebellum and cortex. 
Further analysis using immunocytochemistry indicates that maternal exposure to 
Ro61-8048 maintained the numbers of proliferative progenitors and immature 
granule cell presented by DCX immunoreactivity in the hippocampal dentate 
gyrus. Whereas the increased number of SHH immunopositive cells in this region 
could potentially affect the growth and survival of newly generated granule cells 
and their developing axons. These findings raise the possibility that the early 
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modulation of NMDA receptor function through KYNA on the expression of SHH 
could contribute to the influence on adult neurogenesis. It also suggest that the 
SHH pathway may continue to have an important role in adulthood in regulating 
structural plasticity. We show that these effects of in utero exposure to 
pharmacological substance induced alteration in protein levels which was 
accompanied by a subtle structural modification that can results in changes in 
the cell numbers and survival that was anatomically localized and involved 
specific subpopulations of neurons. We report here that gestational exposure to 
a compound that is able to modulate the balance of KP metabolites, has a long 
lasting stimulatory effect which occurs in concert with other events on the 
generation and development of new neurons in the hippocampal formation, 
particularly in the dentate gyrus. Overall, this scope of research explains on the 
effect of KP modulation which extends from prenatal exposure to postnatal 
outcomes. It provides a partial explanation for the exceptionally brain 
development on long lasting and delayed effects following gestational exposure.   
7.3 Future directions of study 
The alterations in neurodevelopmental proteins especially seen in NMDA 
receptor subunits and synaptic physiology may be responsible to account for 
behavioural abnormalities. It is quite uncertain based on data generated from 
this study, to elucidate which developmental processes are responsible for 
different profile of behavioural abnormalities which constitute a biological 
mechanism of cognitive performance. Our behavioural findings on simple step 
down-avoidance test  may not be appropriate to reflect a more complex task of 
cognitive changes, thus raising  some limitations on conclusive interpretation 
(Forrest et al., 2013b). Thus, further and elaborate studies on the behavioural 
paradigms in relation to antagonistic profiles of Ro61-8048 are warranted. It has 
been shown that increases in endogenous KYNA concentration resulted in 
prepulse inhibition deficits and interferes with spatial working memory in the 
radial arm maze task. These findings are in line with the assumption that 
enhanced inhibition of NMDA receptor and αNCR by  KYNA may contribute to the 
observed deficits in working memory in persons with schizophrenia  (Pocivavsek 
et al., 2011, Chess et al., 2007). As KYNA is known to act on both glutamatergic 
and cholinergic systems that are critically involved in cognitive function and 
normal brain development , thus alterations in KP neuroactive metabolites can 
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influence the levels of neurotransmitters  i.e. glutamate that have been 
implicated in schizophrenia (Muller and Schwarcz, 2006, Stone and Darlington, 
2013). Therefore, further animal studies investigating mRNA/protein levels of 
receptors, neurotransmitter levels and treatment effects of Ro61-8048 in a more 
complex behavioural testing should improve the validity of this animal model.  In 
addition, elucidating mechanisms that underlie the differential effects of Ro61-
8048 at P21 and P60 will require further studies on the anatomical and molecular 
changes with particular interest on some molecular targets that has been linked 
to both glutamatergic and dopaminergic systems.  
It is unclear by what mechanism alteration in the KP metabolites which favour 
KYNA formation upregulates SHH. The increase in expression is likely to involve 
an intermediate regulatory step of transcription factor that transcribes SHH. As 
the SHH pathway is important in the maintenance and proliferation of neural 
progenitor cells in the adult rodent brain, the activation of SHH and its receptor 
components is responsible for the effects that occur during this process. The 
pathway begins when the secreted SHH pep tide binds to its membrane-bound 
receptor Ptc, thus relieving its inhibition of Smo which then lead to a complex 
signalling cascade involving the transcription factors of the Gli family. Future 
studies, possibly involving the suppression of SHH pathway with its antagonist 
will be useful to determine whether SHH signalling is necessary for KP regulation 
to promote the proliferation of adult‟s pool  of progenitor cells in the 
hippocampus. In this respect, incorporating an application of cyclopamine, 
natural product of plant alkaloid that is selectively known to inhibit SHH 
signalling by directly binding to one of the signalling component of the SHH 
receptor complex, is warranted (Charytoniuk et al., 2002, Britto et al., 2002). 
Because high expression of Ptc and Gli1 is an indicator of activity in the SHH 
pathway, it is also important to analyse the expression patterns this signalling 
targets either at mRNA levels or in tissue specimen of immunolabelling 
technique. By incorporating quantitative analysis with other signalling 
components of SHH pathway and inhibition with antagonist may further support 
the evidence of the requirement of the SHH signalling for adult neural progenitor 
cell expansion and development  and that KP metabolism effects on 
hippocampus dependent-activity could be mediated by SHH signalling pathway. 
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Substantial studies have gathered evidence supporting the idea that 
dysregulation of the cell cycle of neural cells plays an important role in diverse 
pathological processes in the CNS. Characterization the cell cycle properties in 
this process and comparative studies of the expression of individual members of 
related proteins under physiological condition, including various developmental 
stages and in exposure to pathological stimuli may provide better and conclusive 
explanation. 
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